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GENERAL INTRODUCTION, AIMS AND OUTLINE
GENERAL INTRODUCTION
Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) is a chronic relapsing inflammatory disorder that affects 
the gastrointestinal tract in children, adolescents and adults and generally consists of two 
types: Ulcerative Colitis (UC) and Crohn’s disease (CD). The exact aetiology of IBD is unclear, 
it is believed that a complex interaction of genetics and environmental factors leads to a 
dysregulated immune response to the commensal intestinal microbiota.1, 2 Genetic and 
environmental factors initiate alterations in epithelial barrier function which leads to 
infiltration of luminal antigens with ultimately inflammation of the bowel wall. When acute 
intestinal inflammation is not resolved, uncontrolled activation of the mucosal immune 
system (e.g. Macrophages, Dendritic Cells, T-cells) causes chronic intestinal inflammation 
which is driven by cytokines (e.g. Tumor Necrosis Factor alpha (TNF-α), Interferon gamma 
(IFN-γ), Interleukin (IL)-1, IL-1β, IL-6, IL-12, IL-22, IL-17, and IL-23).2-4
 Worldwide, an increase in the incidence and prevalence of IBD has been observed.5 
For adults with IBD, the highest incidence has been found in Europe and North America (4-8 
per 100.000 person years).5 For paediatric IBD most recent studies show varying incidence 
rates, from 4.46 (France, up to 2011) to 10 per 100.000/year7 (England, up to 2017). Until 
recently, it was thought that in up to 25% of patients IBD develops and manifests during 
childhood8, with a peak onset in adolescence.9 A recent study however indicates that the 
incidence might be lower, around 8%.6 
Clinical presentation of IBD 
UC and CD have overlapping clinical features but are considered separate entities, clinical 
presentation depends on the site and extent of mucosal inflammation. 
 CD is characterised by a transmural and granulomatous inflammation involving any 
part of the gastrointestinal tract (from mouth to anus), often with a non-contiguous pattern 
(so called skip lesions). Patients with CD mostly suffer from abdominal pain, diarrhoea, 
decreased appetite and weight loss, but anaemia, perianal disease (abscesses or fistula), 
growth failure and delayed puberty are also common.1 Initial symptoms may not be that 
specific and can contribute to delay in diagnosis. 
 UC is characterised by continuous mucosal inflammation of the colon, extending 
from the rectum proximally, without skip lesions or granulomas. Patients with UC suffer 
mostly from abdominal pain, rectal bleeding, diarrhoea and weight loss.
 IBD is not limited to the bowel, up to 30% of patients will develop an extra intestinal 
manifestation (EIM) during their lifetime, mostly arthritis and skin manifestations.10 11
 The bowel inflammation in IBD is characterised by episodes of relapse and 
remission. Literature shows that in general, 30-50 percent of patient has at least one relapse 
per year12-14, which can lead to irreversible damage despite chronic medical treatment. 
There is no cure for IBD, lifelong treatment is focused on mucosal healing (inducing and 
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maintaining remission) and prevention of disease progression and complications with the 
least amount of side effects from medication.
Paediatric versus adult onset IBD
Studies have shown several differences between paediatric and adult onset IBD. Paediatric 
onset IBD is considered to have a more extensive disease location, a more severe phenotype, 
increased use of immunomodulatory therapy, higher rates of intestinal complications 
(strictures, colon surgery and perianal disease) and an increased risk of malignancy later in 
life.15-18 
PSYCHOSOCIAL PROBLEMS IN YOUNG IBD PATIENTS
Adolescence is known as a life phase with significant psychological, physical and social 
changes.19 Suffering from a chronic disease like IBD, poses a threat to a healthy psychosocial 
development. Throughout life, important milestones and transitions (such as transitioning 
into adulthood), may give greater challenges for patients with IBD than for healthy peers. 
Therefore, it is not surprising that adolescent IBD patients frequently experience psychosocial 
problems, such as reduced social functioning, family problems, school problems and 
emotional problems.20, 21 All these problems contribute to a decreased quality of life.22 Several 
clinical, psychological and social factors have been associated with psychosocial outcomes 
and Health Related Quality Of Life (HRQOL) in (young) IBD patients. For example, clinical 
factors such as active disease, Crohn’s disease (compared to UC), corticosteroid treatment 
and a high hospitalization rate have been associated with a poorer QoL in IBD patients.23, 
24 In addition, psychological and social factors such as anxiety or depression25, 26, negative 
illness perceptions27, 28, maladaptive coping29, a lack of social support30, high perceived 
stress31 and work disability24 have also been associated with a lower QoL. As summarized 
in the biopsychosocial model of health and disease, all the factors mentioned above are 
interrelated and influence health.32 For IBD, it is mostly emotional problems, specifically 
anxiety and depression, that have received much attention in the current literature.
Anxiety and depression  
In mental health care, a distinction is made between anxiety and depressive symptoms 
and anxiety and depression as disorders. Disorders reflect severe symptoms that cause 
significant impairment in daily life and are diagnosed based on the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) criteria, using a psychiatric interview. Symptoms are 
usually measured with self-report questionnaires, and patients with elevated symptoms 
(who do not meet all criteria of a disorder) suffer from milder (or so-called subclinical) 
symptoms, but do not experience such a significant impairment in their daily life as patients 
with a diagnosed disorder. However, both subclinical and clinical symptoms affect health 
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status and health care use, and subclinical symptoms hold a risk for progression into clinical 
symptoms.33
 Symptoms of anxiety and/or depression are often found in paediatric IBD patients. 
Reported prevalence rates range from 20-50% for anxiety34-36 and 25-40% for depression.35, 
37, 38 Although some studies report lower rates39, the prevalence in paediatric IBD seems to 
be higher compared to other chronic diseases.40, 41 A systematic review is not yet available, 
but will be presented in this thesis. For adult IBD patients, a recent systematic review 
showed pooled prevalence rates of anxiety symptoms of 35.1% and 21.6% for depressive 
symptoms42, suggesting that psychological problems persist or arise again in adulthood.43 
As illustrated, many studies investigated anxiety/depressive symptoms in paediatric IBD, 
but studies investigating anxiety and depressive disorders in IBD are scarce. This can be 
explained by the time-consuming psychiatric interview which is necessary for diagnosing a 
psychological disorder. 
 As in the general population44, 45, female sex39, 46, 47 and low socio-economic status48 
have been reported to be risk factors for anxiety and depression. More importantly, 
psychological symptoms have repeatedly been shown to be associated with active disease.42, 
46, 49-51 In addition, other disease-related factors such as abdominal pain37, 52, corticosteroid 
use53, fatigue54, extra-intestinal manifestations47, prior surgery and perianal disease47, 55, are 
known to be associated with psychological symptoms in IBD patients
 Moreover, psychological symptoms impact patients’ lives, they are associated 
with a higher symptom burden47, worsening of disease course56, 57, fatigue47, school or work 
absenteeism58, 59, lower therapy adherence50, higher health care utilisation47, 50, 60, more 
steroid courses and biologic therapy47, all leading to high societal costs.61 
Brain-gut axis
The findings above illustrate that psychological symptoms may influence disease course, and 
vice versa. This bidirectional relationship between IBD and psychological problems has been 
previously described62 and can be explained in terms of the hypothetical ‘brain-gut’-axis. This 
axis describes interactions between the central, autonomic, and enteric nerve system, the 
hypothalamic-pituitary-adrenal (HPA) axis, gut microbiome and mucosal immune system. 
Through feedback loops, (para)sympathetic signals reach peripheral organs including cells 
of the immune system. Any kind of (psychological) stress activates the sympathetic system 
and the HPA-axis, with the release of neurotransmitters, hormones and pro-inflammatory 
cytokines. Many of these factors have pro-inflammatory properties, but HPA-axis function 
also serves to limit the effect inflammation by means of the release of cortisol.63 In IBD 
patients, all of these processes may lead to increased colonic motility, increased water 
and ion secretion, increased mucus production, and increased bacterial transfer into the 
mucosa, all contributing to increased intestinal symptoms.62, 64 More specifically, the brain-
gut axis applied to IBD means that the presence of intestinal inflammation might negatively 
influence anxiety and/or depression and vice versa: anxiety and/or depression may increase 
14
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intestinal inflammation and may trigger a relapse of IBD.57, 62, 64, 65 Several studies support this 
by showing an association between clinical disease activity and anxiety36, 42 and depression.42, 
53 In addition, several longitudinal studies also provide support: in a recent systematic review 
5 out of 11 studies reported an association between depression and worsening of disease 
course.56, 66 For anxiety, less studies are available, with mixed results.57, 65, 67-70
Treatment of anxiety and depression in IBD
In the current international guidelines for paediatric71, 72 and adult73-76 patients with IBD, 
screening for psychological problems is not (yet) part of standard care for IBD patients. 
Considering that psychological problems are not always recognised in a 10-minute doctor’s 
or nurse’s consultation in the outpatient clinic, it is likely that these problems are often 
missed and remain untreated. To illustrate, Klag et al. (2017) found in a group of 630 adult 
IBD patients, that half had a high demand for psychological help.77 In addition, it has been 
reported that psychological disorders in IBD are undertreated; a study in 231 adult IBD 
patients showed that only half of the patients with anxiety and/or depressive symptoms 
indicative of a psychiatric disorder received psychological or psychiatric treatment.78
 The most effective evidence based psychological treatment for anxiety and/
or depression for both children, adolescents and adults, is cognitive behavioural therapy 
(CBT).79, 80 CBT has been proven effective in reducing anxiety and depressive symptoms in 
both paediatric81, 82 and adult83 IBD patients. Cognitive behavioural therapy is based on the 
theoretical rationale that thoughts, feelings, and behaviour are interrelated. CBT aims to 
change distorted or dysfunctional thinking patterns, in order to improve negative emotions 
and maladaptive behaviors.80 In addition, relaxation, and exposure (exercising with difficult 
situations) are essential elements in CBT. A few studies investigated the efficacy of CBT in 
IBD patients suffering from anxiety and/or depression.81, 82, 84, 85 In addition, most of these 
studies focused only on psychological outcomes (anxiety, depression).81, 84, 85 Only one study, 
in paediatric IBD, investigated clinical disease course in IBD patients with depression.82 This 
emphasises the need to conduct studies investigating CBT in patients with IBD and anxiety 
and/or depression, and to study both clinical (medical) and psychological outcomes. 
TRANSITION
Next to psychosocial problems, transition to adult care is an important issue in the lives 
of young adult IBD patients. As IBD is a lifelong disease, all patients will need to undergo 
transfer of paediatric to adult care. Transfer to the adult gastroenterology department is not 
always easy. Patients and their parents are frequently reluctant to break the familiar and 
valued relationship with their paediatrician, and can have a negative perception of adult 
health care.86-88 In addition, in many cases parental involvement is high, which can interfere 
with the development of self-management skills.87, 89 Furthermore, there are several other 
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differences between paediatric and adult care that make the transfer to adult health care 
challenging. For example, in paediatrics, endoscopy is usually done under deep sedation or 
general anaesthesia, there is more attention for growth and pubertal development, and the 
outpatient clinic is family-focused and less formal. This in contrast to adult health care, where 
endoscopy is often performed without deep sedation, where gastroenterologists are not 
trained to evaluate growth and pubertal development, and focus on adult-oriented topics, 
such as cancer surveillance and fertility. Furthermore, the organisation of the outpatient 
clinic in adult care is more formal and physicians often only communicate with the patient 
(and not the parents). 
 To help adolescent patients get acquainted with these differences and prepare 
patients and parents for adult health care, it is advised to have a transition period.90, 
91 Transition is defined as the process of purposeful planned movement of adolescents 
and young adults with chronic diseases from child centred to adult oriented healthcare 
systems.92 In the transition process, both patients, parents and the paediatric and adult 
gastroenterologist have specific tasks. Patients should learn to be responsible for their own 
health, acquire (disease) knowledge, autonomy and self-management. Parents need to allow 
and stimulate their adolescent child’s independence. Physicians and nurses should support 
the transition process, be knowledgeable of adolescents’ developmental and health issues 
and prepare adolescents for the changes that will be encountered in the adult health care 
system.86, 93, 94 
 Transitional programs are designed to facilitate all these processes86, 95, 96 and 
prepare the individual patient for his/her transfer by helping to increase knowledge as well as 
to reach a higher level of self-management. Although many different models for transitional 
care have been proposed in IBD, there is no evidence that one particular model is more 
effective than others.90 In addition, not all health care providers working with adolescent 
IBD patients have an IBD transition clinic and transition practices vary greatly between and 
within countries and continents.88, 90 However, the importance of transition is emphasised 
by the fact that studies generally report that adolescent patients lack knowledge about their 
disease, treatment and also lack self-management.97-102
 Inadequate transition arrangements have been associated with adverse outcomes 
across several medical conditions, for example diabetes.103 In IBD, studies investigating the 
outcome or impact of structured transition are scarce. The available studies have showed 
that the lack of a structured transition service negatively impacted adherence104, 105 and 
attendance104, 105, and was associated with a higher hospitalisation and surgery rate.104 On 
the other hand, structured transition programmes have been shown to result in better 
disease related outcomes106, 107, improved self- and disease knowledge and improved quality 
of life.107, 108 
 A clear definition of success of transition, or a scoring system measuring success of 
transition in IBD is not available.86, 104, 109 Therefore, studies investigating outcome or success 
of transition are warranted.
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AIMS OF THIS THESIS
The general aim of this thesis is to investigate two themes relevant to adolescent and young 
adult IBD patients: psychosocial problems, especially anxiety and depression, and transition 
to adult care. 
The specific aims of this thesis are:
 -  To systematically review the scientific international literature with regard to the 
prevalence of anxiety and/or depression in paediatric and adolescent IBD 
 -  To study the prevalence and risk factors of anxiety and/or depression in Dutch 
adolescents and young adult patients with IBD
 -  To investigate the effectiveness of cognitive behavioural therapy on both psychological 
symptoms and clinical disease course in young IBD patients suffering from mild or 
subclinical anxiety and/or depressive symptoms
 -  To identify immunological profiles in IBD patients with anxiety and/or depression, and 
investigate if these profiles are altered by cognitive behavioural therapy
 -  To study outcome of transition, especially identifying which factors health care providers 
and patients find important for success of transition to adult care.
OUTLINE 
Part I (Chapters 2-9) has a focus on anxiety and depression in paediatric IBD. In Chapter 2 
a systematic review with a meta-analysis is presented of all studies that have investigated 
prevalence of anxiety and/or depression in paediatric IBD until December 2017. In Chapter 3 
we present the study protocol of HAPPY-IBD, our multicentre randomised trial investigating 
the effectiveness of cognitive behavioural therapy (CBT) on psychological outcomes ánd 
clinical disease course in young IBD patients with subclinical symptoms of anxiety and/
or depression. HAPPY-IBD is a collaboration between the department of child psychiatry/
psychology and paediatric gastroenterology. Luuk Stapersma, the research psychologist of 
HAPPY-IBD, is responsible for collecting and analysing all psychological data and is the first 
author of three articles included in this thesis. In short, HAPPY-IBD is a two-stage study: the 
first stage is the screening of 374 Dutch adolescents and young adults with IBD on anxiety 
and/or depression. The second stage is a multicentre randomised controlled trial (RCT) with 
IBD patients with elevated mild or subclinical symptoms of anxiety and/or depression. In 
Chapter 4 we present the first results from stage 1: we show the prevalence and severity 
of anxiety and/or depressive symptoms in our large cohort of Dutch adolescents and young 
adults with IBD. In addition, we describe the risk factors found in our cohort for these 
symptoms. In Chapter 5 we aimed to clarify the associations between several psychological 
17
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factors (illness perceptions, coping, anxiety, depression) and Health Related Quality of 
Life (HRQOL) in the 374 patients screened in stage 1. In Chapters 6 and 7, the short- and 
long-term results of the disease specific CBT on psychological outcomes, such as anxiety, 
depression and HRQOL, are presented. Chapter 8 discusses the effect of CBT on several 
clinical outcomes: time to relapse, clinical disease activity scores, C-Reactive protein and 
faecal calprotectin. In Chapter 9 we aim to explore the brain-gut axis in IBD at a molecular 
level. We take a first step in unravelling the relationship between anxiety/depression and 
systemic inflammation in IBD patients. Using a large inflammatory protein panel, we first 
investigate plasma protein profiles in 45 young IBD patients with and without anxiety and/or 
depressive symptoms. Secondly, we study whether CBT changes these profiles in a subgroup 
from the RCT (described in Chapters 3, 6, 7 and 8). 
Part II (Chapters 10 and 11) discusses outcomes of transition. In Chapter 10 we propose 
a composite score measuring success of transition, and evaluate whether self-efficacy is 
a predictor of successful transition according to that score. In Chapter 11 we use a more 
thorough approach in identifying outcomes reflecting successful transition by asking the 
opinion of a large expert and patient panel in a multinational Delphi study. 
In Part III (Chapters 12 and 13), we discuss our main findings and conclusions and give 
recommendations for clinical practice and future research in Chapter 12. In Chapter 13 our 
findings, as described in this thesis, are summarised in English and Dutch. 
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SUMMARY
Background
The co-existence of psychological problems and paediatric inflammatory bowel disease 
(IBD) is receiving increasing attention in literature. Most studies investigated anxiety and 
depression, with prevalence rates varying greatly from 0% to 50%. A systematic review is 
necessary to provide clear insight in the prevalence of anxiety and depression in paediatric 
IBD. 
Aim
To systematically evaluate available data on the prevalence of anxiety and depressive 
symptoms and disorders in paediatric IBD (aged 6-18 year).
Methods
Comprehensive searches were performed in Embase, Medline Ovid, Web of Science, 
Cochrane, PubMed, PsychInfo Ovid, Google scholar for studies published from 1994 to 
2017. Pooled prevalence rates were calculated using inverse variance heterogeneity models. 
Meta-regression was used to study if disease type, disease activity and gender influence 
prevalence.
Results
28 studies (N= 8107, mean age: 14.3) were identified. Pooled prevalence estimates were 
16.4% (95% Confidence Interval [CI] 6.8-27.3%) for anxiety symptoms and 4.2% (95%CI 3.6-
4.8%) for anxiety disorders. Pooled prevalence estimates were 15.0% (95%CI 6.4-24.8%) for 
depressive symptoms and 3.4% (95%CI 0-9.3%) for depressive disorders. Meta-regression 
showed no influence of disease type and gender on these prevalence rates, but studies with 
a higher percentage of active disease had a higher rate of depressive symptoms.
Conclusion
The described pooled prevalence of anxiety and depressive symptoms is lower than in adult 
IBD. However, due to varying instruments/cut-offs for measuring symptoms and few studies 
investigating disorders, the results should be interpreted with caution. Cross-cultural use of 
the same instruments is needed to gain better insight into prevalence rates.
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INTRODUCTION
Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]) is a chronic 
relapsing inflammatory disorder of the intestine, with increasing incidence and prevalence 
worldwide.1 Patients may have abdominal pain, (bloody) diarrhoea, often accompanied by 
systemic symptoms such as lack of appetite, weight loss and fatigue. IBD has an unpredictable 
and fluctuating disease course, with relapses and periods of clinical remission. In up to 25% 
percent of patients, IBD manifests during late childhood and adolescence.2 Adolescence is 
already challenging, due to significant psychological, physical and social changes. Having IBD 
during adolescence can pose a real threat to a healthy psychosocial development. Studies 
indicate that paediatric IBD patients are at risk for several psychosocial and psychological 
problems.3, 4 Most studies focussed on anxiety and/or depressive symptoms, and reported 
greatly varying prevalence rates, from 2%5-50%6 for anxiety symptoms and 0%7-33%8 for 
depressive symptoms. Only a few studies investigated prevalence of anxiety and depressive 
disorders, which ranged respectively from 3%9-7% 10 and 1%11-17%10 .
 In mental health care, a distinction is made between anxiety/depressive symptoms 
and anxiety/depressive disorders for several reasons. First, patients with a clinical disorder 
have severe symptoms that cause significant impairment in their daily life. Patients with 
elevated symptoms (who do not meet all criteria of a clinical disorder) do suffer from these 
milder symptoms, but do not experience such a significant impairment in their daily life. 
Second, disorders comprise a combination of symptoms, and are diagnosed using the 
criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM) in a psychiatric 
interview. On the other hand, symptoms are often measured using a questionnaire.
 The bidirectional relationship between IBD and psychological problems has 
been previously described and can be explained in terms of the “brain-gut”-axis. This axis 
describes that the presence of intestinal inflammation might negatively influence mood and 
vice versa: anxiety and/or depression may increase intestinal inflammation and may trigger 
a relapse of IBD.12-15 While many individual studies looked at the prevalence of anxiety 
and/or depressive symptoms and disorders in paediatric IBD patients, no comprehensive 
systematic review or meta-analysis has been conducted.
 Unfortunately, the few published reviews on psychological outcomes in paediatric 
IBD either differed in scope (e.g. did not focus specifically on prevalence rates of anxiety 
and/or depression) or had several shortcomings. Some reviews only included older studies 
published in the previous decade4, 16, whereas others only included studies with a control 
group4 or included a small portion of the available paediatric studies.17 A review by Brooks 
et al. discussed the impact of psychological morbidity in paediatric IBD (including anxiety 
and depression, but not their prevalence rates).18 Greenley et al. studied psychosocial 
adjustment (including anxiety and depression) of adolescents with IBD, but only included 
studies published before 2007, which used a comparison group or normative data (thus 
excluding cross-sectional or cohort studies without a comparison group). The authors 
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reported that adolescents with IBD had higher rates of depressive disorders than those 
with other chronic conditions. However, their prevalence rates of anxiety and depressive 
symptoms, and anxiety disorders were not significantly different from healthy adolescents 
or those with other chronic diseases.4 A third, nearly a decade old review by Ross et al., 
included studies till 2009, investigating psychosocial functioning and quality of life. They 
found an increased incidence of anxiety and depressive disorders, varying from 25% to 73%, 
in adolescents with IBD.16 A fourth systematic review included studies published between 
2005 and 2014, but studied comorbidity of anxiety and depression in both paediatric 
and adult IBD, and included only a limited number of the available paediatric studies.17 
Considering the previous reviews, there is a clear need to perform a systematic review 
with meta-analysis to provide prevalence rates on anxiety and depression in paediatric IBD, 
including all available studies.
 The current systematic review and meta-analysis aims to systematically assess the 
prevalence rates of anxiety and depressive symptoms and disorders specifically in paediatric 
IBD, using all studies published between 1994 and 2017 (aim 1). In addition, we aimed to 
investigate whether disease type, disease activity, or gender influence these prevalence 
rates (aim 2). It is important to gain more clear insight into the overall prevalence and risk 
factors of anxiety and depression in paediatric IBD, in order to increase awareness, facilitate 
early detection of anxiety and depression, and, if necessary, early psychological treatment.
MATERIALS AND METHODS
This systematic review and meta-analysis was performed following the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA)-guidelines.19
Eligibility criteria
Inclusion criteria were studies concerning, (a) patients 6-18 years of age (or studies with sub 
analyses on this age group), (b) with IBD, diagnosed according to the current international 
guidelines, (c) examining either anxiety and/or depressive symptoms (using validated 
screening instruments with at least child self-report data) or anxiety and/or depressive 
disorders (using a structured psychiatric interview or ICD codes). We chose to include 
any study design that measured prevalence for anxiety and depression in a paediatric IBD 
cohort. For studies measuring anxiety and/or depression at various time points, data of only 
the first assessment was used. 
Exclusion criteria were studies (a) published in non-English languages, (b) published before 
1994 (studies using DSM-IV, introduced in 1994, or higher), (c) using instruments with no 
separate anxiety or depression scale (e.g. the Internalizing scale or syndrome scale Anxious/
Depressed of the Child Behaviour Checklist), (d) with a patient cohort already partly 
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described in another included study (no unique cohort), (e) that described case reports, 
case series, qualitative studies, dissertations, or review papers and conference abstracts 
without published full article.
Information sources and search
An expert research librarian conducted a comprehensive literature search using Pubmed, 
Embase, MEDLINE Ovid, Web of Science, Cochrane, PsychINFO Ovid and Google Scholar in 
December 2017. For Inflammatory Bowel Disease, search terms included Crohn’s Disease 
and ulcerative colitis. For anxiety and depression, search terms included both symptoms and 
disorders, and fear and panic as well as the most common treatments for these problems 
(cognitive behavioural therapy and antidepressants), to find intervention trials for their 
baseline data. The search strategies used for each database are provided in Appendix 1.
Study selection
Studies meeting inclusion criteria were eligible. In step 1, 2 investigators (LS and GB) 
independently screened titles and abstracts of eligible studies. Any disagreement was 
resolved by consensus or a third reviewer. In step 2 abstracts and if necessary full texts of 
selected articles were checked globally for the in-/exclusion criteria (i.e. whether a full text 
was available, if a valid instrument was used, and if the study concerned paediatric patients).
 In step 3, full texts of the remaining articles were reviewed thoroughly (by LS/GB). 
All reference lists were inspected for additional studies. Figure 1 displays the reasons for 
excluding articles. Reference management was done using EndNote X7.
Data collection process & Data items
Two independent investigators, using a data extraction from, extracted the following data 
for each included study: year of publication, study design (e.g. control group present or 
absent), patient setting (in- or outpatient), country, number of included patients, patient 
demographics (age, gender), disease characteristics (disease type [CD vs UC], disease activity 
[active or remission]), measurement method of anxiety and/or depression (questionnaire 
and/or psychiatric interview) and prevalence rates of anxiety and depressive symptoms and 
disorders. If prevalence rates for symptoms and disorders were not reported the manuscript, 
they were calculated using the cut-off for elevated symptoms reported by the authors. 
Disagreement regarding extracted data was resolved by consensus. Original authors were 
contacted if the data provided in the paper was insufficient to extract a prevalence rate. 
Authors were also contacted if it was suspected that several articles reported about the 
same or overlapping patient cohorts. If that was the case, only the article with the most 
complete data was included in this review. After three attempts to contact authors without 
success, articles were excluded.
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Quality and risk of bias 
The quality and risk of bias of the individual studies was assessed, using a checklist developed 
by the research team a priori and specifically for this study. The checklist, with a maximum 
score of 27, was based on the recommendations of Sanderson et al. 200720, the NIH Quality 
Assessment for Observational Cohort and Cross-sectional studies21, 22 and previously 
published checklists.17, 23 Included studies were rated on their method (definition of aim/
primary outcomes), recruitment, sample size, whether or not they included a control group, 
instruments used (psychological and medical), and if confounders were taken into account 
(see Appendix 2 for the complete checklist). The checklist was piloted using a subsample of 
studies with minor adjustments afterwards. 
Data synthesis and statistical analyses
Extracted prevalence rates were pooled using inverse variance heterogeneity models 
(including a double arcsine transformation), that handle between study heterogeneity 
better than the widely used random effects model.24 Heterogeneity was assessed using the 
I2 statistic, with values ≥75% indicating considerable heterogeneity.25 Reporting bias across 
studies (e.g. publication bias) was examined visually using “funnel plots” and the more 
sensitive “Doi plots” and formally using the Luis Furuya-Kanamori (LFK) index 26-29, to see 
if the prevalence rates changed with increasing sample size. In the funnel plots and Doi 
plots a higher prevalence is displayed by a higher “Double Arcsin Prevalence”, and a higher 
standard error indicates a lower sample size. To evaluate whether disease type, disease 
activity or gender influence the prevalence of anxiety and/or depressive symptoms or 
disorders (aim 2), we repeated the meta-analyses and included disease type (% CD), disease 
activity (% active disease) or gender (% male) as covariates in three separate weighted 
meta-regression analyses. Only studies that reported on these covariates were included in 
these meta-regression analyses. Sensitivity analyses were performed by excluding studies in 
the lowest tertile of the reported ‘quality/risk of bias score’ (i.e. with a score of 10 or lower) 
and removing the largest study for each separate analysis. Additional sensitivity analyses 
were performed using the random effects model, to provide the opportunity to compare 
the results with the inverse variance heterogeneity models. All analysis were performed 
using MetaXL version 5.328 and STATA version 15.0 (Stata corp, College station, TX, USA).
RESULTS
Study selection
During the database search 2020 records were found, four additional studies were identified 
through other sources (i.e. reference lists of included records). A total of 495 out of 2024 
records were removed as duplicates. Of 1529 records the title and abstract was screened, 
1344 records did not meet inclusion criteria (step 1). In this first step agreement between 
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the investigators was 87.2%. In step 2, 185 articles were globally screened on the inclusion 
and exclusion criteria, of which 122 were excluded in this step, leaving 63 full-articles to be 
assessed (step 3). Of these 63 articles, 27 were excluded because they reported on a patient 
cohort that was already included, for eight prevalence data were not available after request. 
The remaining 28 articles were included in the meta-analysis. For 13 of the 28 articles, 
prevalence rates were provided after request form the original authors. See Figure 1.
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Figure 1. PRISMA Flow Diagram. 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.
pmed1000097
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Study characteristics
A total of 8107 participants were included in the analyses (of which 2 studies provided 
more than half), 51.3% was male. One study included only female patients.7 The number 
of participants per study ranged from 21 to 2733, with a median sample size of 85. Two 
studies were relatively large with n = 21449 and  n = 273311. Mean age was 14.3 (based 
on 25 studies that reported a mean age). Three studies included only patients with CD.6, 
9, 30 In the remaining studies that reported disease type, 67.1% had CD. In total, nine out 
of 28 studies used a control group. Three studies included healthy adolescents, the other 
6 included patients with other chronic diseases (e.g. Cystic fibrosis, Diabetes, Juvenile 
Idiopathic Arthritis).5, 9, 31-37 With respect to geography, 20 studies were from the United 
States of America, 7 studies were from Europa10, 32, 35, 36, 38-40, and 1 study from Asia34. See 
Table 1 for an overview of the study characteristics.
 Finally, in 23 out of 28 studies, clinical disease activity was measured for CD, with 
the following indices: Paediatric Crohn’s Disease Activity Index (PCDAI)5, 10, 31, 35, 37, 38, 40-44, short-
PCDAI45 abbreviated PCDAI44, 46, Harvey Bradshaw Index6, 47, Physician Global Assessment 
(PGA)32, 37, 44, 48, 49, (part of) Children’s Somatisation Inventory8, IBD-symptom questionnaire33, 
and Short-Crohn’s Disease Activity Index30, 50. Twenty-five studies included UC patients and 
in 21 disease activity was measured using the following indices; Paediatric Ulcerative Colitis 
Activity Index (PUCAI)10, 35-38, 40, 42, 44, 46, 47, 50, Physician Global Assessment31, 32, 37, 44, 48, 49, (part of) 
Children’s Somatisation Inventory8, IBD-symptom questionnaire33, Clinical score of Kozarek41, 
43, Lichtiger Colitis Activity index45, and PCDAI5. Of the 17 studies that reported percentage 
active disease, 35.9% of patients had active disease and 64.1% was in remission.
Study Quality/Risk of bias 
Mean score on our checklist was 12.64 (reported range 8-17) with a standard deviation of 
2.34. Especially on the items regarding using a control group, sample size, and taking into 
account confounders, many studies scored 0 or 1 point(s).
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Prevalence of anxiety symptoms
Ten studies5, 6, 8, 30, 35, 39, 44, 47, 49, 50 (including 1155 participants) reported on the prevalence of 
anxiety symptoms, using seven different instruments). The pooled estimate of prevalence 
of anxiety symptoms was 16.4% (95% Confidence Interval [CI] 6.8-27.3%) with a high level 
of heterogeneity between estimates (I2 = 92.9%, p < .001). See also Figure 2a. Although 
visual inspection of the funnel plot indicates some asymmetry (see Appendix 3, few studies 
present with a lower prevalence and a relatively high standard error), the LFK index revealed 
no significant asymmetry (LFK index: 0.96). This indicates that heterogeneity in outcomes 
between studies may not be due to publication or reporting bias, but to other factors.
 Meta-regression analyses showed that disease type (% CD, ß = .004, p = .699) and 
gender (% male, ß = .027, p = .506) did not explain the heterogeneity in outcomes. The 
meta-regression analysis for disease activity could not be performed due to lack of data 
(only 5 out of 10 studies reported % active disease). 
 To check whether prevalence rates would change if we removed the 5 studies with 
a score in the lowest tertile of reported quality/risk of bias (15.5% [95%CI 2.6-31.5%], I2 = 
95.6%) or removed the largest study with 280 participants (20.2% [95%CI 9.5-32.3%], I2 = 
91.1%) we reran our analyses. Results did not change significantly, and heterogeneity in 
outcomes was still high. The random effects analysis provided a prevalence rate of 18.1% 
(95%CI 10.1-27.8%).
Prevalence of anxiety disorders
Only three studies9-11 reported on the prevalence of anxiety disorders, with a total of 4924 
participants (respectively n=21449, n=4710, n=273311). The pooled estimate of prevalence 
of anxiety disorders was 4.2% (95%CI 3.6-4.8%). See also Figure 2b. The heterogeneity was 
low and not significant (I2 = 2.1%, p = .346). The number of included studies was too low to 
investigate reporting bias, meta-regression or to perform sensitivity analyses. The random 
effects analysis provided a prevalence rate of 4.2% (95%CI 3.6-4.8%). 
Prevalence of depressive symptoms
Twenty-two studies5, 7, 8, 30-38, 40-46, 48-50 reported on depressive symptoms (including 2911 
participants), using nine different instruments, including 3 versions of the Child Depression 
Inventory (CDI). The pooled estimate of prevalence of depressive symptoms was 15.0% 
(95%CI 6.4-24.8%), with a high level of heterogeneity (I2 = 95.0%, p < .001). See also Figure 2c. 
The funnel plot and Doi plot showed significant asymmetry (LFK index: -2.80) (see Appendix 
3). Visual inspection of the funnel plot indicates that there is a lack of studies with a low 
prevalence rate with a relatively high standard error. Hence, heterogeneity between studies 
may be due to publication or reporting bias. Meta-regression analyses showed that disease 
type (% CD, ß = -.009, p = .125) and gender (% male, ß = -.003, p = .748) did not explain the 
heterogeneity in prevalence rates of depressive symptoms between studies. Disease activity 
(% active disease) showed a significant effect on the prevalence of depressive symptoms 
40
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(ß = .021, p < .05), indicating that in studies with a higher percentage of active disease the 
prevalence rate of depressive symptoms was higher. Removing the 6 studies with a score 
in the lowest tertile of reported quality/risk of bias (15.5% [95%CI 5.3-27.2%], I2 = 95.6%) 
or removing the largest study with 765 participants (10.2% [95%CI 4.9-16.2%], I2 = 91.8%) 
did not significantly change the prevalence rate for depressive symptoms, heterogeneity 
was still high. In addition, excluding the study with only female patients7 did not change the 
results. The random effects analysis provided a prevalence rate of 12% (95%CI 6.9-18.2%).
Prevalence of depressive disorders
Four studies9-11, 42 reported on the prevalence of depressive disorders, with a total of 
5689 participants (respectively, n=21449, n=4710, n=273311, n=76542). The pooled estimate 
of prevalence of depressive disorders was 3.4% (95%CI 0-9.3%), with a high level of 
heterogeneity (I2 = 98.3, p < .001). See also Figure 2d. The number of included studies was 
too low to investigate reporting bias, meta-regression or to perform sensitivity analyses. The 
random effects analysis provided a prevalence rate of 6.2% (95%CI 1.6-13.1%).
DISCUSSION
This first systematic review and meta-analysis examining the prevalence of anxiety and 
depression in paediatric IBD showed that the estimated prevalence rate was 16.4% for 
anxiety symptoms (based on 10 studies), 4.2% for anxiety disorders (based on 3 studies), 
15.0% for depressive symptoms (based on 22 studied) and 3.4% for depressive disorders 
(based on 4 studies). Differences between the prevalence rates calculated using the two 
different methods were small.
 Our findings show higher prevalence rates of anxiety and depressive symptoms 
compared to a community sample of Dutch adolescents51, but a lower prevalence of 
depressive symptoms compared to a community sample in the United States. The prevalence 
rate of anxiety symptoms was comparable.52 Furthermore, our meta-analysis shows that 
the prevalence of anxiety /depressive symptoms is lower in paediatric IBD, compared to 
available meta-analyses in other paediatric patient groups, such as diabetes and asthma 
(range 27-33%).53,54 The same trend has been shown in adult IBD; a higher prevalence of 
anxiety/depression, compared to the general population/ healthy controls, but a lower 
prevalence compared to patients with another chronic disease.17 In addition, prevalence 
rates are also lower than reported in adult IBD. Neuendorf et al. showed a pooled prevalence 
rate of 35.1% for anxiety symptoms (based on 51 studies), 20.7% for anxiety disorders 
(based on 4 studies), 21.6% for depressive symptoms (based on 67 studies), and 15.2% 
for depressive disorders (based on 5 studies).55 There are several possible explanations for 
the differences in prevalence rates between children and adults. The prevalence rates of 
anxiety and depressive symptoms are found to be higher in adults than in children and 
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Author and year Statistics per study Prevalence rate and 95% Confidence interval
Prevalence rate Lower limit Upper limit
Mackner et al 20055 1/50 0.020 0.000 0.084
Reigada et al 20156 46/93 0.495 0.393 0.596
Reigada et al 20118 8/36 0.222 0.099 0.374
Arvanitis et al 201630 46/276 0.167 0.125 0.213
Jelenova et al 201635 4/23 0.174 0.042 0.360
Kilroy et al 201139 31/79 0.392 0.287 0.503
Watson et al 201742 4/71 0.056 0.012 0.124
Reigada et al 201647 23/86 0.267 0.179 0.367
Walter et al 201649 24/161 0.149 0.098 0.209
Reigada et al 201750 18/280 0.064 0.038 0.096
Total 0.164 0.068 0.273
–0.1 0 0.1 0.2 0.3 0.4 0.5 0.6
Author and year Statistics per study Prevalence rate and 95% Confidence interval
Prevalence rate Lower limit Upper limit
Loftus et al 20119 81/2144 0.038 0.030 0.046
Engelmann et al 201510 3/47 0.064 0.008 0.156
Barnes et al 201711 121/2733 0.044 0.037 0.052
Total 0.042 0.036 0.048
–0.1 0 0.1 0.2 0.3 0.4 0.5 0.6
Author and year Statistics per study Prevalence rate and 95% Confidence interval
Prevalence rate Lower limit Upper limit
Mackner et al 20055 0/50 0.000 0.000 0.034
Reed-Knight et al 20127 0/31 0.000 0.000 0.055
Reigada et al 20118 12/36 0.333 0.187 0.497
Arvanitis et al 201630 10/276 0.036 0.017 0.062
Marcus et al 200931 1/70 0.014 0.000 0.060
Castaneda et al 201332 11/34 0.324 0.175 0.492
Van Tilburg et al 201533 51/189 0.270 0.209 0.336
Jayanath et al 201434 6/26 0.231 0.086 0.415
Jelenova et al 201635 4/24 0.167 0.040 0.347
Mahlmann et al 201736 4/21 0.190 0.046 0.391
Iturralde et al 201737 2/23 0.087 0.002 0.245
Herzog et al 201338 1/110 0.009 0.000 0.039
Giannakopoulos et al 201640 12/85 0.141 0.074 0.224
Szigethy et al 200741 36/156 0.231 0.168 0.300
Szigethy et al 201442 245/765 0.320 0.288 0.354
Thompson et al 201243 50/191 0.262 0.202 0.327
Watson et al 201744 6/71 0.085 0.029 0.162
Schuman et al 201345 24/122 0.197 0.131 0.272
Reed-Knight et al 201446 10/78 0.128 0.062 0.213
Ryan et al 201348 4/112 0.036 0.008 0.080
Walter et al 201649 8/161 0.050 0.021 0.089
Reigada et al 201750 7/280 0.025 0.009 0.047
Total 0.150 0.064 0.248
–0.1 0 0.1 0.2 0.3 0.4 0.5 0.6
Author and year Statistics per study Prevalence rate and 95% Confidence interval
Prevalence rate Lower limit Upper limit
Loftus et al 20119 118/2144 0.055 0.046 0.065
Engelmann et al 201510 8/47 0.170 0.074 0.293
Barnes et al 201711 28/2733 0.010 0.007 0.014
Szigethy et al 201442 80/765 0.105 0.084 0.127
Total 0.034 0 0.093
–0.1 0 0.1 0.2 0.3 0.4 0.5 0.6
(A)
(B)
(C)
(D)
F IGURE 2 (A) Forest plot prevalence rate anxiety symptoms. (B) Forest plot prevalence rate anxiety disorders. (C) Forest plot prevalence
rate depressive symptoms. (D) Forest plot prevalence rate depressive disorders. Sample sizes can differ from those mentioned in Table 1, due
to missing data on the outcome measure
8 | STAPERSMA ET AL.
Figure 2. Forest Plots
(a)  prevalence rate anxiety symptoms (b) prevalence rate anxiety disorders (c)  prevalence rate depressive 
symptoms (d)  prevalence rate depressive disorders.  
Note: Sample sizes can differ from those mentioned in Table 1. due to missing data on the outcome measure.
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adolescents56, 57, and for some anxiety disorders and for depressive disorders it has been 
found that their prevalence increases with age.58, 59 Furthermore, with longer disease 
duration of IBD, disease related complications due to irreversible bowel damage will occur, 
thus increasing the burden of disease. Finally, the increasing responsibilities in adulthood, 
and the detrimental influence of IBD on relationships and work, impact daily life even more 
than in childhood. However, one has to bear in mind that comparing pooled prevalence 
rates to each other is difficult, considering the great variation in the used instruments and 
cut-offs. A similarity between adult and paediatric studies is, that compared to studies 
investigating anxiety and depressive symptoms, studies investigating anxiety/depressive 
disorders are underrepresented.
 In our meta-analysis, we did not find an influence of disease type on prevalence 
rates of anxiety symptoms, anxiety disorders and depressive disorders. In contrast, in adult 
IBD, an influence of disease type was found, with a higher prevalence rate of depressive 
symptoms in CD patients than in UC patients.55 Methodological differences might explain 
these contrasting findings: we could only study disease type as a proportion (e.g. % CD of 
the total sample), whereas Neuendorf et al. could statistically compare the prevalence in 
patients with CD versus UC. Unfortunately, it was not possible to assess the influence of 
disease activity on anxiety symptoms, whereas this has been shown to significantly influence 
prevalence in adult IBD.55 Disease activity did significantly influence the prevalence rate of 
depressive symptoms: a higher prevalence was found in studies with more patients with 
active disease. These findings are in accordance with earlier findings in adult IBD.17, 55 Future 
studies should investigate whether patients with higher disease activity (e.g. moderate or 
severe) also have a higher prevalence of anxiety/depression compared to the patients with 
mild disease activity.
 Gender did not affect prevalence rates in our study, results of earlier studies 
showed mixed findings.9, 18 To what extent factors such as socio-economic status, use of 
corticosteroids, disease duration, age of diagnosis, or presence of perianal disease impact 
the prevalence of anxiety and depression in paediatric IBD, should be investigated in future 
studies.18
 Several methodological differences of the 28 included studies, give rise to 
heterogeneity and make us cautious in drawing firm conclusions. First, although all studies 
used validated instruments to assess anxiety or depressive symptoms, numerous different 
instruments were used, not all validated in paediatric IBD. Different cut-offs for the same 
instruments were used, and some used raw total scores, while others used (varying) 
T-scores. For example, for the CDI, cut-off scores ranged from 942 to 1938 or 2035 and for the 
SCARED, cut-off scores ranged from 206, 47 to 258 (see also Table 1). For future cross-cultural 
comparison of studies, we recommend to use the same, comparable cut-offs for each 
instrument. In addition, only four studies investigated anxiety/depressive disorders9-11, 42, 
and used two different methods (DSM based psychiatric interview versus ICD codes). These 
different methods, added to the low number of included studies increased heterogeneity 
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and may limit the reliability of the results. More studies investigating anxiety and depressive 
disorders are warranted to evaluate if they are prevalent in paediatric IBD. 
 Second, cross-cultural generalisability of the results is limited, considering that 
most studies came from North America (71%), only a few came from Europe (25%), and 
only one came from Asia (4%). 
 Third, 23 studies measured clinical disease activity, but for some studies the 
suitability of the measures of disease activity is debatable. Two studies used non- validated 
indices for paediatric IBD (i.e. the children’s somatisation index8 and the “IBD symptom 
questionnaire”33), and others used (“adult”) IBD disease activity indexes, also not validated 
in paediatric IBD.6, 30, 41, 43, 45, 47, 50 None of the included studies reported on mucosal disease 
activity, 5 measured the inflammatory marker C-reactive protein (CRP)32, 38, 42, 44, 46 and 
2 measured faecal calprotectin32, 44, but none related this to the presence of anxiety or 
depression.
 Fourth, no study presented prevalence rates separately for IBD subtypes, disease 
activity (active vs remission) and gender. Therefore, if available, these characteristics 
could only be incorporated in the meta-regression analysis as covariates (as percentages, 
e.g. % CD). Presenting data separately for these and other subgroups (e.g. patients that 
had received bowel surgery or perianal disease) would facilitate the use of meta-analytic 
approaches in the future and help understand if certain subgroups are more at risk for 
anxiety and/or depression than others.
 Finally, two studies provided more than half of the included patients, 19/28 (68%) 
studies were small (N<150), only 9 out of 28 (32%) studies had a control group and mean 
study quality was moderate. Larger studies, preferably cohort studies with a control group 
which control for confounders are warranted to increase the quality of research.
 The strengths of our study include a systematic search to include all studies 
examining the prevalence of anxiety and depression in paediatric IBD. In addition, providing 
separate analysis for anxiety/depressive symptoms versus disorders is important and 
insightful. Furthermore, the meta-regression approach strengthens our analyses. Finally, we 
performed the meta-analyses with both the inverse variance heterogeneity and the random 
effects model.
 Inevitably, this work has some limitations. First, inclusion was limited to English 
published papers. Second, conference abstracts without a full published article had to be 
excluded. This may have introduced bias. Third, the heterogeneity between the included 
studies forces us to be careful drawing conclusions. However, we feel performing a meta-
analysis (instead of only presenting the data as systematic review) was useful for several 
reasons. First, knowing about this high heterogeneity is very important. Second, we tried 
to explore with our meta-regression analyses if certain factors could explain the high 
heterogeneity and showed that, in patients with depressive symptoms, this was partly 
explained by disease activity. Future studies would benefit from a study design which allows 
for subgroup-analyses to investigate heterogeneity. 
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 Recommendations for future studies to limit this heterogeneity and improve quality 
of research are extensively described by Mikocka-Walus et al17 and include using the same 
validated screening measures and clinical diagnostic measures (psychiatric interview) with 
the same comparable cut-offs, including comparison groups (healthy and other chronically 
ill controls), control for confounders (psychiatric history), measuring IBD outcomes, present 
data separately for IBD subtypes and for disease activity categories. At last, the results of the 
analyses concerning reporting bias show that publication and reporting bias cannot be ruled 
out.
 In conclusion, this systematic review and meta-analysis indicates that symptoms of 
anxiety and depression are prevalent in paediatric IBD, with comparable pooled prevalence 
rates of anxiety symptoms and depressive symptoms (16.4% and 15.0%). Due to high 
heterogeneity in used instruments and cut-offs, results must be interpreted with caution. To 
gain better insight into the prevalence of anxiety and depressive symptoms it is necessary 
to systematically screen paediatric IBD patients with the same validated instruments, using 
the same cut-offs. More studies are necessary to determine the prevalence of anxiety/
depressive disorders using a standardized psychiatric interview following DSM criteria. 
To assess whether certain subgroups are more at risk than others, it is advised to use the 
same validated methods of assessing clinical disease activity, and to include objective 
inflammatory parameters (such as CRP, faecal calprotectin).
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APPENDICES
Appendix 1. Search strategies for all databases
Embase.com
(‘inflammatory bowel disease’/exp OR ((inflamma* NEAR/3 bowel* NEAR/3 disease*) OR ibd 
OR crohn* OR (ulcer* NEAR/3 (colit* OR colorectit*)) OR Ileocolit* OR (Terminal* NEAR/3 
Ileitis)):ab,ti) AND (‘anxiety’/de OR ‘anxiety disorder’/exp OR ‘fear’/de OR ‘depression’/exp 
OR ‘antidepressant agent’/de OR ‘cognitive therapy’/de OR ‘emotion’/de OR (anxi* OR fear* 
OR depressi* OR panic* OR (cogniti* NEAR/3 therap*) OR emotion* OR antidepress*):ab,ti) 
AND (child/exp OR adolescent/exp OR ‘young adult’/de OR adolescence/exp OR ‘child 
behavior’/de OR ‘child parent relation’/de OR pediatrics/exp OR childhood/exp OR ‘child 
development’/de OR ‘child growth’/de OR ‘child health’/de OR ‘child health care’/exp OR 
‘child care’/exp OR ‘childhood disease’/exp OR ‘child psychiatry’/de OR ‘child psychology’/
de OR ‘pediatric ward’/de OR ‘pediatric hospital’/de OR (adolescen* OR infan* OR child* OR 
kid OR kids OR teen* OR boy* OR girl* OR minors OR underag* OR (under NEXT/1 (age* OR 
aging)) OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* 
OR prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR highschool* OR 
((young OR early*) NEAR/3 (adult* OR women OR men OR woman OR man))):ab,ti) 
Medline ovid 
(exp “Inflammatory Bowel Diseases”/ OR ((inflamma* ADJ3 bowel* ADJ3 disease*) OR ibd 
OR crohn* OR (ulcer* ADJ3 (colit* OR colorectit*)) OR Ileocolit* OR (Terminal* ADJ3  Ileitis)).
ab,ti.) AND (exp “anxiety”/ OR exp “Anxiety Disorders”/ OR “fear”/ OR “depression”/ OR 
“Depressive Disorder”/ OR “Depressive Disorder, Major”/ OR “Antidepressive Agents”/ 
OR “Cognitive Therapy”/ OR “emotions”/ OR (anxi* OR fear* OR depressi* OR panic* OR 
(cogniti* ADJ3 therap*) OR emotion* OR antidepress*).ab,ti.)  AND (exp Child/ OR exp 
Infant/ OR exp Adolescent/ OR exp “Child Behavior”/ OR exp “Parent Child Relations”/ 
OR exp “Pediatrics”/ OR exp “Child Welfare”/ OR “Child Development”/ OR exp “Child 
Health Services”/ OR exp “Child Care”/ OR “Child Psychiatry”/ OR “Psychology, Child”/ OR 
“Hospitals, Pediatric”/ OR (adolescen* OR infan* OR child* OR kid OR kids OR teen* OR boy* 
OR girl* OR minors OR underag* OR (under ADJ age*) OR juvenil* OR youth* OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* 
OR school* OR preschool* OR highschool* OR ((young OR early*) ADJ3 (adult* OR women 
OR men OR woman OR man))).ab,ti.) 
Psycinfo ovid 
(((inflamma* ADJ3 bowel* ADJ3 disease*) OR ibd OR crohn* OR (ulcer* ADJ3 (colit* OR 
colorectit*)) OR Ileocolit* OR (Terminal* ADJ3  Ileitis)).ab,ti.) AND (exp “depression”/ OR exp 
“Anxiety Disorders”/ OR “fear”/ OR “Depression (Emotion)”/ OR “Major Depression”/ OR 
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“Antidepressant Drugs”/ OR “Cognitive Therapy”/ OR “emotions”/ OR (anxi* OR fear* OR 
depressi* OR panic* OR (cogniti* ADJ3 therap*) OR emotion* OR antidepress*).ab,ti.)  AND 
(100.ag.  OR (adolescen* OR infan* OR child* OR kid OR kids OR teen* OR boy* OR girl* OR 
minors OR underag* OR (under ADJ age*) OR juvenil* OR youth* OR kindergar* OR puber* 
OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* 
OR preschool* OR highschool* OR ((young OR early*) ADJ3 (adult* OR women OR men OR 
woman OR man))).ab,ti.) 
Cochrane 
(((inflamma* NEAR/3 bowel* NEAR/3 disease*) OR ibd OR crohn* OR (ulcer* NEAR/3 (colit* 
OR colorectit*)) OR Ileocolit* OR (Terminal* NEAR/3  Ileitis)):ab,ti) AND ((anxi* OR fear* OR 
depressi* OR panic* OR (cogniti* NEAR/3 therap*) OR emotion* OR antidepress*):ab,ti) 
AND ((adolescen* OR infan* OR child* OR kid OR kids OR teen* OR boy* OR girl* OR minors 
OR underag* OR (under NEXT/1 (age* OR aging)) OR juvenil* OR youth* OR kindergar* OR 
puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR 
school* OR preschool* OR highschool* OR ((young OR early*) NEAR/3 (adult* OR women 
OR men OR woman OR man))):ab,ti) 
Web of science   
TS=((((inflamma* NEAR/2 bowel* NEAR/2 disease*) OR ibd OR crohn* OR (ulcer* NEAR/2 
(colit* OR colorectit*)) OR Ileocolit* OR (Terminal* NEAR/2  Ileitis))) AND ((anxi* OR fear* 
OR depressi* OR panic* OR (cogniti* NEAR/2 therap*) OR emotion* OR antidepress*))  AND 
((adolescen* OR infan* OR child* OR kid OR kids OR teen* OR boy* OR girl* OR minors OR 
underag* OR (under NEAR/1 (age* OR aging)) OR juvenil* OR youth* OR kindergar* OR 
puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR 
school* OR preschool* OR highschool* OR ((young OR early*) NEAR/2 (adult* OR women 
OR men OR woman OR man)))) )
Google scholar
“inflammatory bowel disease”|crohn|”ulcerative colitis” 
anxiety|fear|depression|depressive|emotion|antidepressants 
adolescents|adolescence|infants|children|”young|early adulthood|adults|women|men”
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Appendix 2. Quality/risk of bias checklist
Method 
(max. 2 points)
Clearly stated aim/research question (yes = 1 point)
Clearly stated outcome(s) (yes = 1 point)
Recruitment 
(Max. 9 points)
Clearly defined in- and exclusion criteria (yes = 1 point)
Convenience sample (0 points) vs. systematic sampling (consecutive, random, registries: 1 
point) 
Response rate reported (Not reported = 0, less < 50% = 1 point, 50-75% = 2 points, > 75% = 
3 points)
Reasons for non-participation described (yes =1 point)
External validity (monocenter = 0 points, multicenter = 1 point, multicenter and mixed 
[tertiary AND community hospitals] = 2 points)
Study population clearly described? (e.g. age, ethnicity, gender) (yes = 1 point)
Control group?
(Max. 3 points)
Normative data (with ref. and correct language/country; 3 points)
Normative data (with ref. but other language/country; 2 point)
Normative data (otherwise; e.g. not specified, no ref, etc.; 1 point)
OR
Both healthy controls and chronically ill controls (3 points)
Healthy controls (2 points)
Other chronically ill controls (1 point)
Sample Size IBD patients
(Max. 4 points)
Interpretation (low <150 = 1 points – medium 150-250 = 2 point – high >250 = 3 points)1
Power calculation or justification of sample size (yes = 1 point)
Measures IBD activity (max. 3 
points)
Disease activity index (e.g. PCDAI/PUCAI/PGA) (1 point)  
Inflammatory parameters (CRP, ESR, calprotectin) (1 point)
Endoscopy with severity scoring (1 point)
Measures of anxiety and 
depression
(Max. 3 points)
Screening  performed with validated self-report scales (1 point)
Diagnostic interview / DSM or ICD 10 codes (1 point)
Additional parent- or caregiver-report (1 point)
Confounders
(Max. 3 points)
‘Taken into account with regard to anxiety/depression prevalence’
Disease activity taken into account (1 point)
IBD subtype taken into account (1 point)
Objectified prior psychiatric history taken into account (1 point)
Maximum score: 27
1  Based on Arya et al. 2012 – Sample Size Estimation in Prevalence Studies
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Appendix 3. Funnel and Doi plots for anxiety and depressive symptoms
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EDITORIAL:
ANXIETY AND DEPRESSION IN INFLAMMATORY BOWEL DISEASE
Antonina A. Mikocka-Walus, Simon R. Knowles
Anxiety and depression are common comorbidities in patients with inflammatory bowel 
disease (IBD), with 19% of patients reporting symptoms of anxiety and 21% of depression, 
as compared to 9% and 13%, respectively, in healthy controls.1 Anxiety and depression have 
been associated with clinical recurrence in adults with IBD.2 Bidirectionality of IBD and mood 
disorders has also been proposed in adults, with IBD activity at baseline associated with an 
almost six-fold increase in future risk for anxiety, and anxiety at baseline (in quiescent IBD) 
linked to future flares, steroid prescriptions and escalation of therapy.3
 Approximately 25% of IBD cases are diagnosed in paediatric populations,4 with 19% 
of incident cases occurring in the first decade of life,5 and poorer outcomes in those with 
early onset IBD.6 While paediatric IBD is now becoming fairly common, much less systematic 
knowledge is available on anxiety and depression in children with IBD than in adults. The 
excellent systematic review with meta-analysis by Stapersma et al is therefore timely.7
 Analysing 28 studies (n = 8107) published between 1994-2017, they7 showed the 
pooled prevalence of anxiety symptoms to be 16.4% (95% CI: 6.8%-27.3%), of anxiety disorders 
to be 4.2% (95%CI: 3.6%-4.8%), of depressive symptoms to be 15.0% (95% CI: 6.4%-24.8%), and 
of depressive disorders to be 3.4% (95% CI: 0%-9.3%). Except for anxiety disorders, significant 
heterogeneity was noted among the studies, and there were fewer studies reporting disorders 
as opposed to symptoms, which is consistent with previous systematic reviews.1,8
 Reporting anxiety/depression symptoms and disorders separately is a strength of 
the present review. The differences between the two are frequently ignored both in practice 
and in academic papers. Symptoms are derived from screening measures such as the Child 
Depression Inventory, while disorders are typically established during a psychological or 
psychiatric interview, which is more costly and time-consuming, and thus less often used in 
research. Symptoms are common but, as shown7, are not disorders in most cases. This is a 
reassuring finding for clinicians. Nevertheless, the symptoms of anxiety and depression are 
a sign that there is a need for psychological support and, if this can be provided, there is a 
good chance they will not escalate to a diagnoseable psychological disorder.
 As the rates of anxiety and depression are lower in children than in adults,1,7,8 paediatric 
IBD clinics may be ideally situated to provide biopsychosocial integrated care which could 
offer support not only for IBD symptoms and non-intestinal inflammatory issues but also, 
holistically, for overall wellbeing. Studies on psychological therapy, while limited in number, 
show higher efficacy in children with IBD than adults,9 further supporting early psychological 
interventions in IBD. While the impact of anxiety/depression on dis- ease course in 
paediatric IBD was outside the scope of the recent review,7 it sends an important message 
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to clinicians and policymakers working in IBD: it is time to go beyond treating the bowel in 
our approaches to IBD care.
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EDITORIAL:  
ANXIETY AND DEPRESSION IN INFLAMMATORY BOWEL DISEASE – 
AUTHOR’S REPLY
Gertrude van den Brink, Luuk Stapersma, Eva M. Szigethy, Elisabeth M.W.J. Utens, 
Johanna C. Escher
We thank Mikocka-Walus & Knowles1 for their editorial about our systematic review and 
meta-analysis on anxiety and depression in children and adolescents with inflammatory 
bowel disease (IBD).2 Indeed, anxiety and depression are common in IBD, and the bidirectional 
relationship between anxiety/depression and intestinal inflammation can be explained 
in terms of the “brain-gut-axis”.3, 4 In adult (and less so in pediatric) IBD, the association 
between anxiety/depression and clinical recurrence of IBD has been confirmed.5, 6 In almost 
25% of the patients, IBD presents in childhood or adolescence with a disease course often 
more severe compared to adults.7,8 In addition, adolescence is a challenging life phase with 
many biological and psychosocial changes. IBD disrupts normal psychosocial development, 
and increases the vulnerability to developing anxiety/depression. Furthermore, it is known 
that anxiety/depression in adolescence is associated with anxiety/depression in adulthood9, 
10, affecting quality of life, work participation and socioeconomic status11 with subsequently 
high societal costs.12
 There are several ways to integrate psychosocial support in the care for (paediatric) 
IBD patients. First, for early detection, patients should be regularly screened for anxiety/
depressive symptoms. In our Dutch cohort we systematically screened 374 IBD patients, 
aged 10-25 years, and found that 47% suffered from symptoms of anxiety and/or depression, 
with the highest prevalence of anxiety13, and females and patients with active disease having 
the highest risk. Ideally, mental health screening is done routinely in the outpatient clinic 
using a short and easy-to-use screening tool. Second, we fully agree with Mikocka-Walus 
and Knowles that in case of elevated symptoms, a psychiatric interview should check if 
symptoms are mild/subclinical or severe as in a clinical disorder. It is important to make this 
difference in order to determine the best treatment strategy. Third, mental health specialists 
should be part of the multidisciplinary IBD team for young IBD patients, to evaluate the 
outcome of screening and provide psychosocial care if necessary.
 In paediatric IBD, Szigethy et al. found promising results of two psychological 
therapies in obtaining remission of clinical depression (cognitive behavioral therapy [CBT]: 
67.8%, and supportive non-directive therapy: 63.2%).14 However, in our recently published 
multicenter trial we did not find an additional effect of CBT over care-as-usual in improving 
subclinical anxiety and depressive symptoms in 10-25-year-old IBD patients directly post 
treatment15, as patients in both groups improved. Whether psychosocial interventions 
also have an effect on inflammatory disease course remains questionable. In conclusion, 
future studies investigating anxiety and depression in paediatric IBD should use validated 
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instruments cross-culturally, and, importantly, with similar cut-offs. For patients with 
subclinical anxiety/depression, screening and monitoring may be sufficient to prevent their 
development into disorders, but this group could also benefit from e-health (internet-CBT) 
interventions. Patients with clinical anxiety/depression should be referred for CBT. Future 
research will unravel the “dose” and modality of CBT that should be provided to patients 
with (sub)clinical anxiety/depression and the long-term effects of CBT on the course of 
disease.
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CHAPTER 3
ABSTRACT
Introduction
Adolescents with inflammatory bowel disease (IBD) show a higher prevalence of depression 
and anxiety, compared to youth with other chronic diseases. The inflammation-depression 
hypothesis might explain this association and implies that treating depression can decrease 
intestinal inflammation and improve disease course. The present multicentre randomised 
controlled trial (RCT) aims to test the effectiveness of an IBD-specific Cognitive Behavioural 
Therapy protocol in reducing symptoms of subclinical depression ànd anxiety, while 
improving quality of life (QoL) and disease course in adolescents with IBD.
 
Methods and analysis
Adolescents with IBD (10-20 years) from seven hospitals undergo screening (online 
questionnaires) for symptoms of depression and anxiety. Those with elevated scores of 
depression (CDI ≥ 13 or BDI-II ≥ 14) and/or anxiety (SCARED: boys ≥ 26, girls≥ 30) receive a 
psychiatric interview. Patients meeting criteria for depressive/anxiety disorders are referred 
for psychotherapy outside the trial. Patients with elevated (subclinical) symptoms are 
randomly assigned to medical care-as-usual (CAU; n=50) or CAU plus IBD-specific CBT (n=50). 
Main outcomes: 1) reduction in depressive and/or anxiety symptoms after three months, 2) 
sustained remission for 12 months. Secondary outcomes: QoL, psychosocial functioning, 
treatment adherence. In addition, we will assess inflammatory cytokines in peripheral blood 
mononuclear cells and whole blood RNA expression profiles. For analysis, multilevel linear 
models and Generalized Estimating Equations will be used. 
 
Ethics and dissemination
The Medical Ethics Committee of the Erasmus MC approved this study. If we prove that 
this CBT improves emotional well-being as well as disease course implementation is 
recommended. 
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BACKGROUND
Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]) is a chronic 
relapsing inflammatory disorder of the intestine, with increasing incidence and prevalence 
worldwide.1 Patients have abdominal pain, bloody diarrhea, often accompanied by systemic 
symptoms such as lack of appetite, weight loss and fatigue. IBD has a fluctuating course, 
with relapses (increased disease activity) and periods of clinical remission. In up to 25% 
percent of patients, IBD manifests during late childhood and adolescence.2-4 Adolescence is 
a challenging life phase, with significant psychological, physical and social changes. Having 
IBD during adolescence is a threat to healthy psychosocial development, making transition 
to adulthood more difficult. 
 Adolescent IBD patients frequently experience psychological and social problems.5 
They often have low self-esteem and report stress concerning their disease and future.6 
In addition, their quality of life is reduced,2, 7, 8 due to the unpredictable course of disease, 
embarrassing symptoms, frequent hospital visits or admissions and (side effects of) medical 
treatment. Furthermore, the possible extra intestinal manifestations (EIM) (e.g. Primary 
sclerosing cholangitis (PSC), arthritis), complications (e.g. strictures) and surgical treatments 
(e.g. resections) reduce quality of life significantly.2, 8-12
 Depressive symptoms are common, and occur in 20-40% of adolescents with IBD.13-
18 Anxiety, reported in 30-50% of IBD adolescents, is even more common.7, 19 In many young 
patients, symptoms of both depression and anxiety occur together.20, 21 Not surprisingly, 
early onset of mental health problems can predict poor long-term medical and psychological 
outcome.22-24
 Taken together, it is clear that psychological problems are often found in young 
IBD patients. The inflammation-depression hypothesis has been proposed to explain the 
association between psychological problems and IBD, and implies that treating emotional 
symptoms can decrease intestinal inflammation and thus improve disease course.25 This 
hypothesis will be discussed in detail later in this introduction.
Factors associated with depression and anxiety in IBD
Medical, psychological and family factors are associated with depression and anxiety in 
IBD and can influence the effectiveness of treatment of emotional problems in IBD. Known 
medical factors are: being recently diagnosed with IBD,26 a diagnosis of Crohn’s disease 
(versus ulcerative colitis),27 a history of surgery,27, 28 active disease,26-32 non-adherence to 
therapy 31 and IBS (like) symptoms.33 Psychological factors are: high levels of perceived 
stress,26 negative cognitive coping,15 low self-esteem 8, 34 and sleep disturbance.32 Family 
factors are: parental stress,35, 36 low socio economic status,26, 27, 31 stressful life events37 and 
unhealthy family functioning.10, 34, 37 In pediatric patients, active disease15, 18, 19, 38, 39 and low 
socio-economic status15 are associated with depression and/or anxiety.
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 In the opposite direction, emotional problems have also been shown to influence 
disease activity. Psychological stress can trigger a relapse in IBD30, 40-44 and lead to a more 
difficult-to-treat (refractory) disease.30 Moreover, emotional problems decrease the ability 
to cope with physical symptoms, increase the sensitivity to abdominal pain45, increase 
medical service use and decrease therapy adherence.16, 19, 29, 46, 47
 Altogether, these findings emphasize the existence of a bidirectional relationship 
between emotional problems and disease activity in patients with IBD. We therefore expect 
that early recognition and treatment of emotional problems is necessary to improve both 
mental health and the clinical course of disease. 
Inflammation-depression hypothesis 
The ‘inflammation-depression hypothesis’ or ´brain-gut hypothesis’ proposes that intestinal 
inflammation, by means of increased production of pro-inflammatory cytokines (e.g. 
tumour necrosis factor alpha (TNF-α)), is known to directly and indirectly affect the brain 
and thereby increase symptoms of depression.48 It is also suggested that psychological 
stress can increase depressive symptoms by increasing inflammation.25, 48, 49
 Most evidence for this hypothesis comes from animal studies in which experimental 
(psychological) stress has shown to induce and reactivate inflammation in colitis models.44 
It is suggested that these stress induced alterations in inflammation are mediated through 
changes in Hypothalamic-Pituitary-Adrenal (HPA) axis function and alterations in bacterial 
mucosal interactions.25, 44, 50-52 Similarly, human studies also show the pro-inflammatory 
effect of experimental25, 50 and (early) life stress52 and show elevated levels of inflammatory 
markers in depressed patients.49, 53-56
 There are few pediatric IBD studies examining the relationship between 
inflammation and depression.48 Furthermore, the brain-gut hypothesis mainly focuses 
on depression, the relation between inflammation and anxiety has been studied less 
extensively.57 Reviews by Hou et al. (2012) and Salim et al. (2012) show the existing evidence 
in animal models linking inflammation with anxiety.58, 59 In humans, a chronic anxiety state 
has been shown to negatively affect immune function and several studies report a positive 
correlation between anxiety and increased inflammatory markers.57-60 To our knowledge, 
little is known about the association between anxiety and inflammation in IBD. The present 
study will contribute to more understanding of this association.19, 31
CBT for adolescent IBD patients 
From all different psychotherapies, CBT is the most evidence based psychotherapy to reduce 
symptoms of anxiety and depression.12, 61, 62 
 For adolescents with IBD, Szigethy et al. developed a disease-specific CBT program 
called PASCET-PI (Primary and Secondary Control Enhancement Training – Physical Illness) 
(see intervention).63 They performed a RCT (2007) in adolescents with IBD and subclinical 
depression (total N=41). A 40% reduction in depressive severity in the PASCET-PI group 
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was found compared to the control group, receiving care as usual.17 These positive 
effects maintained 1 year after treatment.23 However, anxiety was not addressed. Only 
a few pediatric studies have integrated the clinical course of disease or disease activity 
as an outcome parameter. Szigethy et al. (2014) compared the effect of two different 
psychotherapies in pediatric IBD patients with (sub)clinical depression and found that both 
therapies had a significant impact in improving depression while CBT was associated with 
a greater reduction in disease activity.64 Reigada et al. (2013) showed in a CBT-pilot with 9 
(pediatric) patients and only comorbid anxiety, that 90% no longer had an anxiety disorder 
and half of the patients had a reduction in IBD severity.65 
 Although the aforementioned studies showed promising results, larger scale 
randomised studies are necessary to evaluate the longitudinal effect of CBT in pediatric 
IBD and to identify potential moderators of CBT success. To the best of our knowledge, 
at present there are no RCTs assessing simultaneously the effect of CBT on the two 
psychological outcomes (symptoms of depression or anxiety) and the clinical course of 
disease in adolescent IBD patients.
Aim and hypothesis 
The present study’s aim is to test the effectiveness of the disease specific CBT program (PASCET-
PI) in reducing symptoms of depression and anxiety in adolescents with inflammatory bowel 
disease in order to improve quality of life and to improve the clinical course of disease. 
We hypothesize that the PASCET-PI will reduce symptoms of both depression and anxiety, 
improve quality of life, reduce intestinal inflammation and will promote sustained clinical 
remission. 
METHODS AND DESIGN
Study design
This study is a prospective multi-center RCT, with baseline screening (T0) and three follow-
up assessments (T1 – T3). At baseline, adolescents (age 10-20 years) with IBD are screened 
for symptoms of depression and anxiety by means of an online questionnaire. Patients with 
elevated (subclinical) symptoms of depression and/or anxiety, but no clinical disorder, are 
randomised into two conditions. The control condition entails standard medical care-as-
usual (CAU); psychological care is not standard in the Dutch medical care system. Patients 
in the experimental condition receive standard medical care plus the disease-specific CBT 
(PASCET-PI). Patients are recruited from 2 academic hospitals and 5 community hospitals 
in the South-West region of the Netherlands.1 The design of this study is following the 
CONSORT guidelines for RCT’s.
1   Erasmus MC(-Sophia), Leiden University Medical Centre (LUMC), Haga (Juliana Children’s) Hospital, Reinier de Graaf Gasthuis, 
Maasstad Hospital, Amphia Hospital, and Albert Schweitzer Hospital. 
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Inclusion & exclusion criteria
Inclusion criteria are (1) patients between 10-20 years with diagnosed IBD and (2) informed 
consent provided by patients and (if applicable) parents. 
 Exclusion criteria are (1) mental retardation (parent report), (2) current 
psychopharmacological treatment for depression or anxiety, (3) current psychological 
treatment, (4) having received manualized CBT in the past year (at least 8 sessions), (5) 
insufficient mastery of the Dutch language, (6) diagnosed bipolar disorder, schizophrenia/
psychotic disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic 
or acute stress-disorder or substance use disorder, (7) selective mutism (physician reported), 
and (8) already participating in an intervention study. 
Recruitment and procedure 
See Figure 1 for an overview of the procedure. The treating (pediatric) gastroenterologist, 
nurse practitioner or physician assistant informs eligible patients about this study and hands 
out the written patient information. Parents are asked for informed consent if patients are 
younger than 18 years; if patients aged 18 years or older still live in their parents’ house, 
participation of parents is optional. After having given informed consent, patients (and 
parents) receive an e-mail with online questionnaires (see Table 1). If this screening shows 
self-reported subclinical symptoms of depression and/or anxiety, a patient is selected for 
further participation in the study. The Dutch versions of the Child Depression Inventory (CDI; 
ages 10-17),66 Beck Depression Inventory (BDI-II; ages 18-20)67 are used to assess depressive 
symptoms, whereas the Screen for Child Anxiety Related Disorders (SCARED; ages 10-20)68 
is used to assess anxiety symptoms. Subclinical depressive symptoms are defined as a 
score equal to or above the cut-off on the CDI (13)66 or the BDI-II (14).67 Subclinical anxiety 
symptoms are defined as 1) a score equal to or above the cut-off on the total scale of the 
SCARED (26 for boys, 30 for girls) or 2) a score equal to or above the cut-off (8) on one of 
the subscales.69 
 Next, in patients with these subclinical symptoms, the Anxiety Disorders Interview 
Schedule - Child and Parent Version (ADIS-C/P)70, 71 is administered by a research psychologist 
by telephone. Thereafter, the severity of depressive and/or anxiety symptoms is rated by 
the research psychologist using the Child Depression Rating Scale - Revised (CDRS-R; ages 
10-12),72 the Adolescent Depression Rating Scale (ADRS; ages 13-20),73 and the Pediatric 
Anxiety Rating Scale (PARS; ages 10-20).74 Patients are excluded for randomisation if they 
meet criteria for a clinical depressive or anxiety disorder on the ADIS-C/P and score equal 
to or above the clinical cut-off on the CDRS (20),75 ADRS (40),73 or PARS (18).74 Instead, 
these patients are referred for attuned psychological treatment, since it would be unethical 
to randomise them. For patients with subclinical depression and/or anxiety, the medical 
researcher performs the randomisation and arranges the medical baseline assessment. 
 All patients included in our study are well phenotyped with regard to duration 
and severity of disease, age at diagnosis, growth and pubertal development, clinical 
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course of disease, number and type of surgical interventions and hospitalizations. The 
Paris classification is collected at diagnosis and from the most recent endoscopy, to see if 
extension of disease has occurred.
Diagnos�c assessment
ADIS-C/P + CDRS-R / ADRS + PARS
Baseline screening
CDI / BDI-II + SCARED
IF subclinical symptoms
CDI ≥ 13 or BDI-II ≥ 14 or SCARED ≥ 26 (♂) / ≥ 30 (♀)
or SCARED subscale ≥ 8
Informed consent
Control groupInterven�on group
IF
ADIS-C/P not mee�ng criteria for clinical diagnosis
AND/OR
CDRS-R < 40 / ADRS < 20 OR PARS < 18
Randomisa�on & Medical baseline
Follow up a�er 3,6,12 months
Figure 1. Flow chart study design 
Abbreviations: ADIS-C/P, Anxiety Disorders Interview Schedule—Child and Parent Version; ADRS, Adolescent 
Depression Rating Scale; BDI-II, Beck Depression Inventory—Second Edition; CDI, Child Depression Inventory; 
CDRS-R, Child Depression Rating Scale—Revised; PARS, Pediatric Anxiety Rating Scale; SCARED, Screen for Child 
Anxiety Related Emotional Disorders.
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Randomisation and blinding
Patients are allocated to PASCET-PI or CAU group by means of computer-based, block 
randomisation, stratified per center. Sealed envelopes sequentially numbered are provided 
by the Department of Biostatistics of the Erasmus Medical Center. Participants assigned to 
the treatment group start treatment within a maximum of 4 weeks. 
 To prevent bias in the assessment, the research psychologist completing the 
diagnostic interviews at T0 – T3 is blinded for the outcome of randomisation. In addition, 
physicians assessing the patient’s disease activity are blinded. The patients and therapists 
are asked not to discuss the psychotherapy with the treating physician. Unblinding takes 
place if patients are excluded from the study (either by withdrawal or an acute need for 
care). 
Table 1. Outcomes, covariates, instruments and informants at each time point
Measurements T0
baseline
T1 
3 months
T2
6 months
T3
12 months
Main psychological outcomes
Change in symptoms of 
depression
CDI (10-17 year)
BDI-II (18-20 year)
ADIS-C/P
CDRS-R (10-12 year)
ADRS (13-20 year)
Pt
Pt
Pt, Pr
Ps
Ps
Pt
Pt
Pt, Pr
Ps
Ps
Pt
Pt
Pt, Pr
Ps
Ps
Pt
Pt
Pt, Pr
Ps
Ps
Change in symptoms of anxiety SCARED
ADIS-C/P
PARS
Pt
Pt, Pr
Ps
Pt
Pt, Pr
Ps
Pt
Pt, Pr
Ps
Pt
Pt, Pr
Ps
Main medical outcome
Sustained remission M
Secondary psychological outcomes
(Change in) Quality of life TACQOL (10-15 year)76
TAAQOL (16-20 year)77
IMPACT-III78 
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
(Change in) Psychosocial 
functioning
SSRS79
YSR (10-17 year)80 
ASR (18-20 year)81 
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Secondary medical outcomes
(Change in) Disease activity PUCAI (Ulcerative colitis)
PCDAI (Crohn’s disease)
Physician Global Assessment46 
M
M
M
M
M
M
M
M
M
M
M
M
Inflammatory markers CRP
ESR 
Fecal calprotectin
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Pt
Use of IBD medication Steroids, anti-TNF blockers, 
immunomodulators
M M M M
Necessity of surgical 
intervention
M M M M
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Psychological covariates
Demographic factors Rotterdam’s quality of life 
interview82 
Pr
Illness perception B-IPQ83 Pt Pt Pt Pt
Cognitive Coping Styles CERQ84 Pt Pt Pt Pt
Quality of sleep SSR85 Pt, Pr Pt, Pr Pt, Pr Pt, Pr
Parental anxiety and 
depression
DASS-2186 Pr
Life events Stress scale thermometer87
Life events questionnaire from 
CERQ
Pt, Pr
Pt
Pt, Pr Pt, Pr Pt, Pr
Pt
Family functioning FAD-GF88 Pr Pr Pr Pr
Medical covariates
Disease phenotypes Medical file analysis using Paris 
Classification
M
Treatment strategy Report of treating physician / 
medical file analysis
M M M M
IBS-like symptoms Questionnaire based on ROME III 
criteria IBS
M M M M
RNA expression profiles Blood sample M M
Cytokine levels in plasma & 
peripheral blood mononuclear 
cells (PMBCs) 
Blood sample M M
Abbreviations: Pr = parent report, Pt = patient (self-report), M = medical file/(pediatric) gastroenterologist, Ps 
= psychologist, CDI: Child Depression Inventory, BDI-II, Beck Depression Inventory – Second Edition, ADIS-C/P: 
Anxiety Disorders Interview Schedule - Child and Parent Version, CDRS-R: Child Depression Rating Scale - Revised, 
ADRS: Adolescent Depression Rating Scale, SCARED: Screen for Child Anxiety Related Emotional Disorders, 
PARS: Pediatric Anxiety Rating Scale, TACQOL: TNO-AZL questionnaire for Children’s health-related Quality Of 
Life, TAAQOL: TNO-AZL questionnaire for Adult health-related Quality Of Life, SSRS: Social Skills Rating System, 
YSR: Youth Self-Report, ASR: Adult Self-Report, PCDAI: Pediatric Crohn’s Disease Activity Index, PUCAI: Pediatric 
Ulcerative Colitis Activity Index ,CRP: C-reactive Protein, ESR: Erythrocyte Sedimentation Rate, B-IPQ: Brief - 
Illness Perception Questionnaire, CERQ: Cognitive Emotion Regulation Questionnaire, SSR: Sleep Self-Report, 
DASS-21: Depression, Anxiety and Stress Scale - 21-item version, FAD-GF: Family Assessment Device - General 
Functioning scale, IBS: Irritable Bowel Syndrome, PMBC: peripheral blood mononuclear cells.
Intervention
The PASCET-PI focuses on behavioural activation, cognitive restructuring and problem 
solving skills to change maladaptive behaviors, cognitions and coping strategies.61 Although 
originally designed to treat depression, most of the components of PASCET-PI are common 
for all CBT protocols, and have much overlap with components of CBT protocols specifically 
designed for anxiety (except for a fear hierarchy). Therefore, PASCET-PI can also be properly 
used for anxiety is. Disease-specific components, encompass the illness narrative (i.e. 
perceptions and experience of having IBD), therapy for pain and immune functioning, 
disease-specific psycho-education, social skills training and emphasis on IBD related 
cognitions and behaviors. Parents are provided with psycho-education about being a CBT-
coach helping their child coping with IBD.17, 89
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 The PASCET-PI consists of ten weekly sessions, delivered in three months (see Table 
2). 6 sessions are face to face (1 hour) and 4 sessions are telephone-sessions (30 minutes). 
Three parental sessions are held at the beginning, middle and end of treatment. For adult 
patients (≥ 18 year) who still live with their parents, this is recommended but voluntarily. 
Adult patients who do not live with their parents, participate without their parents. 
Thereafter, three 30-minute booster sessions (one per month) are provided by telephone. 
For the current study the original PASCET-PI was translated into the Dutch language. During 
this study patients will receive medical care according to the current guidelines. Psychological 
interventions ,other than the PASCET-PI for the intervention group, are not allowed.
Training and protocol adherence
Before providing the PASCET-PI, all licensed (Health Care) psychologists had followed a 
PASCET-PI training (developed and given by Eva M. Szigethy). To prevent protocol drifting 
they receive monthly PASCET-PI supervision by a senior clinical psychologist. All treatment 
sessions are audiotaped and a random 20% is rated by independent raters (senior clinical 
psychologist and master’s students Psychology) using the PASCET-PI Protocol Adherence 
Checklist (PPAC).63
Outcome measures
In Table 1 an overview of all variables and instruments at each time point is provided, with 
informants specified. All the psychological questionnaires used are (inter)nationally validated 
instruments, for which psychometric properties have been established in the Netherlands. 
Due to lack of space, instruments for the main psychological and medical outcomes are 
described in detail below. Instruments for secondary outcomes and covariates are mentioned 
only. Covariates will be analysed as either confounder, mediator, or moderator.
Main psychological outcome measures: changes in symptoms of depression and anxiety
Changes in symptoms of depression are assessed by the CDI and the BDI-II (to cover the 
complete age range). The CDI (used for ages 10-17) is a 27 item self-report scale (response 
categories 0-2: total score 0-54). It has excellent reliability (Cronbach’s alpha >.85) and 
moderate to good validity.66 The BDI-II (used for ages 18-20) is a 21 item self-report scale 
(response categories 0-3: total score 0-63). The BDI-II has excellent reliability (Cronbach’s 
alpha >.85) and good to excellent validity.67 In addition, (changes in) the severity of the 
depressive symptoms will be rated with the CDRS-R or the ADRS. The CDRS-R (used for ages 
10-12) is one of the most used rating scales for depression in children.72 The ADRS (used for 
ages 13-20) is developed specifically for adolescent depression.73 Changes in symptoms of 
depression are analysed using Z-scores of CDI and BDI-II, and CDRS-R and ADRS.
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Table 2. Outline of the PASCET-PI61
Session number Content of session
Session 1
Live
Introduction of ACT & THINK model and PASCET-PI, build alliance, psycho-education about IBD and 
depression or anxiety, illness narrative
Session 2
Live
Mood monitoring, explaining link between feelings, thoughts and behaviors, discussing feeling good 
and feeling bad, problem-solving
Session 3
By telephone
Link between behavior and feelings: Activities to feel better
Session 4
Live
Be Calm and Confident: relaxation exercises
Session 5
Live
Be Calm and Confident: positive self vs negative self, training social skills
Session 6
By telephone
Talents: developing talents and skills makes you feel better
Session 7
Live
Social problem solving, discussing the ACT skills and introduction of the THINK skills with discussing 
negative thoughts (Think positive)
Session 8
By telephone
Help from a friend, Identify the ‘Silver Lining’, and No replaying bad thoughts
Session 9
By telephone
Keep trying – Don’t give up, making several plans to use the ACT & THINK skills
Session 10
Live
Quiz on ACT & THINK model, discussing use of ACT & THINK skills in the future, updating illness 
narrative
Booster 1
By telephone
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & THINK skills
Booster 2
By telephone
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & THINK skills
Booster 3
By telephone
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & THINK skills
Family 1
Live
Parental view on IBD, family situation, psycho-education about IBD and depression or anxiety, 
introduction of ACT & THINK model and PASCET-PI
Family 2
Live
Parental view on progress, the ACT & THINK skills that are most effective for patient, expressing 
emotions within family, family communication, family stress game
Family 3
Live
Parental view on progress, family communication, parental depression or anxiety
 Changes in symptoms of anxiety are assessed by the SCARED (used for ages 10-
20), a 69-item screening instrument (response categories 0-2: total score 0-138) containing 
five subscales: general anxiety disorder, separation anxiety disorder, specific phobia, panic 
disorder, and social phobia. Cronbach’s alpha in the normative sample is .92 for the total 
score and between .66 and .87 for the subscales. Satisfactory concurrent validity has been 
shown.68 In addition, changes in the severity of anxiety symptoms will be rated with the 
PARS74, for which a high internal consistency has been reported.75
 For both depression and anxiety, the semi-structured interview ADIS-C/P (child and 
parent version) is administered. This diagnostic interview assesses diagnoses of depressive 
or anxiety disorders. DSM-IV symptoms are reviewed as either present (‘Yes’) or absent 
(‘No’).70, 71
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Main medical outcome measure: sustained remission at 12 months 
Sustained remission of IBD (absence of clinical relapse) is continued clinical remission 
with no relapses, without the need to escalate treatment, use of new induction treatment 
(except for the first 8 weeks after baseline), hospitalise or perform bowel surgery during 
the first 12 months. In case of active disease at the time of enrollment, sustained remission 
at 12 months means continued remission after 8 weeks of induction treatment starting at 
baseline. The Pediatric Crohn’s Disease Activity Index (PCDAI) and the Pediatric Ulcerative 
Colitis Activity Index (PUCAI) are used to score disease activity, and to score remission 
or relapse. The PCDAI (for Crohn’s Disease) is a validated, multi-item, physician-reported 
measure that comprises items on history (abdominal pain, stools, activity level), physical 
examination, height and weight, as well as laboratory parameters. Scores range from 0-100, 
with higher scores representing more active disease.90, 91 The PUCAI is a clinical index on 
disease activity for ulcerative colitis, scored by the physician, which has been validated in 
multiple international drug studies and comprises items on abdominal pain, rectal bleeding, 
stool frequency and consistency and activity level. Scores range from 0-85, with higher scores 
representing more active disease.92 For CD and UC patients, remission is defined as PCDAI 
<10, and PUCAI < 10 , respectively. For CD, relapse is defined as PCDAI >30 or an increase of 
>15 points and intensification of medical treatment. For UC, relapse is defined as PUCAI >34 
or an increase of ≥20 points for UC and intensification of medical treatment.90, 92, 93 
Secondary outcomes 
Secondary psychological outcomes are IBD-related quality of life and social functioning. 
 Secondary medical outcomes are disease activity, inflammatory markers in blood 
(C-reactive protein) and stool (calprotectin), use of IBD medication, and necessity of surgery 
(see Table 1).
Psychological and medical covariates 
Several factors associated with depression and anxiety in IBD (e.g. IBS-like symptoms, 
cognitive coping, parental stress) will be assessed because they can confound, mediate or 
moderate the effect of CBT on medical and psychological outcomes. Psychological covariates 
assessed are: illness perception, cognitive coping, quality of sleep, parental anxiety and/or 
depression, stressful life events, family functioning, and demographic factors. 
 Medical covariates encompass: disease phenotype, treatment strategy, disease 
activity, irritable bowel syndrome – like symptoms. Blood samples for immunological analysis 
will be drawn at baseline and after 3 months. For cytokine analysis, one EDTA tube (10 ml) 
will be drawn. Peripheral blood mononuclear cells (PBMCs) will be isolated and the plasma 
stored at -80C. Serum levels of pro-inflammatory cytokines (TNFα, Il-1, Il-1β, IL6, Il-8) will be 
assessed in plasma and supernatant of PBMCs in culture using respectively Cytokine Bead 
Analysis or ELISA. Furthermore, intracellular flow cytometry will be performed on in vitro 
stimulated PBMCs. For the RNA expression analysis, 2,5 ml venous blood will be collected in 
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PAXgene tubes (PreAnalytiX) and stored at –20°C until RNA extraction. Total cellular RNA will 
be extracted using the PAXgeneTM blood RNA kit (Qiagen) according to the manufacturer’s 
protocol. Gene expression profiles of pro- and anti-inflammatory genes in peripheral blood 
leucocytes will be assessed by Affymetrix U133 2.0 plus GeneChips.
Data Collection: follow up assessments 
Follow-up assessments take place at similar moments in the CBT and CAU group: three (T1), 
six (T2) and twelve (T3) months after randomisation. Each follow-up assessment consists of 
a regular medical visit and a psychological assessment (online questionnaires and diagnostic 
psychiatric interview) for the patient and, if applicable, parents. Patients with a clinical 
depressive or anxiety disorder (according to the same criteria as at baseline) or with an 
urgent need of psychological help, are excluded. To ensure participation throughout the 
study, patients receive a small reward after completing the last follow-up assessment.
Withdrawal
Patients can withdraw from the study without any consequences at any time for any reason. 
Those who withdraw are asked to complete the follow-up assessments.
Sample size
The target population is a group of approximately 350 IBD patients aged 10-20 years. Based 
on our previous studies concerning psychological problems in physically ill adolescents, the 
expected response rate will be above 80%,94 which corresponds with ± 280 patients. Based 
on literature, around 40% of adolescents with IBD will suffer from increased symptoms of 
depression or anxiety. Of those patients 10% will experience clinical depression or anxiety. 
Of the remaining ±100 patients 50 patients will be randomised to the treatment condition 
(CBT and CAU) and 50 to CAU. Sample size is based on two-tailed tests with size of α = 0.05 
using a repeated measures design with estimated correlation between time-points of 0.6. 
For the effect of CBT on symptoms of depression small to medium effect sizes are expected 
(Cohen’s d > 0.3),95, 96 for the effect on symptoms of anxiety medium to large effect sizes are 
expected (Cohen’s d > 0.6).97, 98 For the effect of CBT on sustainment of remission (no clinical 
relapse), a medium effect size is expected (ω = 0.3). Based on clinical experience in our 
hospital, in the CAU group 40% of patients will have sustained remission during 12 months. 
We hypothesize that 70% of patients will have sustained remission in the treatment group, 
reflecting a medium effect size. Using the target population of N = 100 and the estimated 
effects on depression, anxiety and sustainment of remission, we will have sufficient power 
(> 0.85).
Statistical analyses
The main analyses will be conducted using an intention-to-treat approach. Where appropriate, 
secondary analysis will be conducted using a per protocol basis. To test the effectiveness of 
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the PASCET-PI, we will compare the CBT group to the CAU group on 1) change in symptoms 
of depression and anxiety, and 2) sustained remission (absence of clinical relapse). For 1) 
multilevel linear models will be used, for 2) a Generalized Estimating Equation approach 
(GEE) will be used. Covariates (e.g. illness perception, cognitive coping, disease phenotypes, 
medical treatment strategy, inflammatory markers) will be included into the multilevel linear 
models and the GEE to identify which factors influence the effectiveness of the disease-
specific CBT. Multiple imputation will be used to deal with missing values.
DISCUSSION 
PASCET-PI has proven to be effective in reducing depression in adolescent IBD patients. 
However, the effect on anxiety, quality of life, and disease course has hardly been studied 
systematically. We will perform a prospective randomised controlled trial to examine the 
effectiveness of the PASCET-PI on both symptoms of depression and anxiety, on quality of 
life, and on clinical course of the inflammatory disease.
 This study has several strengths. First, as this study examines the effect of disease-
specific CBT on both psychological problems and disease course, it will provide insight in the 
complex interplay between inflammation and depression or anxiety in pediatric patients. 
We will study possible effects of reduction in depression or anxiety on cytokine expression 
and RNA expression profiles before and after CBT for subclinical depression or anxiety. 
Second, the disease-specific CBT will target both depression and anxiety, which is important 
as these problems have a negative impact on medication adherence and long-term 
medical and psychological outcomes.16, 19, 23, 24, 29, 45-47 Third, this study will provide important 
information about the prevalence of depression and anxiety among adolescent IBD patients 
in an European country such as the Netherlands, as compared to other studies that were 
performed mainly in the United States. Cultural differences may play a role in coping with 
disease-related anxiety and depression. Fourth, the PASCET-PI encompasses IBD-specific 
components, which matches patients’ IBD-related concerns and problems very well. If 
proven effective, the PASCET-PI can be very helpful for treatment of current and also for 
prevention of future psychological problems. A fifth strength of the study is the random and 
longitudinal nature of the design. Patients will be randomly assigned to the experimental 
or control condition. It is known that academic hospitals treat more severe IBD cases than 
community hospitals. Therefore, the randomisation will be stratified for academic versus 
community hospitals. Randomised patients will complete several follow-up assessments, 
which allows us to evaluate long-term effects of the PASCET-PI.
 In conclusion, there is a compelling need to improve the emotional wellbeing of 
the adolescent IBD patients who suffer from (subclinical) depression or anxiety symptoms. 
If the PASCET-PI proves to be effective, in treating both subclinical depression and anxiety, 
in improving quality of life, and in preventing clinical relapse, screening for and treatment of 
psychological problems in IBD adolescents should be incorporated in standard care.
375
STUDY PROTOCOL HAPPY-IBD 
REFERENCES
1  Baumgart DC, Bernstein CN, Abbas Z, et al. IBD Around the world: comparing the epidemiology, 
diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory 
Bowel Disease Task Force meeting. Inflamm Bowel Dis. 2011;17(2):639-644.
2  Greenley RN, Hommel KA, Nebel J, et al. A meta-analytic review of the psychosocial adjustment 
of youth with inflammatory bowel disease. J ped psychology. 2010;35(8):857-869.
3  Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin 
gastroenterol. 2004;18(3):509-523. 
4  Rabizadeh S, Dubinsky M. Update in pediatric inflammatory bowel disease. Rheum dis clin North 
Am. 2013;39(4):789-799.
5  Engelmann G, Erhard D, Petersen M, et al. Health-related quality of life in adolescents with 
inflammatory bowel disease depends on disease activity and psychiatric comorbidity. Child 
Psychiatry Hum Dev. 2015;46(2):300-307.
6  Lynch T, Spence D. A qualitative study of youth living with Crohn disease. Gastroenterol Nurs. 
2008;31(3):224-230; quiz 231-222.
7  Kilroy S, Nolan E, Sarma KM. Quality of life and level of anxiety in youths with inflammatory 
bowel disease in Ireland. J Pediatr Gastroenterol Nutr. 2011;53(3):275-279.
8  Ross SC, Strachan J, Russell RK, Wilson SL. Psychosocial functioning and health-related quality of 
life in paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53(5):480-488.
9  Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with 
inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(11):1755-1764.
10  Mackner LM, Greenley RN, Szigethy E, Herzer M, Deer K, Hommel KA. Psychosocial issues 
in pediatric inflammatory bowel disease: report of the North American Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr.2013;56(4):449-458.
11  Szigethy E, Craig AE, Iobst EA, et al. Profile of depression in adolescents with inflammatory 
bowel disease: implications for treatment. Inflamm Bowel Dis. 2009;15(1):69-74.
12  Szigethy E, McLafferty L, Goyal A. Inflammatory bowel disease. Pediatr Clin North Am. 
2011;58(4):903-920, x-xi.
13  Burke P, Meyer V, Kocoshis S, et al. Depression and anxiety in pediatric inflammatory bowel 
disease and cystic fibrosis. J Am Acad Child Adolesc Psychiatry. 1989;28(6):948-951.
14  Burke PM, Neigut D, Kocoshis S, Chandra R, Sauer J. Correlates of depression in new onset 
pediatric inflammatory bowel disease. Child Psychiatry Hum Dev. 1994;24(4):275-283.
15  Clark JG, Srinath AI, Youk AO, et al. Predictors of depression in youth with Crohn disease. J 
Pediatr Gastroenterol Nutr. 2014;58(5):569-573.
16  Reigada LC, Bruzzese JM, Benkov KJ, et al. Illness-specific anxiety: implications for functioning 
and utilization of medical services in adolescents with inflammatory bowel disease. J Spec 
Pediatr Nurs. 2011;16(3):207-215.
76
CHAPTER 3
17  Szigethy E, Kenney E, Carpenter J, et al. Cognitive-behavioral therapy for adolescents with 
inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry. 
2007;46(10):1290-1298.
18  Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel 
disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr. 
2004;39(4):395-403.
19  Reigada LC, Hoogendoorn CJ, Walsh LC, et al. Anxiety symptoms and disease severity in children 
and adolescents with crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(1):30-35.
20  Axelson DA, Birmaher B. Relation between anxiety and depressive disorders in childhood and 
adolescence. Depress Anxiety. 2001;14(2):67-78.
21  Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. 
Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel 
disease patients: a literature review. Inflamm Bowel Dis. 2007;13(2):225-234.
22  Copeland WE, Shanahan L, Costello EJ, Angold A. Childhood and adolescent psychiatric disorders 
as predictors of young adult disorders. Arch Gen Psychiatry. 2009;66(7):764-772.
23  Thompson RD, Craig A, Crawford EA, et al. Longitudinal results of cognitive behavioral treatment 
for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med 
Settings. 2012;19(3):329-337.
24  Loftus EV, Jr., Guerin A, Yu AP, et al. Increased risks of developing anxiety and depression in 
young patients with Crohn’s disease. Am J Gastroenterol. 2011;106(9):1670-1677.
25  Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 
2013;144(1):36-49.
26  Goodhand JR, Wahed M, Mawdsley JE, Farmer AD, Aziz Q, Rampton DS. Mood disorders in 
inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other 
factors. Inflamm Bowel Dis. 2012;18(12):2301-2309.
27  Bennebroek Evertsz F, Thijssens NA, Stokkers PC, et al. Do Inflammatory Bowel Disease patients 
with anxiety and depressive symptoms receive the care they need? J Crohns Colitis. 2012;6(1):68-
76.
28  Panara AJ, Yarur AJ, Rieders B, et al. The incidence and risk factors for developing depression 
after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharm Ther. 
2014;39(8):802-810.
29  Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a 
review of comorbidity and management. Inflamm Bowel Dis. 2009;15(7):1105-1118.
30  Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with 
inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Medicine. 
2004;66(1):79-84.
31  Nahon S, Lahmek P, Durance C, et al. Risk factors of anxiety and depression in inflammatory 
bowel disease. Inflamm Bowel Dis. 2012;18(11):2086-2091.
32  Keethy D, Mrakotsky C, Szigethy E. Pediatric inflammatory bowel disease and depression: 
treatment implications. Curr Opin Pediatr. 2014;26(5):561-567.
377
STUDY PROTOCOL HAPPY-IBD 
33  Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in 
inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated 
psychological factors. Am J Gastroenterol. 2002;97(2):389-396.
34  Engstrom I. Inflammatory bowel disease in children and adolescents: mental health and family 
functioning. J Pediatr Gastroenterol Nutr. Review. 1999;28(4):S28-33.
35  Gray WN, Graef DM, Schuman SS, Janicke DM, Hommel KA. Parenting stress in pediatric IBD: 
relations with child psychopathology, family functioning, and disease severity. J Dev Behav 
Pediatr. 2013;34(4):237-244.
36  Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two 
nationally representative Canadian surveys. Inflamm Bowel Dis. 2006;12(8):697-707.
37  Mackner LM, Crandall WV. Psychological factors affecting pediatric inflammatory bowel disease. 
Curr Opin Pediatr. 2007;19(5):548-552.
38  Szigethy EM, Youk AO, Benhayon D, et al. Depression Subtypes in Pediatric Inflammatory Bowel 
Disease. J Pediatr Gastroenterol Nutr. 2014 May;58(5):574-81.
39  Reed-Knight B, Lobato D, Hagin S, et al. Depressive symptoms in youth with inflammatory bowel 
disease compared with a community sample. Inflamm Bowel Dis. 2014;20(4):614-621.
40  Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based 
study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010;105(9):1994-2002.
41  Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohn’s disease: a biopsychosocial 
model. Gut. 2008;57(10):1386-1392.
42  Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative 
colitis: a longitudinal study. Am J Gastroenterol. 2003;98(10):2203-2208.
43  Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective 
study of patients enrolled in remission. Am J Gastroenterol. 2000;95(5):1213-1220.
44  Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and 
therapeutic implications. Gut. 2005;54(10):1481-1491.
45  Srinath AI, Goyal A, Zimmerman LA, et al. Predictors of abdominal pain in depressed pediatric 
inflammatory bowel disease patients. Inflamm Bowel Dis. 2014;20(8):1329-1340.
46  Ryan JL, Mellon MW, Junger KW, et al. The clinical utility of health-related quality of life screening 
in a pediatric inflammatory bowel disease clinic. Inflamm Bowel Dis. 2013;19(12):2666-2672.
47  Gray WN, Denson LA, Baldassano RN, Hommel KA. Treatment adherence in adolescents with 
inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/
depressive symptoms. J Ped Psychology. 2012;37(3):282-291.
48  O’Donovan A. Inflammation and depression: unraveling the complex interplay in inflammatory 
bowel disease. J Pediatr Gastroenterol Nutr. 2014;58(5):541-542.
49  Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of 
depression. Trends in immunology. Review. 2006;27(1):24-31.
50  Mawdsley JE, Rampton DS. The role of psychological stress in inflammatory bowel disease. 
Neuroimmunomodulation. Review. 2006;13(5-6):327-336.
78
CHAPTER 3
51  Reber SO. Stress and animal models of inflammatory bowel disease--an update on the role of 
the hypothalamo-pituitary-adrenal axis. Psychoneuroendocrinology. 2012;37(1):1-19.
52  Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social 
signal transduction theory of depression. Psychol bull. 2014;140(3):774-815.
53  Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of 
depression: biological mechanisms and the role of depression symptom profile. BMC medicine. 
2013;11:129.
54  Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, 
and pathophysiology. Neuropsychopharmacology. 2011;36(12):2375-2394.
55  Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-
6: a meta-analysis. Psychosomatic medicine. 2009;71(2):171-186.
56  Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. 
Biol Psychiatry. 2010;67(5):446-457.
57  Vogelzangs N, Beekman AT, de Jonge P, Penninx BW. Anxiety disorders and inflammation in a 
large adult cohort. Transl Psychiatry.2013;3:e249.
58  Hou R, Baldwin DS. A neuroimmunological perspective on anxiety disorders. Human 
psychopharmacology. Review. 2012;27(1):6-14.
59  Salim S, Chugh G, Asghar M. Inflammation in anxiety. Adv protein chem struct biol. 2012;88:1-
25.
60  Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, Simon NM. Broad Spectrum of 
Cytokine Abnormalities in Panic Disorder and Posttraumatic Stress Disorder. Depress Anxiety. 
2009;26(5):447-455.
61  Szigethy E, Weisz JR, Findling RL. Cognitive-Behavior Therapy for Children and Adolescents. 
Arlington: American Psychiatric Publishing, 2012:331-378
62  Thompson RD, Delaney P, Flores I, Szigethy E. Cognitive-behavioral therapy for children with 
comorbid physical illness. Child adoles psychiatr clin of N Am. 2011;20(2):329-348.
63  Szigethy E, Whitton SW, Levy-Warren A, DeMaso DR, Weisz J, Beardslee WR. Cognitive-behavioral 
therapy for depression in adolescents with inflammatory bowel disease: a pilot study. J Am Acad 
Child Adolesc Psychiatry. 2004;43(12):1469-1477.
64  Szigethy E, Bujoreanu SI, Youk AO, et al. Randomized efficacy trial of two psychotherapies for 
depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry. 
2014;53(7):726-735.
65  Reigada LC, Benkov KJ, Bruzzese JM, et al. Integrating illness concerns into cognitive behavioral 
therapy for children and adolescents with inflammatory bowel disease and co-occurring anxiety. 
J Spec Pediatr Nursing. 2013;18(2):133-143.
66  Timbremont B, Brat C, Roelofs J. Handleiding Children’s Depression Inventory (herziene versie). 
Amsterdam, NL: Pearson, 2008.
67  van der Does AJW. BDI-II-NL. Handleiding. De Nederlandse versie van de Beck Depression 
Inventory. Lisse, NL: Harcourt Test Publishers, 2002.
379
STUDY PROTOCOL HAPPY-IBD 
68  Muris PB, D.; Hale, W.; Birmaher, B.; Mayer, B. Vragenlijst over angst en bang zijn bij kinderen en 
adolescenten. Handleiding bij gereviseerde Nederlandse versie van de Screen for Child Anxiety 
Related Disorders. Amsterdam, NL: Boom, 2007.
69  Bodden DH, Bogels SM, Muris P. The diagnostic utility of the Screen for Child Anxiety Related 
Emotional Disorders-71 (SCARED-71). Behav Res Ther. 2009;47(5):418-425.
70  Siebelink BM, Treffers PDA. Anxiety Disorders Interview Schedule for DSM-IV-Child version, 
ADIS-C Handleiding. Amsterdam: Harcourt Test Publishers; 2001.
71  Silverman WK, Albano AM. Anxiety Disorders Interview Schedule for DSM-IV Child Version, Child 
Interview Schedule. San Antonio The Psychological Corporation; 1996.
72  Poznanski EO, Mokros H. Children’s Depression Rating Scale Revised (CDRS-R). Los Angeles 
Western Psychological Services; 1996.
73  Revah-Levy A, Birmaher B, Gasquet I, Falissard B. The Adolescent Depression Rating Scale 
(ADRS): a validation study. BMC Psychiatry. 2007;7:2.
74  The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad 
Child Adolesc Psychiatry. 2002;41(9):1061-1069.
75  Ginsburg GS, Keeton CP, Drazdowski TK, Riddle MA. The Utility of Clinicians Ratings of Anxiety 
Using the Pediatric Anxiety Rating Scale (PARS). Child Youth Care For. 2011;40(2):93-105.
76  Vogels T, Verrips GHW, Koopman HM, Theunissen NCM, Fekkes M, Kamphuis RP. Child Quality of 
Life Questionnaire (TACQOL). Manual parent and child form. Leiden, NL: LUMC-TNO; 1999.
77  Bruil J, Fekkes M, Vogels T, Verrips GHW. TAAQOL Manual. Leiden, NL: Leiden Center for Child 
Health and Pediatrics LUMC-TNO; 2004.
78  Loonen HJ, Grootenhuis MA, Last BF, de Haan RJ, Bouquet J, Derkx BH. Measuring quality of life 
in children with inflammatory bowel disease: the impact-II (NL). Qual Life Res. 2002;11(1):47-56.
79  Liber JM, Van Lang NDJ, Treffers PDA. Confirmatory factor analysis of the Dutch version of the 
Social Skills Rating System:Curium, Academic Center for Child and Adolescent Psychiatry, LUMC 
2006.
80  Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms & profiles. Burlington, VT: 
University of Vermont, Research Center for Children, Youth, & Families; 2001.
81  Achenbach TM, Rescorla LA. Manual for the ASEBA Adult Forms & Profiles. Burlington, VT: 
University of Vermont, Research Center for Children, Youth, & Families; 2003.
82  Utens EMWJ, van Rijen EHM, Erdman RAM, Verhulst FC. Rotterdam’s Kwaliteit van Leven 
Interview. Erasmus MC Rotterdam, Netherlands. Department of Child and Adolescent Psychiatry 
and Psychology, 2000.
83  Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J 
Psychosom Res. 2006;60(6):631-637.
84  Garnefski NK, Spinhoven, P. CERQ: Manual for the use of the Cognitive Emotion Regulation 
Questionnaire. A questionnaire for measuring cognitive coping strategies. Leiderdorp, NL.: 
Datec V.O.F.; 2007.
85  Owens JA, Spirito A, McGuinn M, Nobile C. Sleep habits and sleep disturbance in elementary 
school-aged children. J Dev Behav Pediatr. 2000;21(1):27-36.
80
CHAPTER 3
86  Beurs E, Van Dyck R, Marquenie LA, Lange A, Blonk RWB. De DASS: een vragenlijst voor het 
meten van depressie, angst en stress. Gedragstherapie. 2001;34:35-53.
87  Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for 
psychosocial distress in oncologic practice: use of the Distress Thermometer. Cancer. 
2008;113(4):870-878.
88  Epstein NB, Baldwin LM, Bishop DS. The McMaster family assessment device. J Mar Fam Ther 9, 
(2), 171-180.
89  Weisz JR, Thurber CA, Sweeney L, Proffitt VD, LeGagnoux GL. Brief treatment of mild-to-
moderate child depression using primary and secondary control enhancement training. J 
Consult Clin Psychol. 1997;65(4):703-707.
90  Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease 
activity index. J Pediatr Gastroenterol Nutr. 1991;12(4):439-447.
91  Turner D, Griffiths AM, Walters TD, et al. Mathematical weighting of the pediatric Crohn’s 
disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 
2012;18(1):55-62.
92  Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative 
colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423-432.
93  Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy 
for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 
2007;132(3):863-873; quiz 1165-1166.
94  Utens EM, Verhulst FC, Duivenvoorden HJ, Meijboom FJ, Erdman RA, Hess J. Prediction of 
behavioural and emotional problems in children and adolescents with operated congenital 
heart disease. Eur Heart J. 1998;19(5):801-807.
95  Klein JB, Jacobs RH, Reinecke MA. Cognitive-behavioral therapy for adolescent depression: 
a meta-analytic investigation of changes in effect-size estimates. J Am Acad Child Adolesc 
Psychiatry. 2007;46(11):1403-1413.
96  Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and 
adolescents: a meta-analysis. Psychol bull. 2006;132(1):132-149.
97  In-Albon T, Schneider S. Psychotherapy of childhood anxiety disorders: A meta-analysis. 
Psychotherapy and psychosomatics. 2007;76(1):15-24.
98  Reynolds S, Wilson C, Austin J, Hooper L. Effects of psychotherapy for anxiety in children and 
adolescents: a meta-analytic review. Clin Psychol Rev. 2012;32(4):251-262.


Clinical disease activity is associated 
with anxiety and depressive 
symptoms in adolescents and young 
adults with inflammatory bowel 
disease
Gertrude van den Brink, Luuk Stapersma, Lotte E. Vlug,  
Dimitris Rizopolous, Alexander G. Bodelier, Herbert van Wering,  
Pamela C.W.M. Hurkmans, Rogier J.L. Stuyt, Danielle M. Hendriks,  
Joyce A.T. van der Burg, Elisabeth M.W.J. Utens, Johanna C. Escher. 
Aliment Pharmacol Ther. 2018;48(3):358-369
CHAPTER 4
SUMMARY
Background 
Youths with inflammatory bowel disease (IBD) are at risk for developing anxiety and 
depressive symptoms with a reported 20-50% prevalence rate. 
Aim
This prospective study aimed to: 1) describe the prevalence and severity of anxiety and 
depressive symptoms in a large Dutch cohort of young IBD patients, and 2) identify 
demographic and clinical risk factors for anxiety and depression.
Methods
IBD patients (n=374; 10-25 years) were screened for anxiety, depression and quality of life 
using validated age-specific questionnaires. Patients with elevated scores for anxiety and/
or depressive symptoms received a diagnostic interview assessing psychiatric disorders. 
Demographic and clinical characteristics were retrieved from medical charts. Multiple logistic 
regression analysis was performed to identify risk factors for anxiety and/or depression.
Results
Patients (mean age 18.9 years, 44.1% male, Crohn’s disease 60.4%) had disease in remission 
(75.4%), or mild, moderate and severe clinical disease activity in respectively 19.8%, 2.7% 
and 2.1%. Mild anxiety/depressive symptoms were present in 23.5% and severe symptoms 
in 12.4% of patients. Elevated symptoms of either anxiety (28.3%), depression (2.9%) or 
both (15.8%) were found and did not differ between adolescents (10-17 years) and young 
adults (18-25 years). Active disease significantly predicted depressive symptoms (Odds Ratio 
(OR) 4.6 [95% Confidence Interval [CI] 2.4-8.8], p<0.001). Female gender (OR 1.7 [95%CI 1.1-
2.7]), active disease (OR 1.9 [95%CI 1.1-3.2]) and a shorter disease duration (OR 1.3 [95%CI 
0.6-1.0) (all p<0.025) significantly predicted anxiety and/or depressive symptoms. 
Conclusions
Considering the high prevalence of anxiety and depressive symptoms, psychological 
screening is recommended in young IBD patients. Screening facilitates early recognition 
and psychological treatment. Female patients and patients with active disease are the most 
vulnerable. 
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INTRODUCTION
Inflammatory bowel disease (IBD; Crohn’s disease (CD) and ulcerative colitis (UC)) is a chronic 
relapsing inflammatory disorder of the intestine, with rising incidence, in the United States 
as well as in Europe.1 In up to 25% of patients IBD develops and manifests during childhood 
or adolescence,2 a phase with significant physical, cognitive and psychosocial challenges.3
 A chronic disease, at this age, is a threat to a healthy psychosocial development.4 
It has been observed that particularly adolescents with IBD are at risk for psychological 
problems such as anxiety and depression, and thereby decreased quality of life.5, 6 The 
bidirectional relationship between IBD and psychological problems has been described 
before and can be explained in terms of the ‘brain-gut’-axis, meaning that the presence 
of anxiety and/or depression can increase intestinal inflammation and may contribute to 
disease relapse, and vice versa: intestinal inflammation can negatively influence mood.7, 8 
 Symptoms of anxiety and/or depression are often found in paediatric IBD patients. 
Reported prevalence rates range from 20-50% for anxiety9-11 and 25-40% for depression.5, 
10, 12 Although some studies report lower rates13, prevalence in paediatric IBD seems to be 
higher compared to other chronic diseases.14, 15 In adult IBD patients, a recent systematic 
review showed similar prevalence rates,16 suggesting that psychological problems persist or 
arise in adulthood.17 As it is known that anxiety can precede depression, and anxiety and 
depressive symptoms often occur together18, it is worthwhile to study them simultaneously. 
In addition, combining adolescents and young adult patients in research is also important19, 
considering they are at a unique stage in their emotional, cognitive and social development. 
The impact of a chronic disease and the accompanied challenges in this stage are different 
from their paediatric or adult counterparts. 
 Insight in risk factors for anxiety and depression in young IBD patients is necessary 
to help health care professionals identify those at risk. It may assist in selecting patients 
that need psychological screening and/or treatment. In patients with emotional problems, 
improving psychological health is expected to lead to a decrease in IBD related morbidity,20 
reduced health care utilisation21 and improvement of quality of life.21 
 Previous studies report a variety of risk factors for anxiety and depression. In adult 
IBD, active disease has been associated with both anxiety and depression.16, 22, 23 Other 
studies showed that female IBD patients23 and patients with lower socio economic status24 
are at risk for anxiety, and that a younger age at diagnosis is associated with depression.25 
In addition, prior surgery and perianal disease are correlated with both anxiety and 
depression.26 
 In paediatric IBD, the majority of studies also show active disease to be associated 
with both anxiety and depressive symptoms.5, 11, 21 Furthermore, female gender13, older age 
at diagnosis,5 fatigue,27 abdominal pain,12, 28 low socioeconomic status29 and steroid use5, 29 
were correlated with depression. In addition, female gender13 and abdominal pain11 have 
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shown a correlation with anxiety. In both paediatric and adult patients, disease type5 and 
anti-TNF-α use29 did not seem to be a risk factor for anxiety and depression. 
  The current study investigates the presence of and risk factors for anxiety and 
depressive symptoms in a unique large European cohort of young IBD patients, consisting 
of adolescents (10-17 years) and young adults (18-25 years) from regional as well as tertiary 
hospitals. In addition, this study provided a unique opportunity to also study the severity 
of anxiety and/or depressive symptoms. This study aims (1) to describe the prevalence and 
severity of anxiety and depressive symptoms; and (2) to identify demographic and clinical 
risk factors for symptoms of anxiety and/or depression. We hypothesise that clinical disease 
activity will be the greatest risk factor. Additionally, we expect female sex and steroid use to 
be associated with anxiety and/or depressive symptoms. 
MATERIALS AND METHODS
Design
In the present cross-sectional study a large cohort of adolescents (10-17 years) and young 
adults (18-25 years) with IBD were screened for anxiety and depressive symptoms and 
HRQOL. According to the World Health Organisation, adolescence encompasses individuals 
in the age group 10-19. In The Netherlands governmental legislation as well as medical 
practice uses the age of 18 years to define the start of adulthood. At 18, a patient has finished 
high school and is also transferred from paediatric to adult medical care. Therefore, in this 
study, the adolescent group consists of 10-17 year old patients and the young adult group 
of 18-25 year old patients. This study preceded a randomised controlled trial investigating 
the effectiveness of cognitive behavioural therapy in youth with IBD and subclinical anxiety 
and/or depression (NCT02265588). For the randomised trial, based on previous literature 
regarding the effectiveness of CBT for anxiety and depressive symptoms, medium to 
large effects for anxiety symptoms30 and medium effects for depressive symptoms31 were 
expected. This corresponds to j >0.40 for anxiety symptoms, and to j >0.30 for depressive 
symptoms. With 70 patients included in the randomised trial, the study had a power of 
>85% for anxiety symptoms (beta-error 0.14) and medium power for depressive symptoms 
(>60%), (beta-error 0.39) with an alpha-error of 0.05 (2 sided test).
 To include 70 patients in the randomised trial, a total of 350 patients needed to 
be screened. This was calculated based on the following: (a) 5% of patients will have on or 
more exclusion criteria (b) an expected participation rate of 80% (based on previous studies 
in chronically ill adolescents)32, (c) and expected prevalence rate of anxiety/depressive 
symptoms of 35%.5, 9, 11 Taking into account a 5% drop out rate, we aimed to include 375 
patients. 
 The following in- and exclusion criteria were used: (1) age 10 to 25 years and (2) 
diagnosis of IBD, according to the current diagnostic criteria .33-35 Exclusion criteria were: (1) 
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intellectual disability, (2) current treatment for mental health problems (pharmacological 
and/or psychological), (3) insufficient mastery of the Dutch language, (4) a diagnosis of 
selective mutism, bipolar disorder, schizophrenia, autism spectrum disorder, obsessive-
compulsive disorder, posttraumatic or acute stress-disorder, or substance use disorder, (5) 
cognitive behavioural therapy in the past year (at least 8 sessions), and (6) participation in 
another interventional study. 
 Initially, only patients aged 10-20 years were included. A few months after the start 
of recruitment, patients of 21-25 years were also included, to include the young adult group 
and to be able to include a sufficient number of patients for the randomised controlled trial.
 In-and exclusion criteria were assessed by the treating physicians. Insight into 
the numbers of patients with exclusion criteria was only provided by the paediatric 
departments (so for patients 10-17 years of age). In total 384 of these adolescents with 
IBD were treated in the participating hospitals. Of those, 174 patients gave consent to 
participate. Of the remaining 210 patients, 125 patients had no interest in participating in 
the study and 85 patients fulfilled the exclusion criteria (intellectual disability n=14, current 
psychological treatment n=33 (exact diagnosis not provided), autism spectrum disorder 
n=20, posttraumatic stress-disorder n=3, obsessive-compulsive disorder n=2, already 
participating in an intervention study n=9, insufficient mastery of the Dutch language n=4). 
This study conformed to the principles of the Declaration of Helsinki and was approved 
by the Institutional Review Board of the Erasmus Medical Center and of each participating 
center.
Procedure
Consecutive patients were recruited between October 2014 and September 2016 from the 
outpatient clinic in two academic hospitals and four community hospitals in the Southwest 
region of the Netherlands. We aimed to include a diverse cohort, including all stages of 
disease. However, the majority of patients was included at least 3 months after diagnosis 
(nine patients were included within 3 months after diagnosis). After written informed 
consent of patients and, if applicable, their parents or caregivers, an e-mail with a link to 
online questionnaires was sent. It was emphasised that results would be most valuable 
if patients and parents completed the questionnaires without help of their parents (and 
vice versa), and if they would give honest answers. Assistance was offered by the research 
team by email or telephone if necessary. In addition, it was stressed that irrespective of 
the outcome of the questionnaires, patients could decide whether or not to proceed in the 
randomised controlled trial. It was explained to patients that participation in the screening 
phase was valuable in itself, because it would increase insight in the prevalence of anxiety 
and depressive symptoms of adolescents and young adults with IBD and it would give 
patients insight in their own level of anxiety and depressive symptoms. 
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Measures 
Demographic characteristics
Gender and age were retrieved from the medical charts. Socioeconomic status was classified 
using the occupational level from the parents or, if patients lived on their own, patients 
themselves.36 
Clinical characteristics
Clinical disease activity was assessed by four validated instruments. For CD, the short 
Pediatric Crohn’s Disease Activity Index37 (10-20 years) and the Crohn’s Disease Activity 
Index38 (21-25 years) was used. For UC, the Paediatric Ulcerative Colitis Activity Index39 (10-
20 years) and the partial Mayo score40, 41 (21-25 years).To combine all four measures, the 
categorical predefined classifications remission, mild, moderate, and severe were used.
 Disease type, age at diagnosis, disease duration, presence of perianal disease at 
diagnosis, previous bowel surgery, current therapy, steroid dependence past three months 
and number of relapses the preceding year were retrieved from the medical charts. Relapse 
was defined as ‘physician reported relapse necessitating treatment intensification’. Disease 
location at diagnosis and extension of disease was assessed using the Paris or Montreal 
classification 42. We defined limited disease as ‘E1’ or ‘E2’ for UC and ‘L1’ for CD. Extensive 
disease was defined as ‘E3’ or ‘E4’ for UC and ‘L2’, ‘L3’ or ‘L4a/b’ for CD. The following 
inflammatory parameters were collected if available: C-reactive protein, Erythrocyte 
Sedimentation Rate, hemoglobin, haematocrit, leukocyte count, thrombocyte count and 
faecal calprotectin.
Anxiety and depression
Anxiety was assessed using the 69-item Screen for Child Anxiety Related Disorders (SCARED, 
for ages 10-20) and the anxiety scale of the Hospital Anxiety and Depression Scale (HADS-A, 
for ages 21-25), both self-report instruments. Five SCARED- subscales were used: general 
anxiety disorder, separation anxiety disorder, specific phobia, panic disorder, and social 
phobia (response categories 0-2: total score 0-138). Satisfactory reliability and validity have 
been reported.43 The cut-offs for elevated symptoms of anxiety were total SCARED score ≥ 
26 for boys, ≥ 30 for girls, or a SCARED-subscale score ≥ 8.44 The HADS anxiety scale consists 
of 7 items, rated on a 4-point scale (response categories 0-3; total score 0-21). Excellent 
reliability has been found. Patients had elevated symptoms of anxiety if they scored 8 or 
higher.45 Because initially only 10-20 year old patients were included, we chose to use the 
SCARED, which is validated up to 19 years of age46, also for 20 year old patients. Later, when 
21-25 year old patients were included as well, the HADS-A was added.
 Depression was assessed using the Child Depression Inventory (CDI, for ages 10-
17) and the Beck Depression Inventory, second version (BDI-II, for ages 18-25). The CDI is 
a 27-item self-report scale (response categories 0-2, total score 0-54). Good reliability and 
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validity of the Dutch version have been established and a CDI score of 13 or higher reflected 
elevated symptoms of depression.47 The BDI-II is a 21-item self-report scale (response 
categories 0-3, total score 0-63), with a score of 14 or higher indicating elevated symptoms 
of depression.48 It has excellent reliability and good to excellent validity.48 
Severity of anxiety and depression
In patients with elevated anxiety and/or depressive symptoms, severity was assessed by a 
(telephonic) psychiatric diagnostic interview performed by a trained psychologist (Anxiety 
Disorders Interview Schedule - Child and Parent Version (ADIS-C/P).49, 50 Severity of anxiety 
was rated using the Paediatric Anxiety Rating Scale (PARS; ages 10-20) 51 and the Hamilton 
Anxiety rating scale (HAM-A; ages 21-25)52. Depressive severity was rated using the Child 
Depression Rating Scale - Revised (CDRS-R; ages 10-12)53, the Adolescent Depression Rating 
Scale (ADRS; ages 13-20)54, and the Hamilton Depression Rating Scale (HAM-D ; ages 21-
25).55 For this study, we grouped the patients with anxiety and/or depressive symptoms, to 
describe the patients with ‘a psychological burden’. This group includes patients suffering 
from either anxiety symptoms or depressive symptoms, or both. The term ‘anxiety/
depressive symptoms’ is used to refer to this patient group. Anxiety/depressive symptoms 
were classified as ‘severe’ if they met the criteria for a clinical depressive or anxiety disorder 
on the ADIS-C/P and a score equal to or above the clinical cut-off on the CDRS (40)56, ADRS 
(20)54, or PARS (18).51 The remaining group of patients was classified as having subclinical or 
mild anxiety and/or depression. See Figure 1. 
Screening ques�onnaires anxiety and depression
Above cut oﬀ 
anxiety and/or depression?
Elevated symptoms anxiety and/or 
depression on ques�onnaires
Anxiety
SCARED (10-20 years)
HADS-A (21-25 years)
Below cut oﬀ 
anxiety ánd depression?
Depression
CDI (10-17 years)
BDI-II (18-25 years)
Psychiatric interview (ADIS-C) (10-25 years)
Clinical
anxiety/depressive
disorder
No clinical
anxiety/depressive
disorder
Subclinical / mild 
symptoms
Clinical / severe 
symptoms*
No 
symptoms
Figure 1. Flowchart screening anxiety/depression 
Note: Cut-off scores for each questionnaire are specified in the text * indicative of a disorder
Abbreviations: SCARED = Screen for Child Anxiety Related Emotional Disorders, HADS-A = Hospital Anxiety and 
Depression Scale – Anxiety scale, CDI = Child Depression Inventory, BDI-II = Beck Depression Inventory-second 
edition ADIS-C = Anxiety Disorders Interview Schedule for Children
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Health-related Quality of Life
Health-related Quality of Life (HRQoL) was assessed by the IBD-disease specific self-report 
questionnaires IMPACT-III (ages 10-20, because initially only 10-20 year old patients were 
included) and IBDQ (ages 20-25), both having good psychometric properties.57-60 The IMPACT-
III contains of 35 items (score 1-5; range 35-175) which cover six domains: IBD-related 
symptoms, systemic symptoms, emotional functioning, social functioning, treatment related 
concerns, and body image. The IBDQ contains 32 items (score 1-7; range 32-224) that cover 
four domains: bowel, systemic, social, and emotional functioning. For both questionnaires, 
a higher score reflects better quality of life. 
Statistical analysis
Frequency analyses were conducted to describe the prevalence of anxiety and depressive 
symptoms (aim 1). Exploratory tests (one-way ANOVA, Kruskal-Wallis and Chi-Square test) 
were conducted to provide insight in differences between patients with no, mild and severe 
anxiety and/or depressive symptoms. 
 Multiple imputation with chained equations (MICE) with ten imputations (m=10) 
was used to impute the missing values in the variable socio-economic status.61 Missing data 
on outcome variables were not imputed. Results for complete cases and multiple imputation 
analysis were compared. To compare the variables in the regression model to each other, 
the continuous variables were standardised and used in the model as z-scores.
 To identify risk factors for symptoms of anxiety and depressive symptoms (aim 2), 
we conducted four regression analyses with the following outcomes. I: absence/presence 
of anxiety/depressive symptoms, II: severity of anxiety/depressive symptoms, III: absence/
presence of anxiety symptoms and IV: absence/presence of depressive symptoms. Analysis III 
and IV were performed to investigate risk factors specific for anxiety or depressive symptoms. 
For analysis I, III and IV a binomial logistic regression and for analysis II a multinomial logistic 
regression was conducted. Subgroup analysis was performed for patients 10-17 and 18-25 
years. In the regression analysis, the α-level was adjusted for multiple comparison, considering 
Bonferroni correction is considered conservative62, it was set at p < 0.025. Adequacy of the 
models was assessed using the appropriate ”Goodness-of-Fit” tests. 
 Data analysis were performed using Statistical Package for the Social Sciences, 
Version 21.0 (IBM SPSS Statistics for Windows, Armonk, NY, USA) and the computing 
environment R for multiple imputation (R Development Core Team, 2016. R Foundation for 
Statistical Computing, Vienna, Austria). 
RESULTS
Patients characteristics
A total of 374 adolescents and young adults (mean age: 18.92 years, SD 4.13) completed the 
assessment. Almost fifty percent of patients were < 18 years of age. Most patients had CD 
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(60.4%) and the majority had inactive disease (75.4%), but 33.4% had relapsed in the year 
prior to this assessment. More than one third of the patients was receiving treatment with a 
biological (35.8%) and 285 patients (76.2%) had extensive disease. 16.3% received IBD-related 
surgery in the past, of which half had a resection of small and/or large intestine (7.5%) and half 
had abscess drainages, fistula surgery or balloon dilatations (8.8%). See Table 1. 
Table 1. Patient characteristics (N=374)
Mean ± SD or n (%)
Gender, Male  165 (44.1)
Age (years) (% <18 years)
Age at diagnosis (years) (% < 18 years)
Duration of disease (years) (Median;IQR)
18.92 ± 4.13 (45.5%)
15.40 ± 4.33 (71.4%)
2.45 (1.1-5.1)
Socioeconomic status (N = 346)         Low
Middle
High 
61 (17.6)
144 (41.6)
141 (40.8)
Type of disease       CD
UC
IBD-U
226 (60.4)
128 (34.2)
20 (5.3)
Paris/Montreal classification at diagnosis†: CD: location‡, (N = 226)
L1 
L2 
L3 
+ L4a/L4b 
CD: behaviour 
nonstricturing. nonpenetrating (B1)
stricturing. penetrating or both (B2B3)
perianal disease 
UC: extent (N = 148)§
limited: E1 + E2
extensive: E3 + E4
UC: severity. ever severe 
38 (16.8)
38 (16.8)
100 (44.2)
50 (22.1)
216 (95.6)
10 (4.4)
47 (20.8)
51 (34.5)
97 (65.5)
20 (13.5)
Clinical disease activity Remission
Mild 
Moderate 
Severe
282 (75.4)
74 (19.8)
10 (2.7)
8 (2.1)
Current medication use Aminosalicylates
Immunomodulators
Biologicals
Corticosteroids¶
Topical treatment¥  
No medication 
116 (31.0)
175 (46.8)
134 (35.8)
36 (9.6)
20 (5.3)
26 (7.0)
Steroid dependence past 3 months 55 (14.7)
Relapses preceding year 1 relapse
≥2 relapses
103 (27.5)
22 (5.9)
Bowel resection in history 28 (7.5) 
Extra intestinal Manifestations II 57 (15.2) 
Abbreviations: SD: standard deviation, IQR: interquartile range, CD: Crohn’s Disease, UC: ulcerative colitis, IBD-U: 
IBD-unclassified.
Notes: †UC includes IBD-U patients ‡L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: upper gastrointestinal tract 
proximal and L4b distal from Treitz ligament §E1: proctitis, E2: left sided colitis distal of splenic flexure, E3: 
extensive colitis distal of hepatic flexure, E4: pancolitis ¶prednisone (oral and intravenous) and budesonide (oral) 
¥ aminosalicylate or corticosteroid enemas ||EIM: involving skin (31.5%), eyes (1.75%), liver and biliary tracts 
(10.5%), joints (33.3%) and bones (28.1%)
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Prevalence of anxiety and depression 
372 patients completed the depression questionnaires (CDI and BDI), 373 the anxiety 
questionnaires (SCARED, HADS-A). Of the 371 patients with complete data on both anxiety 
and depression, 176 (47.4%) patients experienced elevated symptoms of anxiety and/or 
depression. Anxiety symptoms were more prevalent than depression: elevated symptoms 
of either anxiety, depression or both were found in respectively 106 (28.3%), 11 (2.9%) and 
59 (15.8%) patients. 195 patients (52.1%) did not show any elevated symptoms. Of the 371 
patients, 168 patients were included in the two tertiary hospitals, 204 in four community 
hospitals. Prevalence rates did not significantly differ between academic or community 
hospitals for elevated symptoms of either anxiety (27.5% vs 29.4%), depression (2.4% vs 
3.4%) or both (15.0% vs 16.7%) (χ2(3)=.98, p=0.808). Of the patients < 18 years, 34.9% 
showed elevated anxiety, compared to 23.2% in the ≥18 age group. This was not significantly 
different. For depression and anxiety/depression combined, differences between the <18 
and ≥18 age group were small and not significantly different. 
 Of the 131 patients with elevated anxiety, < 21 years of age (and who completed the 
SCARED questionnaire), 122 of 131 patients (93.1%) scored above the established cutoff for 
1 or more anxiety domains. Specified per domain, generalised anxiety was found in 45.8%, 
separation anxiety in 23.7%, specific phobia (consisting of animal phobia, blood phobia and 
situational phobia) in 55.7%, panic symptoms in 19.8% and social phobia in 48.8% of the 131 
patients. 
Health-related Quality of Life 
Mean IMPACT score (patients < 21 years, N=256) was 142.7 (±19.3 SD, range: 76-174) and 
mean IBDQ score (patients ≥21 years, N=110) was 178.7 (range: 97-224 [data not shown]).
Prevalence of mild and severe anxiety/depressive symptoms 
Of the 177 patients with elevated symptoms of anxiety/depression, 134 patients completed 
a psychiatric interview assessing severity of psychological symptoms. The other 43 patients 
did not consent to the interview, because they only consented to the questionnaires and/
or were not willing to participate in the larger research project, including the randomised 
controlled trial, for which the psychiatric interview was a necessary part. Clinical, severe 
symptoms were found in 46 (34.3%) and mild symptoms in 88 (65.6%) patients. Of the 46 
patients with clinical symptoms, 23 (50%) fulfilled the criteria for an anxiety disorder, 5 
(10.8%) for a depressive disorder, and 15 (32%) fulfilled the criteria for both anxiety and 
depressive disorders. The other three patients did not fulfill the criteria for an anxiety or 
depressive disorder, but severity of other psychological problems was clearly reported by 
parents during the psychiatric interview. One patient showed extreme rebellious behavior, 
the other irritability and tantrums. For the last patient, only parents reported depressed 
mood and signs of social and specific anxiety. In all three patients, family functioning was 
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severely disturbed and continuing in the randomised controlled trial was not ethical, so 
psychological help was provided directly after screening. 
Differences between patients with no mild and severe anxiety/depressive symptoms 
Exploratory analysis showed that clinical disease activity was significantly higher in patients 
with severe anxiety/depressive symptoms, compared to patients with mild (U = 1092.5, z = 
-5.1, p<0.001) and no anxiety/depressive symptoms (U = 2255.0, z = -6.8, p<0.001). Faecal 
calprotectin and Erythrocyte Sedimentation Rate were significantly higher in patients with 
severe anxiety/depressive symptoms compared to patients with no anxiety/depressive 
symptoms. See Tables 2 and 3 and Figure 2.
Table 2. Differences between patients with no, mild and severe symptoms of anxiety/
depression†  
NO
N = 195
MILD
N = 88
SEVERE
N = 46
p
Gender Female n (%) 97 (49.7) 58 (65.9) 34 (73.9) 0.002
Disease duration (years) Median; (IQR) 2.7; (1.3-6.1) 2.0; (1.0-4.8) 1.7;(0.9-3.6)  0.014
Disease activity Remission
Mild
Moderate
Severe
n (%)
n (%)
n (%)
n (%)
162 (83.1)
26 (13.3)
6 (3.1)
1 (0.5)
67 (76.1)
21 (23.9)
0 
0
16 (34.8)
21(45.7)
2 (4.3)
7 (15.2)
<0.001
Steroid use n (%) 13 (6.7) 9 (10.2) 9 (19.6) 0.025
Relapse preceding year No
1
>1
n (%)
n (%)
n (%)
137 (70.3)
49 (25.1)
9 (4.6)
57 (64.8)
27 (30.7)
4 (4.5)
22 (47.8)
17 (36.9)
7 ( 15.2)
0.025
HRQOL IMPACT-III (N=226) Mean ± SD 152.9 ± 13.9 138.4 ± 14.7 115.0 ± 17.4 <0.001
IBDQ (N=101) Mean ± SD 192.8 ± 16.9 164.5 ± 15.4 138.9 ± 26.6 <0.001
Abbreviations: IQR: interquartile range, SD: standard deviation, HRQOL: Health-related quality of life, IBDQ: 
Inflammatory Bowel Disease Questionnaire. 
Notes: †Total= N=329 (134/177 patients with elevated symptoms received the psychiatric interview, resulting in 
88 patients with mild and 46 patients with severe anxiety/depressive symptoms).
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Table 3. Inflammatory parameters in patients with no, mild and severe anxiety/depressive 
symptoms
NO
N = 195
MILD
N = 88
SEVERE
N = 46
p
C-Reactive protein (mg/L) available samples 154 73 37
median (IQR) 2.0 (1.0-5.0) 2.2 (0.7-6.0) 3.0 (1.0-9.0) 0.087
Hemoglobin (mmol/L) available samples 166 82 41
median (IQR) 8.2 (7.7-9.0) 8.2 (7.7-8.7) 7.9 (7.1-8.3) 0.011
Hemocrit (L/L) available samples 160 79 40
median (IQR) 0.41 (0.38-0.44) 0.40 (0.38-0.42) 0.39 (0.36-0.40) 0.024
Leukocytes (109/L) available samples 165 81 41
median (IQR) 6.7 (5.4-8.4) 5.8 (5.5-8.8) 7.2 (6.0-10.2) 0.362
Trombocytes (109/L) available samples 164 82 41
median (IQR) 296 (243.3-357.5) 311.5 (246.8-358.8) 326 (228.5-387.5) 0.671
Erythrocyte Sedimentation 
Rate (mm/h)
available samples
median (IQR)
89
7.0 (3.0-19.0)
52
6.0 (3.3-19.5)
23
16.0 (6.0-23.0) 0.047
Faecal calprotectin (µg/g) available samples 67 48 23
median (IQR) 106.0 (34.0 -645.0) 295.1 (30.8-807.8) 602.3 (163.0-1173.0) 0.037
Abbreviations: IQR: interquartile range 
Multiple regression analysis: risk factors for anxiety and depressive symptoms
Risk factors for anxiety/depressive symptoms 
Female patients (Odds Ratio (OR) 1.7 [95%CI 1.1-2.7], p=0.021) and patients with active 
disease (OR 1.9 [1.1-3.2], p=0.023) had higher odds of experiencing anxiety/depressive 
symptoms than male patients or patients in remission (see Table 4). Subgroup analysis 
showed that active disease (OR 3.07 [95%CI 1.3-7.3], p=0.011) and disease duration (OR 
0.66 [95%CI 0.5-0.9], p=0.018) were significantly associated with having anxiety/depressive 
symptoms in patients ≥18 years (data not shown). 
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Figure 2. 
(A) Patients with severe anxiety/depressive symptoms had more relapse preceding year compared to patients 
with mild or no anxiety/depressive symptoms. 
(B) A higher percentage of active disease was found patients with severe anxiety/depressive symptoms compared 
to patients with mild or no anxiety/depressive symptoms *p<0.05
Risk factors for mild and severe anxiety/depressive symptoms 
Overall multinomial logistic regression analysis showed that gender (χ2(2)=9.2, p=0.010) 
and disease activity (χ2 (2)=26.0, p<0.001) significantly influenced severity of anxiety/
depressive symptoms. Firstly, when comparing no to mild anxiety/depressive symptoms, 
analysis showed that female gender (OR 2.2 [95%CI 1.2-3.8], p=0.008) was associated with 
mild anxiety/depressive symptoms. Secondly, when comparing mild to severe anxiety/
depressive symptoms analysis showed that active disease (OR 7.1 [95%CI 2.8-17.7, p<0.001) 
was associated with severe anxiety/depressive symptoms (data not shown). Lastly, when 
comparing no to severe anxiety/depressive symptoms, analysis showed that active disease 
(OR 7.8 [95%CI 3.3-18.0], p<0.0001) was associated with severe anxiety/depressive 
symptoms.
Risk factors for anxiety symptoms
Female patients (OR 1.8 [95%CI 1.1-2.9], p=0.013) and patients with active disease (OR 1.9 
[95%CI 1.1-3.2], p=0.019) had higher odds of experiencing anxiety symptoms than male 
patients and patients in remission. See Table 4. Subgroup analysis showed that active 
disease was significantly associated with anxiety symptoms in patients ≥18 years (OR 2.6 
[95%CI 1.1-6.1], p=0.025) (data not shown). 
Risk factors for depressive symptoms
Patients with active disease had higher odds of having depressive symptoms, compared 
to patients in remission (OR 4.6 [95%CI 2.4-8.8], p<0.001) (See Table 4). Subgroup analysis 
showed that active disease was significantly associated with depressive symptoms in 
patients ≥18 years (OR 7.7 [95%CI 2.8-21.2], p<0.001) (data not shown).
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DISCUSSION
This study is unique in describing the prevalence, severity and risk factors of symptoms of 
anxiety and depression, in Europe’s largest cohort of paediatric and young adult patients 
with IBD. In the current study, the prevalence of anxiety/depressive symptoms was high, 
almost 50%. This is almost three times higher than reported in a community sample of 
Dutch adolescents.63 Anxiety symptoms where far more prevalent than depressive 
symptoms (28.3% vs 2.9%), but they also often occurred concomitantly (15.8%). It is well 
known that anxiety and depressive symptoms can coexist18, but few studies investigated the 
presence of both anxiety and depressive symptoms in young patients with IBD. Compared 
to previous studies, our cohort has a higher prevalence of anxiety symptoms9-11, whereas 
prevalence of depressive symptoms seems to be lower.5, 10, 64 We expect that the prevalence 
rates vary depending on the activity and severity of disease. For example, a prevalence of 
±5% was reported in a study cohort of mild and uncomplicated disease (only patients in 
remission, oral medication (no steroids) and IBD diagnosis >1 year).13 The most prevalent 
anxiety domains found in our study were social phobia, generalised anxiety and specific 
phobia, which is similar to other studies.11, 12 The low prevalence of depressive symptoms 
in our cohort can be explained by the low CDI total cutoff score used in the other studies, 
using cut off points of 95 or 1012, which correspond to (T-)scores within the average range.64, 
65 It could have been that patients in those studies were labeled as having depressive 
symptoms, where in fact their scores might have been in the normal range. Secondly, the 
higher percentage of patients with active disease in the other studies could also explain the 
higher rates of depressive symptoms. 
 A major strength of our study is that we studied the severity of anxiety/depressive 
symptoms, based on severity scores given during the psychiatric interview. Of the 177 
patients with elevated anxiety/depressive symptoms, 134 patients agreed to this interview. 
46 patients were diagnosed with severe symptoms and where referred for psychological 
consultation and treatment (12.2% of the total sample). Exploratory analysis showed that 
patients with severe symptoms had significantly higher disease activity, used steroids more 
frequently, experienced more relapses in the preceding year and had a lower quality of 
life than patients with mild or no symptoms. It is important to note that, relapses in the 
preceding year, as an indicator for disease severity, were associated with severity of anxiety/
depressive symptoms. In addition, disease duration was also significantly shorter in the 
group with mild and severe anxiety/depressive symptoms, which may indicate that patients 
with a longer disease duration have more time to adapt and build adaptive coping strategies. 
This is supported by the study from Walter et al. 201613, that included only patients with a 
longer that one year prior diagnosis of IBD and found a 13% prevalence of anxiety and 
depressive symptoms. It is not likely that patients in the mild and severe group suffered 
from an adjustment disorder due to recent diagnosis of IBD, as the majority of patients 
had a disease duration >3 months. Considering the fact that not all patients agreed to the 
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psychiatric interview (24.2% refused), the severe group could well be an underestimation, 
implying that the group with severe anxiety/depressive symptoms might even be larger.  
 Our findings confirm our hypothesis that clinical disease activity is an important 
risk factor for anxiety and depression. This corresponds to previous findings5, 11, 16, 21, 22, 29 and 
implies that disease control is important for physical health as well as mental health. It also 
emphasises that attention should be given to emotional health in times of active disease. 
Support for this recommendation is found in studies that have shown an association 
between anxiety/depression and relapse.8 In addition, in line with previous studies 66, we 
showed that female gender is a significant risk factor for anxiety and depression. This is 
probably not a consequence of an IBD-specific cause, because it parallels the well-known 
gender differences in the general population.67 We failed to find a significant association 
between steroid use and anxiety and/or depressive symptoms, which is in agreement with 
the finding from Reed-Knight et al. 201464 and several studies in adults with IBD66 , but in 
contrast to other paediatric IBD studies.5, 29 This is likely due to the low number of patients 
using steroids in our cohort (9.6%). Due to these small numbers we were not able to take 
the dosage into account, which most aforementioned studies did. Moreover, this study 
investigated whether the risk factors for anxiety symptoms or for depressive symptoms 
would be different. Analysis showed that age and gender were significantly associated with 
anxiety, but not with depressive symptoms. This could reflect the actual situation, but could 
also be a consequence of the fact that the group with depressive symptoms was smaller. 
Surprisingly, socio economic status was not associated with anxiety and/or depression, 
whereas other studies did find this association.29
 Major strengths of this study are that data were collected consecutively and concern 
a unique study population: paediatric as well as young adult IBD patients from regional as 
well as tertiary medical centers, which makes the results generalisable. In addition, and 
contrary to other studies5, 11, 27, 29, we assessed anxiety and depression concomitantly as this 
has implications for subsequent psychological treatment. Furthermore, to the best of our 
knowledge, we are the first to address the severity of the anxiety and depressive symptoms 
and show that 12.2% of our cohort suffers from severe anxiety/depressive symptoms. 
Moreover, our large cohort has few missing values, allowing us to directly perform multiple 
regression analysis, which does not introduce the (multiple testing) bias which is applied in 
studies that first perform univariate analysis to select significant variables for the multiple 
or multivariate analysis.
 This study has several limitations. Firstly, considering that most patients were in clinical 
remission in our cohort and that the group with active disease mostly consisted of patients 
with mild disease activity, the prevalence estimates of anxiety and depressive symptoms 
could have been an underestimation. Secondly, because of the wide age range (10-25 years) 
we had to use 2 different validated questionnaires both for anxiety and depression and 
consequently could not work with continuous data. While the use of validated cut off scores 
is highly accepted, it does limit options for analyses. Furthermore, the BDI as well as the CDI 
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contains questions concerning for example sleep disturbance, fatigue and reduced appetite. 
These items are also called ‘somatic items’ because they can both relate to a physical illness 
or be an indicator of depression. It is suggested that these instruments could overestimate 
the presence of depressive symptoms in physically ill patients. There is ongoing debate about 
the best strategy for this issue: some argue that these items should be removed, but others 
argue the entire screen instrument is more valid because these symptoms do not always 
correlate to disease activity and do respond to psychological treatment.68 Further research 
is necessary to provide an evidence based strategy regarding the use of these instruments in 
physically ill patients. In addition, we tried to investigate differences in risk factors for anxiety 
and depressive symptoms between the paediatric and young adult population. Analysis 
did not show significant risk factors in the < 18 age group, which could have reflected the 
actual situation, but could also be explained by low power, or the fact that other predictors, 
that were not included in the regression model (for example fatigue or abdominal pain), 
more strongly influence anxiety/depressive symptoms in younger patients. Thirdly, not all 
patients were willing to participate in the psychiatric interview and this could have led to and 
underestimation of the group with severe anxiety/depressive symptoms. Furthermore, the 
purpose of the psychiatric interview was to differentiate severe/clinical from mild/subclinical 
anxiety/depressive symptoms and not to establish the presence of other psychiatric disorders. 
Although this would have been interesting, the study was not designed to do so, and there 
is not much evidence to suspect the presence of other psychiatric disorders in youth with 
IBD.69 Fourthly, due to logistic constraints inflammatory markers (e.g. C-Reactive protein , 
faecal calprotectin) were not available for all patients and could not be used in the regression 
models, but have shown to be different between the severe and no anxiety/depressive 
symptoms group. Although the validated clinical disease activity indices are frequently used in 
research, there is debate about the actual correlation to intestinal inflammation. Finally, our 
study did not encompass validated measures of abdominal pain, irritable bowel syndrome 
and fatigue, while these factors are shown to be correlated with anxiety and depression.28 
Including these measures would have increased the length of our questionnaire and the risk 
of non-completion, therefore we chose not to include them in this study. 
 Despite these limitations, this study provides valuable information about the 
prevalence and risk factors of anxiety and/or depression in adolescents and young adult 
patients with IBD. We report a high prevalence of anxiety/depressive symptoms of almost 
50%. Analyses showed active disease and female gender to be the most important 
predictors. In conclusion, we have shown that the prevalence of anxiety and depressive 
symptoms is high in adolescent and young adult IBD patients. These psychological problems 
can have a significant impact on the burden of disease and can lead to increased health 
care costs. Therefore we recommend psychological screening in adolescent and young adult 
IBD patients. Screening facilitates early recognition and early psychological treatment, in 
order to improve psychological well-being and clinical course of disease. Physicians should 
be aware that female patients and patients with active disease are the most vulnerable. 
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CHAPTER 5
ABSTRACT
Background 
In youth with inflammatory bowel disease (IBD), health-related quality of life (HRQOL) has 
been shown to be affected by individual disease factors and specific psychological factors. 
The innovative aim of this study is to examine the combined impact of psychological factors 
(illness perceptions, cognitive coping, anxiety, and depression) on HRQOL, over and above 
the associations of demographic and disease factors with HRQOL in youth with IBD.
Methods 
Data on clinical disease activity, illness perceptions, cognitive coping, anxiety, depression, and 
HRQOL were prospectively collected in 262 consecutive youth (age 10-20, 46.6% male) with 
confirmed IBD. Multiple linear regression analyses tested the associations of demographic, 
disease, and psychological variables with HRQOL in separate groups for Crohn’s disease (CD; 
N = 147) and ulcerative colitis and IBD unclassified (UC/IBD-U; N = 115), using age-specific 
validated instruments.
Results 
In both disease groups more negative illness perceptions (ß = -.412; ß = -.438, p < .001) and 
more depression (ß = -.454; ß = -.279 , p < .001) were related to lower HRQOL. In the UC/
IBD-U group, more anxiety was related to lower HRQOL (ß = -.201, p = .001). The model 
with the psychological variables explained a large and significant amount of variance in both 
groups: 74%; 83%; respectively (p < .001). 
Conclusions 
In 10-20-year-old IBD patients, negative illness perceptions and depression were significantly 
and more strongly associated with lower HRQOL than demographic and disease factors. 
Thus, it is important to integrate psychological factors in the treatment for IBD patients. To 
improve HRQOL in young IBD patients, psychological interventions should be targeted at 
negative illness perceptions and depression.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a disabling chronic gastrointestinal condition, with 
two predominant subtypes: Crohn’s disease (CD) and ulcerative colitis (UC). In 25% of 
patients, IBD starts in late childhood or adolescence .1, 2 The designation IBD unclassified 
(IBDU) is used for patients in which it not (yet) possible to make a distinction between 
CD and UC. IBD is characterized by periods of clinical disease activity and remission, and 
presents with symptoms such as abdominal pain, bloody diarrhea, fatigue and weight loss.3 
In adolescence, growth failure and delayed pubertal development is common, specifically 
in Crohn’s disease. The adolescent life phase is characterized by development on several 
domains (psychological, social, cognitive, academic). IBD can affect for example becoming 
more independent from parents, developing long-term friendships, starting secondary 
education, forming an own identity, but also experimenting with alcohol and drugs, finding 
a (side) job and having romantic relationships.4 IBD and its medical treatment may severely 
impact psychosocial functioning: health-related quality of life (HRQOL) in children and 
adolescents (further referred to as youth) with IBD is significantly lower than in healthy 
peers.5, 6 Furthermore, high prevalence rates varying from 20-50% for anxiety and depression 
are found in these patients.7-10 A recent meta-analysis in children and adolescents showed 
pooled prevalence rates for anxiety and depressive symptoms of 15%, and for anxiety and 
depressive disorders of 3-4% .11
 Other psychological factors are also important to consider in patients with IBD, such 
as illness perceptions and coping. Illness perceptions refer to the cognitive and emotional 
representations a patients forms about his or her disease.12 These representations cover 
several dimensions, i.e. consequences (the expected effects of the disease), timeline 
(expectations about the duration of the disease), cause (thoughts about the cause of the 
disease), controllability (the extent to which the individual believes he or she can control the 
disease with or without treatment), identity (how the individual describes the symptoms 
and perceives as part of the disease), concern (worries about the disease), and emotions 
(the emotional response to the disease).12, 13 Coping refers to the strategies an individual 
uses in dealing with harm, threat or challenges14, i.e. their disease for patients with IBD. A 
complete description of coping is outside the scope of this study. In short, several types of 
coping are described earlier, for example emotion-focused-coping (strategies to deal with 
the emotional responses to threat) versus problem-focused coping (strategies to deal with 
the threat itself), and adaptive coping (coping strategies that are associated with favorable 
outcomes) versus maladaptive coping (coping strategies associated with undesirable 
outcomes) or cognitive versus behavioral coping.15
 The Common Sense Model (CSM) is a model to describe the relationships between 
disease characteristics, illness perceptions, coping, and anxiety, depression and HRQOL.12 In 
this model, illness characteristics (such as clinical disease activity) lead to certain thoughts 
about the illness, the so-called illness perceptions of a patient. These illness perceptions 
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influence the type of coping the patient uses to deal with his/her symptoms. Together, 
these factors lead to positive or negative illness outcomes, for example anxiety, depression, 
or HRQOL. In patients with IBD, several relationships have been found between these 
variables, mostly in adults (below it is explicitly mentioned if studies were conducted in 
youth with IBD). For example, more clinical disease activity has been found to be associated 
with more anxiety and depression separately.16, 17 Previous studies have also demonstrated 
a relationship between clinical disease activity and HRQOL, with a mediating role for anxiety 
and depressive symptoms .16, 18-20 Furthermore, more negative illness perceptions are 
associated with lower HRQOL in adults with IBD21 and also with more psychological problems 
in youth with IBD.22 Coping was associated with anxiety and depression19 or adjustment23 in 
adults, and found as predictor of depression in youth with IBD as well.24 
 Unfortunately, very little is known on how all these factors combined affect health 
outcomes, more specifically HRQOL in young IBD patients. In adults, illness perceptions and 
coping have been reported to separately impact the relationship between clinical disease 
activity on HRQOL.19, 20 Recently, Van Tilburg et al.25 showed in adolescents with IBD that 
patient-reported disability (as outcome) was associated not only with clinical disease 
activity, but also with a combined latent construct ‘psychological factors’ (including coping, 
pain beliefs, anxiety, and depression). However, they did not control for demographic 
factors (gender, age, socioeconomic status), and did not include other disease factors, such 
as disease type, and disease duration. In addition, there is some evidence that these disease 
factors are associated with HRQOL17, 26, 27, and with anxiety and/or depression as well.22, 28 
Moreover, because the authors used a combined psychological construct their findings 
provide no insight on which psychological factors in particular psychological interventions 
should focus.
 The complex interplay between clinical disease activity, illness perceptions, coping, 
anxiety, and depression makes it challenging to attune both the medical and psychological 
treatment to the individual needs of IBD patients, to improve their HRQOL. The surplus value 
of the present study in a prospective cohort of youth with IBD is that it aims to clarify the 
association of a combination of psychological factors (illness perceptions, cognitive coping, 
anxiety, and depression) with HRQOL, over and above demographic and disease factors. 
More specific insight on how psychological factors are associated with HRQOL can offer 
guidance on which factors psychological interventions should focus. We hypothesize that 
clinical disease activity is negatively associated with HRQOL. Furthermore, we hypothesize 
that psychological factors (i.e. illness perceptions, cognitive coping, anxiety, and depression, 
when tested simultaneously, are associated with HRQOL, even after controlling for clinical 
disease activity and other demographic and disease factors.
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MATERIALS AND METHODS
Design
The present cross-sectional cohort study is based on a large patient sample (N = 374), 
completing the baseline assessment of a multicenter randomized controlled trial (RCT), 
investigating a disease-specific cognitive behavioral therapy in youth with IBD and symptoms 
of anxiety and/or depression (trial registration number: NCT02265588, see also Van den 
Brink & Stapersma et al.32). In the current study only data from patients aged 10-20 years 
were used (N = 262).
 Inclusion criteria were: 1) age 10 to 20 years and 2) diagnosis of IBD, according to 
the consensus criteria.33 34, 35
 Exclusion criteria were: 1) intellectual disability; 2) current treatment for mental 
health problems (pharmacological and/or psychological); 3) insufficient mastery of the 
Dutch language; 4) a diagnosis of selective mutism, bipolar disorder, schizophrenia, autism 
spectrum disorder, obsessive-compulsive disorder, posttraumatic or acute stress-disorder, 
or substance use disorder; 5) cognitive behavioral therapy in the past year (at least eight 
sessions); and 6) participation in another intervention study.
Procedure
Consecutive patients and their parents were recruited between October 2014 and 
September 2016 from the outpatient clinic in two academic hospitals and four community 
hospitals in the Southwest region of the Netherlands. Patient information was given and 
written informed consent was requested in all patients and, if applicable their parents 
or caregivers. Patients (and parents), who consented to participate, received an e-mail 
with a link to online questionnaires. Clinical disease activity was scored by the (pediatric) 
gastroenterologist around the time of inclusion (i.e. within approximately a month around 
the time of inclusion, median = 3.42 weeks).
Measures 
Control variables 
Gender, age, disease type, and disease duration of the patients were derived from their 
medical record. Socioeconomic status (SES) was determined using the occupational level 
from the parents or, if they lived on their own, patients themselves. Using the standard 
coding system of Statistics Netherlands36, occupations were categorized in low, middle and 
high. For gender and SES dummy variables were created to use in the analyses.  
 Clinical disease activity was assessed by two validated clinical disease activity 
instruments. For CD the short Pediatric Crohn’s Disease Activity Index (sPCDAI) and for UC the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) was used. The sPCDAI comprises six items 
on medical history (abdominal pain, stools), well-being, physical examination (abdomen), 
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weight and extra-intestinal manifestations.37 Scores range from 0 to 90 points.38 The PUCAI 
comprises six items on abdominal pain, rectal bleeding, stool frequency and consistency, 
and activity level. Scores range from 0 to 85.
Psychological factors
Illness perceptions were assessed by the Brief Illness Perceptions Questionnaire (B-IPQ; 14, 
39). This 9-item self-report questionnaire assesses cognitive and emotional representations 
of illness, covering eight dimensions: consequences, timeline, personal control, treatment 
control, identity, concern, emotions, and understanding. All dimensions are scored on an 
11-point Likert-scale (0: not at all – 10: very much/severely). A higher score represents more 
negative illness perceptions. Good test-retest reliability and concurrent validity has been 
found14, and the B-IPQ has been used before in adolescents with IBD.40 Internal consistency 
(Cronbach’s alpha) for the current sample was .81 in the CD group and .81 in the UC/IBD-U 
group.
 Cognitive coping was measured with the Cognitive Emotion Regulation 
Questionnaire (CERQ). This self-report scale consists of 36 items, scored 1 to 5 points, with 
nine subscales (e.g. self-blame, acceptance, putting into perspective, positive refocusing, 
positive reappraisal, and catastrophizing). These scales are divided into two domains: 
adaptive cognitive coping (e.g. positive reappraisal, putting in perspective) and maladaptive 
cognitive coping (e.g. self-blame, catastrophizing). A higher score indicates more use of 
a particular coping style. Good reliability and construct validity has been found.41 Both 
adaptive coping and maladaptive coping were used as variable in the analyses. For adaptive 
cognitive coping, internal consistency was .90 in the CD group and .93 in the UC/IBD-U 
group. For maladaptive cognitive coping, internal consistency was .88 in the CD group and 
.90 in the UC/IBD-U group.
 Anxiety was assessed using the 69-item self-report questionnaire Screen for Child 
Anxiety Related Disorders (SCARED). The SCARED contains five subscales: general anxiety 
disorder, separation anxiety disorder, specific phobia, panic disorder, and social phobia, 
rated on a 3-point scale (0-2: total score 0-138). Satisfactory reliability and validity has been 
reported.42 The cutoffs for elevated anxiety were total score ≥ 26 for boys, ≥ 30 for girls, or 
subscale score ≥ 8.43 These were only used to decide whether patients had elevated anxiety, 
i.e., could be included in the RCT. Internal consistency for the current sample was .95 in the 
CD group and .94 in the UC/IBD-U group.
 Depression was assessed using the Child Depression Inventory (CDI, for ages 10-
17) and the Beck Depression Inventory, second version (BDI-II, for ages 18-20). The CDI is 
a 27-item self-report scale (0-2, total score 0-54). Good reliability and validity have been 
established. A CDI score of 13 or higher reflected elevated depression.44 The BDI-II is a 21-
item self-report scale (0-3, total score 0-63). It has excellent reliability and good to excellent 
validity. A BDI-II score of 14 or higher reflected elevated symptoms of depression.45 The 
cutoffs for the CDI and BDI-II were only used to decide whether patients had elevated 
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depression, i.e. could be included in the RCT. For the CDI, internal consistency was .85 in the 
CD group and .86 in the UC/IBD-U group. For the BDI-II, internal consistency was .91 in the 
CD group and .84 in the UC/IBD-U group. To be able to combine patients of all ages within 
the disease groups, depression scores were created a Z-score for depression using either the 
CDI or the BDI-II (depending on age).
 Health-related quality of life was assessed by the IBD-disease specific self-report 
IMPACT-III, which covers six domains: IBD-related symptoms, systemic symptoms, emotional 
functioning, social functioning, treatment related concerns, and body image.46 The 35 items 
are scored (1-5; total score 35-175). Good psychometric properties have been found.47 The 
total score was used, and a higher total score indicates better HRQOL. Although the IMPACT-
III originally was designed for youth up to 18 years, we also used it for the patients of 19 and 
20 years. This allowed us to combine all patients in to one group for each disease type. This 
was substantiated by excellent internal consistency in both disease groups: .93 in the CD 
group and .94 in the UC/IBD-U group.
Statistical analyses 
To test whether the associations of demographic, disease and psychological factors with 
HRQOL are different for CD than for UC/IBD-U, multiple linear regression analyses were 
performed for the two disease groups separately: CD (N = 147) and UC/IBD-U (N = 115). UC 
and IBD-U were combined, since the group with IBD-U patients was quite small (N = 18), 
IBD-U often resembles UC more than CD48, and IBD-U has often a similar treatment approach 
as UC.49 All variables were continuous, except for gender and SES. For these variables dummy 
variables were included in the analyses. The abovementioned cutoffs for the SCARED, CDI, 
and BDI-II were only used to determine the proportion of patients with elevated anxiety or 
depressive symptoms. For the remaining questionnaires, no cutoffs were used. 
 The multiple linear regression analyses were run with two blocks/models, using 
HRQOL as outcome. In the first block, the demographic and disease variables (gender, age, 
disease duration, SES, and clinical disease activity) were entered simultaneously in the first 
regression model. In the second block the psychological factors (illness perceptions, cognitive 
coping, anxiety, and depression) were added simultaneously to the variables entered in the 
first block. To account for missing values, multiple imputation with chained equations was 
applied using SPSS (m = 15 for approximately 15% of missing data50). As a sensitivity analysis 
we also performed a complete case analysis (N = 116; N = 104 for the CD and UC/IBD-U 
groups respectively), to see whether the multiple imputations had an effect on the results. 
A p-value of < .05 was considered significant. SPSS Version 24 was used for the analyses (IBM 
Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp). 
A statistician (JE) supported and advised in analyzing and interpreting the data and results.
Ethical considerations
This study was performed conform the Declaration of Helsinki and approved by the 
Institutional Review Board of the Erasmus MC and of each participating center.
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RESULTS
Patient characteristics
In total 552 patients (aged 10-25 years) were invited for a randomized controlled trial (RCT) 
and 382 agreed to participate (response rate = 69%). Eight patients had incomplete data. 
From the final 374 youth, 262 were aged 10-20 years and were included in the current 
study. Demographic, disease and psychological characteristics are presented in Table 1. In 
disease groups (CD and UC/IBD-U), the percentage of patients with active disease (mild-
moderate-severe) was 31.3% and 30.4%, respectively. Overall, 50% of the patients had 
elevated anxiety, 17.9% had elevated depression, and 16.8% had both.  
 For HRQOL, illness perceptions, and cognitive coping no cutoffs are available, so 
means with ranges are provided in Table 1.
Influence of demographic, disease and psychological variables on HRQOL; results of 
multiple linear regression analyses per disease group
In Table 2-3, the standardized estimates, their significance, and the proportion of explained 
variance for each regression model (model 1 with demographic and disease factors and 
model 2 with psychological factors added) in the two disease groups are provided. Results 
are presented from the analyses on the imputed datasets. Results from the complete case 
analyses were similar (data not shown).
 As is seen in Table 2, in the CD group (N = 147), female gender and clinical disease 
activity were significantly associated with HRQOL in the first model, explaining 37% of the 
variance in HRQOL. After adding the psychological factors, clinical disease activity (ß = -.170, 
p = .001), more negative illness perceptions (ß = -.412, p < .001), and more depressive 
symptoms (ß = -.454, p < .001) were associated with lower HRQOL. The second model 
explained 74% of the variance in HRQOL, with a significant change in explained variance (R2 
change = 37%, p < .001).
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Table 1. Demographic and disease characteristics of total sample of IBD patients (10-20 
years)   
Group
CD UC/IBDU Total
N 147 115 262
Demographic characteristics
Age (years), mean (SD) 17.19 (2.52) 16.15 (2.98) 16.74 (2.77)
Male (%) 50.3 41.7 46.6
SES (%)a Low 17.7 13.0 15.6
Middle 32.7 40.9 36.3
High 38.1 43.5 40.5
Disease characteristics
Disease type (%) CD 100 0 56.1
UC 0 84.3 37.0
IBDU 0 15.7 6.9
Age at diagnosis (years), mean (SD) 14.25 (3.02) 13.18 (3.97) 13.78 (3.50)
Disease duration (years), median (IQR) 2.26 (0.97-4.39) 1.90 (0.62-4.73) 2.03 (0.81-4.56)
Active disease (%)b 31.3 30.4 30.9
Psychological characteristics
Elevated anxiety (%)c 49.7 50.4 50.0
Elevated depression (%)c 15.6 20.9 17.9
Elevated anxiety and depression (%)c 14.3 20.0 16.8
HRQOL, mean (range) 143.36 (76-174) 141.91 (82-173) 142.72 (76-174)
Illness perceptions, mean (range) 34.75 (3-69) 36.69 (9-70) 35.63 (3-70)
Adaptive cognitive coping, mean (range) 57.67 (20-92) 55.72 (21-97) 56.78 (20-97)
Maladaptive cognitive coping, mean (range) 25.05 (16-59) 25.12 (16-56) 25.08 (16-59)
Notes: a Not for all patients SES was available: CD N=130, UC/IBDU N=112. Total group N=242. b Scored above 
cutoff for active disease on sPCDAI (≥10 points) or PUCAI (≥10 points). c Scored above cutoff on SCARED (anxiety), 
CDI (depression; 10-17 year) and/or BDI-II (depression 18-20 year).
Abbreviations: SD: standard deviation, SES: socio-economic status, CD: Crohn’s Disease, UC: ulcerative colitis, 
IBDU: inflammatory bowel disease unclassified, IQR: Inter Quartile Range, HRQOL: health-related quality of life, 
sPCDAI: short Pediatric Crohn’s Disease Activity Index, PUCAI: Pediatric Ulcerative Colitis Activity Index, SCARED: 
Screen for Child Anxiety Related Emotional Disorders, CDI: Child Depression Inventory, BDI-II: Beck Depression 
Inventory, Second edition.
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Table 2. Influence of demographic, disease, and psychological variables on HRQOL; results 
of multiple linear regression analysis – CD group (N=147)
Model 1 Model 2
ß SE ß p-value ß SE ß p-value
Block 1
Gender Male
Female -.230 .072 .002* -.055 .051 .283
Age -.075 .077 .330 -.054 .056 .330
SES Low
Middle .029 .098 .768 .070 .069 .315
High .051 .097 .600 -.042 .067 .533
Disease duration .123 .072 .086 .064 .049 .193
Clinical disease activity -.482 .071 < .001* -.170 .053 .001*
Block 2
Illness perceptions -.412 .063 <.001*
Adaptive cognitive coping .012 0.49 .803
Maladaptive cognitive coping .018 .058 .759
Anxiety .019 .077 .801
Depression -.454 .077 <.001*
R2 (CI), p-value .37 (.24-.49), p < .001* .74 (.65-.80), p < .001*
Abbreviations: SE = standard error, SES = socioeconomic status, CI = confidence interval
In the UC/IBD-U group (N = 115), female gender, age, disease duration, and clinical disease 
activity were significantly associated with HRQOL in the first model, explaining 32% of the 
variance in HRQOL. After adding the psychological factors, female gender (ß = -.101, p = 
.022), lower age (ß = -.193, p < .001), shorter disease duration (ß = .087, p = .045), more 
negative illness perceptions (ß = -.438, p < .001), more anxiety symptoms (ß = -.201, p = .001), 
and more depressive symptoms (ß = -.279, p < .001) were associated with lower HRQOL. The 
second model explained 83% of the variance, with a significant change in explained variance 
(R2 change = 51%, p < .001).
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Table 3. Influence of demographic, disease, and psychological variables on HRQOL; results 
of multiple linear regression analysis – UC/IBDU group (N=115)
Model 1 Model 2
ß SE ß p-value ß SE ß p-value
Block 1
Gender Male
Female -.276 .081 .001* -.101 .044 .022*
Age -.298 .082 <.001* -.193 .045 <.001*
SES Low
Middle -.130 .126 .302 -.033 .066 .619
High -.101 .126 .424 -.047 .067 .483
Disease duration .201 .083 .015* .087 .044 .045*
Clinical disease activity -.289 .081 <.001* -.066 .046 .156
Block 2
Illness perceptions -.438 .056 <.001*
Adaptive cognitive coping .036 .046 .156
Maladaptive cognitive coping -.029 .052 .584
Anxiety -.201 .060 .001*
Depression -.279 .061 <.001*
R2 (CI), p-value .32 (.18-.46), p < .001* .83 (.76-.88), p < .001
Abbreviations: SE = standard error, SES = socioeconomic status, CI = confidence interval
DISCUSSION
This study examined the influence of psychological factors on HRQOL over and above the 
influence of demographic and disease factors in youth with IBD and analysed the results 
separately for CD and UC/IBD-U. Partly in line with our first hypothesis, in the first model, 
without the psychological factors included, female gender and clinical disease activity were 
significantly associated with HRQOL, as were age and disease duration only in the UC/IBD-U 
group. However, when adding a combination of all psychological factors simultaneously 
in the second model, the influence of demographic and disease factors was reduced. 
Subsequently, illness perceptions and depression were associated with HRQOL in youth 
with IBD, even when controlling for demographic and disease factors. More negative illness 
perceptions and more depression were associated with a lower HRQOL, in both the CD 
group and the UC/IBD-U group. A difference between the disease groups was that, in the 
UC/IBD-U group, anxiety was associated with HRQOL as well. Most importantly, adding 
the psychological factors resulted in a significant increase in the proportion of explained 
variance, from approximately 35% by the first model to 74-83% by the second model, in 
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both groups. This high proportion of explained variance underlines the importance of 
psychological factors contributing to HRQOL in patients with IBD.
 These results provide insight in which psychological factors play a role in youth with 
IBD. Consistently in the two disease groups, negative illness perceptions and depression in 
particular prove their significant role, whereas cognitive coping and was not associated with 
HRQOL. This was also found in previous studies, which reported that illness perceptions and 
depression were associated with disease outcomes.22, 28 Therefore, we recommend to pay 
attention to these factors when treating patients. Our results suggest that in youth with UC/
IBD-U, anxiety should be considered as well. 
 There are several explanations for only finding an association between anxiety 
and HRQOL in youth with UC/IBD-U. Firstly, the nonsignificant relationship between anxiety 
and HRQOL in youth with CD cannot be explained by a difference in the prevalence of 
elevated anxiety symptoms between the CD and UC/IBD-U groups (49.7% versus 50.4%). 
Secondly, one might postulate that anxiety is not strongly related to HRQOL in youth with 
IBD. Although we found a high prevalence of anxiety symptoms in the current sample (see 
Table 1 and31), presence of anxiety symptoms as such may not have to impact the HRQOL of 
youth with CD. In children and adolescents the available studies did not show evidence for 
differences between CD and UC23, but Sarid et al.51 showed worse psychosocial outcomes in 
patients with UC.27, 52 Thirdly, anxiety and depression are highly comorbid, have overlapping 
symptoms and anxiety is considered a precursor of depression.53, 54 So anxiety may have 
played a role in preceding depressive symptoms in these patients. It is possible that anxiety 
and depression both explained variance in HRQOL, but that depression is more strongly 
related to HRQOL, and therefore diminished the relationship between anxiety and HRQOL in 
the patients with CD. More research is needed to unravel the interplay between anxiety and 
depression in youth with IBD. In their benchmark review, Cummings et al.55 describe several 
pathways for the anxiety and depression comorbidity in children and adolescents. They 
also stress the importance of studying specific anxiety disorders for their comorbidity with 
depression. In IBD, very few studies tested specific anxiety problems (e.g.,11). As a result, to 
our knowledge, there are no studies that investigated how specific anxiety problems are 
related to depressive symptoms in patients with IBD. Fourthly, in adults, several studies 
reported on the relationship between anxiety and HRQOL in both patients with CD and UC.56, 
57 Anxiety might be more impairing for adults with IBD than for youth with IBD, since adults 
may have to deal with more disease-related anxieties and worries concerning their daily 
and social functioning (impact of IBD on employment, career perspectives, income, finding 
a sexual partner, starting a family, etc.). Lastly, anxiety symptoms may be IBD-specific, i.e., 
anxiety or worries surrounding their IBD symptoms (e.g., bloody stools, the necessity of a 
stoma or surgery). These worries are often exorbitant to the actual context but can have a 
negative impact.58,59 More specifically, higher IBD-specific anxiety was associated with lower 
HRQOL in youth with both CD and UC.58 However, we are not aware of studies that examined 
differences between CD and UC with respect to IBD-specific anxiety in youth. Perhaps, youth 
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with UC/IBD-U experience different IBD-specific worries than youth with CD, for example 
since youth with UC/IBD-U more often have alarming bloody stools than youth with CD.
 Although the CSM postulates that coping is an important factor, in our study, 
cognitive coping was not significantly related to HRQOL, when simultaneously added to the 
model with the other psychological factors. Cognitive coping may not be related to HRQOL 
in IBD patients, as was also found in earlier studies examining individual psychological 
factors.27, 52 This is in contrast with the results of a review including a wide range of illnesses 
in adults, that found that coping was a stronger predictor for health outcomes than illness 
perceptions.60 Perhaps, coping plays a different role in IBD than in other illnesses. On the 
other hand, the type of coping may be of importance , since we only tested cognitive coping 
styles (and not for example behavioral). However, the results of two adult IBD studies 
including problem-focused and emotion-focused coping are mixed61, 62, and therefore do 
not support this explanation completely.
 Comparing the results between patients with CD and UC/IBD-U, showed differences 
in the second model: a significant association of clinical disease activity with HRQOL in the 
CD group, and a significant association of gender, age and disease duration with HRQOL in de 
UC/IBD-U group. Most likely, these differences cannot be explained by differences between 
the two groups, since the groups were similar with respect to the percentages of active 
disease, males versus females and the disease duration (see Table 1). Only in the CD group, 
clinical disease activity was associated with HRQOL, even after adding the psychological 
factors to the model. To our knowledge, in youth, no studies have specifically examined 
differences between CD and UC with respect to the relationship between clinical disease 
activity and HRQOL. Patients with CD have a more heterogeneous clinical presentation 
and are affected by growth failure, more often than patients with UC and IBD-U.1 The 
heterogeneous clinical presentation and growth failure can lead to a lower HRQOL. A 
recent review of Knowles et al.63 showed that HRQOL was significantly lower for patients 
with active disease, although no information was provided about differences between CD 
and UC/IBD-U. In children and adolescents with IBD (both CD and UC), some studies have 
shown that clinical disease activity remained associated with HRQOL, even when anxiety/
depression19 21 64, and parental stress64, 65 were included as mediators. It was therefore not 
tested, as in our study, what the influence is of demographic, disease, and psychological 
factors on the relationship between clinical disease activity and HRQOL. It seems that the 
relationship between clinical disease activity and HRQOL is not a direct relationship as such. 
 Only in the UC/IBD-U group, gender, age, and disease duration were significantly 
associated with HRQOL, even after adding the psychological factors to the model. For 
gender, previous studies in youth with IBD did not find an association with HRQOL.66-68 These 
studies all included both CD and UC patients, but the majority of youth had CD (>70%), 
which may have masked the association between gender and HRQOL in the UC patients. 
However, it remains unclear what role gender has in affecting HRQOL, especially since 
gender is associated with more anxiety and depressive symptoms in general69, as well as in 
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our own cohort.31 Anxiety and depressive symptoms are known to affect HRQOL in youth 
with IBD.21, 64 For age, our results indicated that older age was associated with lower HRQOL 
in youth with UC/IBD-U. This is accordance with Otley et al.68, who also reported that older 
age was associated with lower HRQOL in the first year after diagnosis of IBD. However, in 
their sample a large majority of youth was diagnosed with CD (77%). Other studies did not 
find association between age and HRQOL30, 70 or the reversed association (lower HRQOL 
in younger patients20). These mixed findings were confirmed in a review on predictors of 
HRQOL in youth with IBD.6 Finally, in our study a shorter disease duration was associated 
with a lower HRQOL in youth with UC/IBD-U. Previous studies have suggested that it seems 
that disease duration is not associated with HRQOL in general, but only within the first 
months after diagnosis (of both CD and UC/IBD-U).30, 68 However, these studies included 
mainly CD patients (77% and 100% respectively).30, 68 In our sample, only 20% had a disease 
duration of 6 months or shorter. Therefore, our results suggest that for youth with CD in the 
first 6 months after the diagnosis, disease duration is not associated with HRQOL. For UC and 
IBD-U this relationship is unclear. Although these differences between the disease groups 
are important to notice, the most important finding remains that, overall, in both disease 
groups, illness perceptions and depression were significantly associated with HRQOL.
Strengths
Our sample (N = 262) is one of the largest European samples and innovative in studying 
the influence of both disease, demographic and psychological factors in youth with IBD. 
Our large sample covers a broad age range, using internationally validated and age-attuned 
instruments. This age range is an important life phase, as several biological and psychosocial 
changes take place, and a chronic disease such as IBD can have negative consequences for 
the transition to adulthood. In addition, our sample was derived from 6 centers (both urban 
and rural areas), making generalization of our findings stronger. In addition, and contrary 
to other studies that only included either anxiety or depression (e.g.8, 11), we assessed both 
anxiety and depression, as this had implications for subsequent psychological treatment. 
Most importantly, whereas previous studies mostly examined individual relationships 
between disease factors, psychological factors and HRQOL, we aimed to test the influence 
of disease, demographic and psychological factors simultaneously. An advantage of this 
approach is that the current study took into account the interrelationships between all the 
factors in their associations with HRQOL.
Limitations
The number of patients with active disease (mostly mild clinical disease activity) was low 
(25%), although this number is often found in population-based cohorts of patients with 
IBD. It may be that the associations between the psychological variables and HRQOL are 
not the same for patients that have more active disease. Nevertheless, studies with a 
higher proportion of patients with active disease reported similar results.6, 21, 64, 65 However, 
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despite these findings, it is still possible that for patients with moderate to severe clinical 
disease activity, the relationships between illness perceptions, depression and HRQOL are 
different. Since evidence has been found for a negative impact of clinical disease activity on 
anxiety, depression and/or HRQOL (e.g.11, 23), even stronger relationships may be found in 
patient populations with more active disease. Another limitation is that our data were cross-
sectional and conclusions on causal relationships cannot be drawn. Longitudinal studies are 
needed to examine causal relationships over time. Until now, only few studies have been 
conducted that were able to draw conclusion on causal relationships. For example, a recent 
study in adults with IBD found evidence for a bidirectional and causal relationship between 
disease activity and anxiety/depression.71 However, such studies have not been conducted 
investigating HRQOL. A last limitation is that we had a response rate of approximately 70%, 
which can have caused bias, for example if patients with a lower HRQOL were more inclined 
to participate than those with higher HRQOL. However, we were not able to compare the 
HRQOL of responders and nonresponders.
Clinical implications
These results stress the importance of psychological factors for HRQOL in youth with 
IBD, over and above demographic and disease variables. In our study sample, 75% of 
the patients were in clinical remission. Therefore, treating (pediatric) gastroenterologists 
should pay attention to these psychological factors, in all patients and not only in patients 
with active disease. We recommend screening for negative illness perceptions and 
internalizing problems. This can be done either during a medical visit or using short (online) 
questionnaires prior to the medical visit. Our results also have implications for psychological 
treatment of these patients: interventions for improving HRQOL should focus on negative 
illness perceptions and depression, and also on anxiety for youth with UC/IBD-U. For 
example, cognitive behavioral therapy (CBT) has been proven effective in using techniques 
to restructure thoughts, such as negative illness perceptions.72 Importantly, at the beginning 
of a psychological intervention disproportionate, unrealistic or incorrect thoughts and ideas 
should be identified. At this phase, it is important to determine whether a patient has 
disproportionate or incorrect negative illness perceptions. These can then be crucial when 
practicing cognitive and behavioral techniques. Naturally, the techniques of CBT can be used 
to improve depression and anxiety as well.73, 74
 In conclusion, our study found that negative illness perceptions and depression 
are negatively associated with HRQOL in youth with IBD, even after controlling for several 
demographic and disease factors, with also other psychological factors (i.e., coping, anxiety) 
taken into account. These factors seriously influence HRQOL, even in our cohort with low 
clinical disease activity, and should be considered by the medical team. Our results indicate 
that, irrespective of the clinical disease activity, psychological treatment should focus on the 
way these young IBD patients perceive their disease and on their depressive symptoms. For 
youth with UC and IBD-U, anxiety and worries should receive attention as well.
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CHAPTER 6
ABSTRACT
Objective
To evaluate the effectiveness of a disease-specific cognitive behavioral therapy (CBT) 
protocol on anxiety and depressive symptoms, and health-related quality of life (HRQOL) in 
adolescents and young adults with inflammatory bowel disease (IBD).
Methods
A parallel group randomized controlled trial, conducted in 6 centers of (pediatric) 
gastroenterology. Included were 70 adolescents and young adults (10-25 years) with IBD and 
subclinical anxiety and/or depressive symptoms. Patients were randomized into two groups, 
stratified by center: a) standard medical care (Care-As-Usual; CAU) plus disease-specific 
manualized CBT (Primary and Secondary Control Enhancement Therapy for Physical Illness; 
PASCET-PI), with 10 weekly sessions, 3 parent sessions and 3 booster sessions (n=37) or b) 
CAU only (n=33). Primary analysis concerned the reliable change in anxiety and depressive 
symptoms after 3 months (immediate post-treatment assessment). Exploratory analyses 
concerned 1) the course of anxiety and depressive symptoms and HRQOL in subgroups 
based on age, and 2) the influence of age, gender, and disease type on the effect of the 
PASCET-PI.
Results
Overall, all participants improved significantly in their anxiety and depressive symptoms and 
HRQOL, regardless of group, age, gender, and disease type. Primary chi-square tests and 
exploratory linear mixed models showed no difference in outcomes between the PASCET-PI 
(n=35) and the CAU group (n=33).
Conclusions
In youth with IBD and subclinical anxiety and/or depressive symptoms, preliminary results 
of immediate post-treatment assessment indicated that a disease-specific CBT added to 
standard medical care did not perform better than standard medical care in improving 
psychological symptoms or HRQOL. 
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are two types of inflammatory bowel disease 
(IBD). IBD is a chronic disease, that is characterized by episodes of exacerbation (with 
increased clinical symptoms) and clinical remission. Symptoms are abdominal pain, (bloody) 
diarrhea, fatigue, fever, and weight loss.1 In pediatric IBD (especially CD) malnutrition, 
resulting in delay of growth and puberty is common.2 Adolescents and young adults (also 
referred to as youth) with IBD have a high risk for anxiety and/or depression3, possibly 
related to the unpredictable disease course and embarrassing symptoms.4 Moreover, the 
inflammation-depression(-/anxiety) hypothesis is thought to explain the bidirectional 
association between inflammation in IBD and anxiety and/or depression. This hypothesis 
states that inflammation increases vulnerability for emotional symptoms and that treating 
these symptoms can decrease inflammation and thus improve disease course.5 
 In general, prevalence studies show elevated levels of anxiety and depressive 
symptoms in respectively 39-50%6, 7, and in 38-55%8, 9 of adolescents with IBD. Only, a few 
studies report lower prevalence rates.10 Furthermore, a meta-analysis showed higher rates of 
depressive and internalizing disorders in IBD youth, compared to other chronic conditions.4
 At present, cognitive behavioral therapy (CBT) is the most effective evidence-based 
psychological treatment for anxiety and depression in youth.11 Until now, only a few studies 
evaluated CBT for youth with IBD. In a randomized controlled trial (RCT) Szigethy et al.12 
found promising results of a disease-specific CBT in reducing depressive symptoms in 41 
adolescents with IBD and subclinical depression. Furthermore, in a later study (N=178) the 
same disease-specific CBT was effective in reducing depressive symptoms and improving 
health-related quality of life. However, supportive nondirective therapy (SNDT) had equally 
favorable outcomes.9 Reigada et al.13 found improvement in anxiety, pain, and disease 
activity in 9 adolescents with anxiety disorders receiving CBT. In addition, a large recent trial 
in pediatric patients with IBD (N=185), not selected on the presence of either somatic or 
psychological symptoms at baseline, examined the effect of a social learning and cognitive 
behavioral therapy (SLCBT) of only three sessions versus educational support. Although 
SLCBT outperformed educational support in improving IBD-related quality of life and school 
attendance, the authors found no difference between the two groups on anxiety and 
depression. The authors proposed low levels of disease activity and the short duration of 
the psychological treatment as possible explanations.14
 Taken together, CBT for youth with IBD seems beneficial. The mixed findings 
described above may be due to differences in the included patients, since some studies 
focused on either anxiety or depression separately9, 12, 13 or included all IBD patients rather 
than those selected on anxiety or depression.14 However, anxiety can precede depression, 
and anxiety and depression often occur together15, 16, so investigating both is important. 
Moreover, for CBT to be effective for anxiety/depression, patients have to experience at least 
elevated levels of anxiety and/or depressive symptoms, so selecting patients at baseline 
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may be necessary.17 Therefore, the present multicenter RCT aims to test the effectiveness 
of a disease-specific CBT on symptoms of both anxiety and depression, as well as on health-
related quality of life (HRQOL) in adolescents and young adults with IBD (age 10-25 years). 
This age range was chosen to cover the clinically relevant phases of adolescence and young 
adulthood, when IBD is often diagnosed2 and can affect the many psychosocial changes that 
take place (e.g. becoming independent and identity formation).
 The primary research question was as follows: Compared with standard medical 
care only, what is the effect of a disease-specific CBT added to standard medical care, on the 
level of anxiety and depressive symptoms, from pre- to post assessment, in adolescents and 
young adults with IBD aged 10-25 years? 
 Additional research questions were: 1) What is the course of anxiety and depressive 
symptoms and HRQOL in subgroups based on age, regarding the effect of CBT? 2) What 
is the influence of age, gender, and disease type on the course of anxiety and depressive 
symptoms and HRQOL, regarding the effect of CBT? By these questions we aim to examine 
which patients may benefit most from the disease-specific CBT. We hypothesized that 
patients in the disease-specific CBT group would improve more on anxiety and/or depressive 
symptoms and HRQOL compared to patients who received only standard medical care. In 
addition, we expected to find more effect of CBT in young adult patients (as they already 
face more life challenges, and could benefit more from the CBT skills than children), in 
women (as they often experience more anxiety and/or depressive symptoms than men) 
and in patients with CD (as the systemic symptoms in CD increase the burden of disease). 
We also investigated how patients (and parents) evaluate the disease-specific CBT (i.e. what 
is the social validity of the disease-specific CBT).
METHODS
Design and procedure
This multicenter parallel group randomized controlled trial was designed according to the 
CONSORT guidelines for trials of non-pharmacologic treatments.18 The trial had two arms. 
Patients in the experimental group received a disease-specific CBT protocol (Primary and 
Secondary Control Enhancement Training for Physical Illness; PASCET-PI)12 added to standard 
medical care. The control group received standard medical care (Care-As-Usual, CAU) 
only, as this resembles the current care best. Initially, only patients aged 10-20 years were 
included. A few months after the start of the recruitment, patients of 21-25 years were also 
included, to include more patients in young adulthood as well, to cover the transition phase. 
The research protocol was approved by the Medical Ethics Committee of the Erasmus MC 
and confirmed by the ethical boards of all participating hospitals. The study was registered 
with ClinicalTrials.gov as study number NCT02265588.
6133
SHORT TERM EFFECT OF CBT ON PSYCHOLOGICAL OUTCOMES
 After having provided written informed consent, patients (and parents) completed 
validated psychological instruments at 2 points in time (see Outcome measures). At baseline, 
patients completed online questionnaires (at home) and a clinical interview (by phone) (no 
longer than 2 weeks before the start of the PASCET-PI). The immediate post(-treatment) 
assessment was similar to the baseline and was performed approximately 3 months after 
baseline, no later than 2 weeks after completing the PASCET-PI. Timing and method of 
assessments were the same in the experimental and control group.
Recruitment (see also Figure 1)
Step 1: Inclusion baseline screening 
Included for baseline screening for symptoms of anxiety and depression were adolescents 
and young adults of age 10-25 years with a confirmed diagnosis of IBD (Crohn’s disease, 
ulcerative colitis or inflammatory bowel disease unclassified). Between October 2014 
and October 2016, patients were consecutively recruited from the pediatric or (pediatric) 
gastroenterology departments of 2 academic hospitals and 4 community hospitals. The 
centers were medium sized to large hospitals from mixed rural and urban regions. Parents 
participated for all patients aged 17 years or younger, parental participation for patients aged 
18-20 was voluntary. Exclusion criteria were 1) intellectual disability, 2) current treatment 
for mental health problems (pharmacological and/or psychological), 3) insufficient mastery 
of the Dutch language, 4) a diagnosis of selective mutism, bipolar disorder, schizophrenia/
psychotic disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic 
or acute stress-disorder, or substance use disorder (parent- or self-reported or from medical 
file), 5) CBT in the past year (at least 8 sessions), and 6) participation in another interventional 
study, all assessed by the treating physician using medical files (unless otherwise specified).
Step 2: Inclusion RCT 
Only youth with subclinical anxiety and/or depressive symptoms were included in the RCT. 
Patients with clinical anxiety and/or depression were excluded as we deemed it unethical to 
randomize them. 
 Subclinical anxiety and/or depressive symptoms were defined as a score equal 
or above the cutoff of age-appropriate questionnaires, but not meeting criteria for clinical 
anxiety and/or depression (see next paragraph). For anxiety the Screen for Child Anxiety 
Related Emotional Disorders (SCARED; 10-20 years; cutoff ≥26 for boys and ≥30 for girls)19 
and the Hospital Anxiety and Depression Scale – Anxiety Scale (HADS-A; 21-25 years; cutoff 
≥8)20 were used. For depression the Child Depression Inventory (CDI; 10-17 years; cutoff 
≥13)21 and the Beck Depression Inventory – second edition (BDI-II; 18-25 years; cutoff ≥14)22 
were used. 
 Clinical anxiety and/or depression was defined as follows: for patients who scored on 
or above the cutoffs for elevated symptoms of anxiety and/or depression, the psychologist-
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investigator (LS) administered a clinical interview. The Anxiety Disorders Interview Schedule 
for Children (ADIS-C)23 was delivered by telephone to patients, and if applicable, parents. 
In the ADIS-C, if a patient meets criteria for a clinical disorder a Clinician’s Severity Rating 
(CSR, a 0-8 rating of symptom severity and functional impairment) is assigned by the 
interviewer. In addition, severity of anxiety and/or depressive symptoms was rated by the 
interviewer using age-appropriate rating scales. For anxiety the Pediatric Anxiety Rating 
Scale (PARS; 10-20 years; cutoff ≥18)24 and Hamilton Anxiety Rating Scale (HAM-A; 21-25 
years; cutoff ≥15)25, 26 were used. For depression the Child Depression Rating Scale Revised 
(CDRS-R; 10-12 years; cutoff ≥40)27, Adolescent Depression Rating Scale (ADRS; 13-20 years; 
cutoff ≥20)28, and the Hamilton Depression Rating Scale (HAM-D; 21-25 years; cutoff ≥17)29, 
30 were used. If patients met criteria for an anxiety or depressive disorder on the ADIS-C 
(i.e. a CSR of at least 4) and score equal to or above the clinical cutoff on the rating scale 
this indicates a clinical anxiety or depressive disorder. These patients were excluded and 
received immediate referral to mental health care. Within the group of patients included in 
the RCT (all with subclinical anxiety and/or depressive symptoms, n = 70) a subdivision was 
made based on the ADIS-C. If patients had one or more CSR’s of at least 4 (but scored below 
the cutoff on either the CDRS, ADRS, HAM-D, PARS or HAM-A) they were considered ‘high’ 
subclinical, if not they were considered ‘low’ subclinical.
Randomization
Patients with subclinical anxiety and/or depressive symptoms (but not clinical anxiety and/
or depression) were randomized to PASCET-PI and CAU versus CAU alone, with a ratio of 1:1 
An independent biostatistician provided a computer-generated blocked randomization list 
with randomly chosen block sizes (with a maximum of 6) and stratification by center using 
the blockrand package in the R software package thereby providing numbered envelopes 
per center. Patients were enrolled by one of the investigators (GB). To prevent drop-out, 
before randomization it was thoroughly checked with the patients whether they would 
be motivated enough to complete the CBT. For example, they were asked about their 
motivation and concerns regarding traveling and time investment, or regarding discussing 
private information.
Intervention
The PASCET-PI is a disease-specific CBT protocol, developed for adolescents with IBD and 
depression. Disease-specific components encompass the illness narrative (i.e. perceptions 
and experience of having IBD), disease-specific psycho-education, techniques for pain 
and immune functioning, social skills training and emphasis on IBD related cognitions and 
behavior.12 Parents receive psycho-education about coaching their child to cope with IBD. 
 In the current study the PASCET-PI contained ten weekly individual sessions, 
delivered in three months. Conform the protocol, six of these sessions were face-to-face, the 
remaining 4 sessions were by phone at a pre-arranged moment (to advance adherence and 
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lower the treatment burden). In addition, 3 family sessions (for patients and their parents) 
were held (only for patients ≤ 20 years), and following the weekly sessions, 3 monthly 
individual booster sessions were held by telephone (this was after the immediate post[-
treatment] assessment). As the original PASCET-PI was developed for depression, therapists 
were instructed how to make the exercises more anxiety-tailored, an anxiety hierarchy and 
step-by-step exercise was added, and an extra anxiety hand-out was provided to the patients. 
For patients 21-25 years of age the practice book was made more age-appropriate. See Van 
den Brink & Stapersma et al.31 or Appendix 1 for a more detailed description of this Dutch 
modification of the PASCET-PI. The therapy was provided by all licensed (healthcare/CBT) 
psychologists, who received onsite training from the developer (EMS) and performed the 
therapy in their own hospital or center. To ensure treatment integrity, monthly supervision 
was provided by EMWJU (clinical psychologist/professor) and audiotaped sessions were 
rated by EMWJU and five master level Psychology students. Of all sessions, 30% was rated on 
adherence by at least one rater, and of that 30% half was evaluated by at least 2 raters (i.e. 
15% of all sessions). Audiotapes were randomly selected to be rated by two of the raters. 
However, which pair of two raters rated the sessions varied strongly, so there were too few 
standardized pairs of raters to use for example intraclass correlation.32 Therefore, interrater 
agreement was globally calculated using Pearson’s correlation between two data columns 
with 1) all first ratings and 2) all second ratings for all patients and sessions combined. CAU 
consisted of regular medical appointments with the (pediatric) gastroenterologist every 3 
months, consisting of a 15 minute consultation discussing overall wellbeing, disease activity, 
results of diagnostics tests, medication use, and future diagnostic/treatment plans.
Outcome measures (online questionnaires)
Demographic data were assessed with a general questionnaire, based on a semi-structured 
interview.33 Socioeconomic status was based on occupational level from parents or, if they 
lived on their own, patients themselves. It was divided into low, middle, and high.34 Ethnicity 
was based on mother’s country of birth or if the mother was born in the Netherlands, the 
father’s country of birth.35 Disease characteristics were extracted from the medical charts.
 Symptoms of anxiety were assessed with the SCARED (for 10-20 years), and the 
anxiety scale of the HADS (for 21-25 years). Both are self-report questionnaires. The SCARED 
has 69-items with 3 response categories (0-2; total score 0-138). It contains five subscales: 
general anxiety disorder, separation anxiety disorder, specific phobia, panic disorder, and 
social phobia.19, 36 The anxiety scale of the HADS has 7-items with 4 response categories (0-3, 
total score 0-21).20 Internal consistency was .86 and .92 for the SCARED and .54 and .77 for 
the HADS-A at baseline and follow-up, respectively (Cronbach’s α).
 Symptoms of depression were assessed using the CDI (for 10-17 years) and the 
BDI-II (for 18-25 years) self-report symptom scales. The CDI has 27-items with 3 response 
categories (0-2, total score 0-54).21. The BDI-II has 21-items with 4 response categories (0-3, 
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total score 0-63).22 Internal consistency was .70 and .77 for the CDI and .54 and .83 for the 
BDI-II at baseline and follow-up, respectively.
 Health-related quality of life was assessed with the self-reports IMPACT-III (10-20 
years) and Inflammatory Bowel Disease Questionnaire (IBDQ; 21-25 years). The IMPACT-III 
has 35 items, scored 1-5 (total score 35-175).37 The IBDQ contains 32 items, scored 1-5 (total 
score 32-160).38 A higher score of both instruments indicates better quality of life. Internal 
consistency was .86 and .89 for the IMPACT-III and .71 and .92 for the IBDQ at baseline and 
follow-up, respectively.
 Clinical disease activity was assessed with four validated clinical disease activity 
measures. For patients of 10-20 years with CD the short Pediatric Crohn’s Disease Activity 
Index (sPCDAI)39 was used, whereas for patients with UC and IBD-U the Pediatric Ulcerative 
Colitis Activity Index was used (PUCAI).40 For patients of 21-25 years with CD the Crohn’s 
Disease Activity Index (CDAI)41 was used, whereas for patients with UC and IBD-U the partial 
Mayo score42 was used. All indices were scored by the physician during the medical visit and 
provide four categories of clinical disease activity: remission, mild, moderate, and severe.
 Social validity questions were included in the online questionnaire to gain insight 
in how the patients in the CBT group (and if applicable parents) evaluated the PASCET-
PI. For this study we chose to assess three relevant aspects of social validity: satisfaction, 
usefulness, and recommendation. Patients and/or parents awarded 3 items with 0-10 points 
(0 = ”Not at all” to 10 = “Very much”) regarding 1) their satisfaction with the protocol, 2) 
how useful it was for them, and 3) whether they would recommend it to other patients.
Blinding
The interviewer (LS) and treating physicians were blinded for the result of randomization 
(they were not informed and had no access to files containing this information). Patients 
could not be blinded. They were explicitly asked not to discuss the group they were 
randomized into with their physician.
Statistical analysis
Descriptive statistics were computed for demographic and disease characteristics. 
Independent t-tests and chi-square tests were used to assess differences between these 
variables in the two groups at baseline. An intention-to-treat principle was applied in the 
analyses. 
 For each participant we calculated a Reliable Change Index (RCI)43 value for anxiety 
and depression (but not for HRQOL, since no data on test-retest reliability was available 
for the HRQOL instruments, which is necessary to calculate the RCI). By calculating RCI’s, 
we were able to combine all participants in one analysis. The RCI is calculated using the 
standard error of measurement (SEM) of the pretest and the test-retest reliability of the 
instrument. The RCI can have three possible values: reliably improved, no reliable change, 
and reliably deteriorated. See Appendix 2 for the details of calculating the RCI variable. A 
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chi-square test was used to compare the RCI values between the two groups, using complete 
cases (n = 68). For exploratory analyses we first used six linear mixed models (which take 
into account missing data) to compare change between the groups from baseline to directly 
after CBT for anxiety (SCARED or HADS-A), depression (CDI or BDI-II), and HRQOL (IMPACT-
III or IBDQ). Time, group (PASCET-PI vs. CAU) and the interaction between time and group 
were included as fixed factors. We repeated these linear mixed models in subgroups to 
examine the influence of gender, and disease type. The influence of age is incorporated in 
the first set of linear mixed models, as the questionnaires for the specific age-group were 
used. Using an Identity covariance structure, random intercepts were estimated for each 
participant. No random slopes could be specified, because we only had two time points. 
Restricted maximum likelihood (REML) was applied as estimation method. A p-value of less 
than .05 was considered statistically significant. Reported Cohen’s d’s represent the effect 
size between groups at follow-up. For the SCARED, HADS-A, CDI, and BDI-II a negative effect 
size is in favor of CBT, for the IMPACT-III and IBDQ a positive effect size is in favor of CBT. Data 
were analyzed using SPSS version 21.
Sample size and power
Considering literature regarding effectiveness of CBT for anxiety and depressive symptoms 
in youth without a somatic disease, as well as earlier studies of CBT in youth with IBD9, we 
expected medium to large effects on anxiety symptoms44 and medium effects for depressive 
symptoms.45 This corresponds to j >0.40 for anxiety symptoms, and to j >0.30 for depressive 
symptoms. For the chi-square tests for anxiety and depressive symptoms this means that a 
total of 70 patients provides us with sufficient power for the anxiety outcomes (>85%) and 
with medium power for the depression outcomes (>60%). 
RESULTS
Demographic, disease and intervention characteristics
Figure 1 displays the patient flow throughout the study. In total, 70 patients were randomized 
(10-20 years n = 50, 21-25 years n = 20). In Table 1 demographic and disease characteristics 
are displayed for both groups. No significant differences were found between the PASCET-PI 
group and the CAU group on demographics (e.g. gender, age) and disease characteristics 
(disease type, duration, activity), neither as to whether patients were included based on 
anxiety, depression or both.
 Regarding treatment integrity, in the PASCET-PI group 33 (89.2%) patients followed 
all 10 treatment sessions, 1 patient (2.7%) followed 8 sessions, 1 patients (2.7%) followed 
5 sessions, 1 patient (2.7%) followed 3 sessions and 1 patient (2.7%) followed 1 session. 
The mean number of treatment sessions followed was 9.38. In the 21 patients of whom 
parents participated as well, 76.2% of the parents followed all three family sessions. The 
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mean number of family sessions was 2.57. In all sessions at least 75%, and in 75% of the 
sessions at least 80% of the required topics were discussed, indicating good adherence to 
the protocol (i.e. treatment integrity). A global estimation of interrater agreement, over all 
sessions and patients combined, was calculated. Treatment adherence ratings correlated 
.41 between the 6 raters.46 No patients in the control group sought mental health care and 
no study-related adverse events occurred during the trial.
Excluded  (n=178)
•Declined to participate – screening (n=169)
•No screening data (n=9)
Lost to follow-up (n=0)
Allocated to Care-As-Usual (n=33)
11 care providers in 6 centers performed intervention
Number of patients treated by each
•care provider (median=3, IQR=2, min=1, max=9)
•center (median=5, IQR=2.5, min=1, max=15)
Allocated to Cognitive Behavioral Therapy (n=37)
•Received allocated intervention (n=37)
•Did not receive allocated intervention (n=0)
Lost to follow-up (n=2; missing data post assessment)
Discontinued intervention (n=2; dropped out intervention, 
but provided post assessment data)
Allocation
Follow-Up
Step 2: Inclusion RCT
Randomized (n=70)
Enrollment
Analysed  (n=33)
•Baseline data (n=33)
•Post assessment data (n=33)
•Excluded from analysis (n=0)
Analysed
•Baseline data (n=37)
•Post assessment data (n=35)
•Excluded from analysis (n=0)
Analysis
Allocation
Excluded  (n=304)
•Not meeting inclusion criteria (n=195)
•Too severe anxiety/depression (n=46)
•Declined randomisation (n=61)
•Incomplete screening data (n=2)
Step 1: Inclusion baseline screening
Screened for anxiety/depression (n=374)
Assessed for eligibility 
(n=552)
Figure 1. CONSORT study flow chart
6139
SHORT TERM EFFECT OF CBT ON PSYCHOLOGICAL OUTCOMES
Table 1. Baseline demographic and disease characteristics
PASCET-PI group 
(n=37)
CAU group (n=33) p value
Demographic status
Male, n (%) 10 (27.0) 12 (36.4) .401a
Age, mean (SD), years 18.62 (4.27) 17.69 (4.82) .393b
SES, n (%) 
Low 8 (21.6) 4 (12.9)
.348aMiddle 15 (40.5) 10 (32.3)
High 14 (37.8) 17 (54.8)
Ethnicity, n (%) (n = 64)
Dutch / Western 30 (81.1) 25 (80.6)
.749a
Other 7 (18.9) 6 (19.4)
Included on, n (%)
Anxiety 30 (81.1) 20 (60.6)
.070a
Depression 0 (0.0) 3 (9.1)
Both 7 (18.9) 10 (30.3)
IBD subtype, n (%) 
Crohn’s disease 18 (48.6) 18 (54.5)
.808aUlcerative colitis 14 (37.8) 12 (36.4)
IBD-U 5 (13.5) 3 (9.1)
Paris classification at diagnosis, n (%)
CD: location† (n = 36)
L1 4 (22.2) 2 (11.1)
.813a
L2 4 (22.2) 4 (22.2)
L3 6 (33.3) 8 (44.4)
+ L4a/L4b 4 (22.2) 4 (22.2)
CD: behavior (n = 36)
Nonstricturing, nonpenetrating 18 (100.0) 16 (88.9)
.243c
Stricturing, penetrating, or both 0 (0.0) 2 (11.1)
UC: extent‡ (n = 34)
Limited: E1 + E2 11 (57.9) 4 (26.7)
.069a
Extensive: E3 + E4 8 (42.1) 11 (73.3)
UC: severity
Never severe 18 (94.7) 11 (73.3)
.104c
Ever severe 1 (5.3) 4 (26.7)
Clinical disease activity, n (%)
Remission 27 (73.0) 26 (78.8)
.571a
Mild 10 (27.0) 7 (21.2)
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Disease duration, mean (SD), years 1.65 (0.72) 1.55 (0.67) .536b
IBD Medications, n (%)
Aminosalicylates 18 (48.6) 12 (36.4) .300a
Immunomodulators 16 (43.2) 16 (48.5) .660a
Biologicals 8 (21.6) 12 (36.4) .173a
Corticosteroids§ 2 (5.4) 5 (15.2) .170c
Enemas 3 (8.1) 1 (3.0) .352c
No medication 2 (5.4) 1 (3.0) .543c
Abbreviations: PASCET-PI = Primary and Secondary Control Enhancement Training for Physical Illness; CAU = 
Care-As-Usual; SD = Standard Deviation; IBD = Inflammatory Bowel Disease; IBDU = Inflammatory Bowel Disease 
Unclassified; SES; Socioeconomic Status
Notes: all demographic and disease characteristics were not significantly different between groups. a chi-square, 
b ANOVA, c Fisher’s Exact Test | * UC includes IBD-U patients, † L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: upper 
gastrointestinal tract proximal, and L4b distal from Treitz ligament ‡ E1: proctitis, E2: left sided colitis distal of 
splenic flexure, E3: extensive colitis distal of hepatic flexure, E4: pancolitis § prednisone (oral and intravenous) and 
budesonide (oral)
Effect of disease-specific CBT on symptoms of depression and anxiety, HRQOL
As some cells in the cross-tabulation were smaller than 5, a Fisher’s exact test was performed. 
In the primary analysis, RCI values did not differ between the two groups for both anxiety (χ2 
(2) = 1.656, p = .465, j = .159) and depression (χ2 (2) = 1.648, p = .523, j = .161), see Table 
2. Overall, patients in both groups either remained stable or improved in their symptoms of 
anxiety and depression.
 In the exploratory analyses (see Table 3) the same pattern was seen. No significant 
time-group interaction effect was found for anxiety (SCARED n=50: t(47.460) = -0.639, p = 
.526, d = -0.15; HADS-A n=20: t(16.047) = 0.976, p = .343, d = -0.06), depression (CDI n=35: 
t(32.004) = -1.272, p = .212, d = -0,11; BDI-II n=35: t(30.739) = -0.363, p = .719, d = -0.47), 
and HRQOL (IMPACT-III n=50: t(45.363) = 1.033, p = .315, d = 0.23; IBDQ n=20: t(18.124) = 
-0.539, p = .597, d = 0.44). For the SCARED (t(48.059) = -5.709, p < .001), HADS-A (t(16.431) 
= -4.375, p < .001), the BDI-II (t(31.236) = -4.778, p < .001), the IMPACT-III (t(45.849) = 4.847, 
p < .001), and the IBDQ (t(18.738) = 2.367, p < .05) the effect of time was significant, for 
the CDI this was not the case (t(32.525) = -1.554, p = .130). These findings show that, after 
three months, all patients improved in their symptoms of anxiety and depression, as well 
as in their HRQOL. Even when these analyses were carried out only in patients who showed 
relatively ‘high’ subclinical problems (‘high’ n=40 vs. ‘low’ n=30), no group differences were 
found on the anxiety and depression outcomes (data not shown).
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Table 2. Crosstabulation RCI of symptoms of anxiety and depression versus group
No reliable change Reliable increase of score / 
deterioration
Reliable decrease of score / 
improvement
Total
RCI categories anxiety (SCARED or HADS-A)
CAU 20 (60.6%) 0 (0%) 13 (39.4%) 33
CBT 17 (48.6%) 1 (2.9%) 17 (48.6%) 35
Notes: χ2 =1.656, df = 2, p = .465, φ = .159 (95%BI 0.00-0.36). Numbers in parentheses indicate row percentages
RCI categories depression (CDI or BDI-II)
CAU 14 (42.4%) 1 (3.0%) 18 (54.5%) 33
CBT 14 (40.0%) 4 (11.4%) 17 (48.6%) 35
Notes: χ2 =1.648, df = 2, p = .523, φ = .161 (95%BI 0.00-0.37). Numbers in parentheses indicate row percentages
Table 3. Estimated Marginal Means at Baseline and after 3 months for Anxiety, Depression 
and Health-Related Quality of Life
Variable Baseline 3 Months p 
(time effect)
p 
(time x group)
Cohen’s d (95%CI) 
(after 3 months) 
SCARED (0-138) Mean (SE) Mean (SE)
CBT 36.2 (2.7) à 22.9 (2.6)
< .001
CAU 40.5 (2.8) à 25.0 (2.9)
CBT vs. CAU .526 -0.15 (-1.02-0.71)
HADS-A (0-14)
CBT 9.9 (0.7) à 7.1 (0.7)
< .001
CAU 9.1 (0.8) à 7.3 (0.8)
CBT vs. CAU .343 -0.06 (-1.49-1.37)
CDI (0-54)
CBT 8.5 (1.1) à 7.2 (1.1)
.130
CAU 10.8 (1.2) à 7.7 (1.2)
CBT vs. CAU .212 -0.11 (-1.11-1.02)
BDI-II (0-63)
CBT 11.3 (1.1) à 5.9 (1.1)
< .001
CAU 14.2 (1.2) à 8.2 (1.2)
CBT vs. CAU .719 -0.47 (-1.51-0.58)
IMPACT-III (35-175)
CBT 137.1 (2.8) à 148.1 (2.8)
< .001
CAU 137.4 (2.9) à 144.9 (3.0)
CBT vs. CAU .315 0.23 (-1.28-0.49)
IBDQ (32-224)
CBT 164.6 (5.8) à 179.6 (5.8)
< .001
CAU 161.6 (6.4) à 171.2 (6.7)
CBT vs. CAU .597 0.44 (-2.02-0.77)
Notes: For the SCARED, HADS-A, CDI, and BDI-II a negative Cohen’s d favors CBT, for the IMPACT-III and IBDQ a 
positive Cohen’s d favors CBT.
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Influence of age, gender, and disease type on effect of disease specific CBT on anxiety 
and depression
In exploratory analyses for the four separate age groups (classified by the four age-attuned 
questionnaires: SCARED [10-20 years], HADS [21-25 years], CDI [10-17 years], BDI-II [18-
25 years)] no differences were found between the groups as to the change in anxiety, 
depression, or HRQOL. As we did not find group differences in all four age groups, an age 
effect seems absent. We explored the possible influence of gender and disease type on the 
effect of the PASCET-PI by conducting linear mixed model analyses separately in subgroups 
(male vs. female and CD vs. UC & IBD-U). Overall, none of the subgroup analyses showed 
a difference between two groups on either anxiety, depression, or HRQOL, except for a 
significant lower score on the BDI-II in the CAU group (n=6) than in the CBT group (n=3) for 
the subgroup analysis in males (data not shown). Therefore, gender and disease type do not 
seem to influence the effect of CBT.
Social validity
With respect to satisfaction, patients reported a mean of 7.82 (out of 10), whereas parents 
reported a mean of 7.50 (out of 10). Mean scores of patients and parents for usefulness 
were 6.82 and 6.06 (out of 10), respectively. Furthermore, patients reported a mean of 6.96 
(out of 10) for recommending it to other patients, and parents reported a mean of 7.25 
(out of 10). These results indicate that, in general, patients and their parents evaluated the 
PASCET-PI positively.
DISCUSSION
The current study, which had very low attrition (< 3%), tested the effect of a disease-
specific CBT compared to CAU in reducing subclinical anxiety and/or depressive symptoms 
and in improving HRQOL, in adolescents and young adults with IBD. At the immediate 
post(-treatment) assessment disease-specific CBT added to standard medical care did not 
perform better than standard medical care. Overall, both the PASCET-PI and CAU group 
significantly improved over time, on all three outcomes, 3 months after baseline (i.e. at the 
immediate post[-treatment] assessment). Furthermore, in subgroup analyses we did not 
find indications for differences between age groups, boys versus girls, nor between CD and 
UC/IBD-U regarding the effect of the PASCET-PI on anxiety, depression, or HRQOL. 
 Our results are in contrast to results of earlier trials with positive findings of CBT 
treatment for youth with IBD9, but are in accordance with some of the evidence from studies 
in adults with IBD.47 There are several explanations for our findings. 
 First, just by participating in the study, patients in the CAU group did not exactly 
receive standard medical care. They were psychologically assessed at two points in time 
with questionnaires and interviews. This is not done in routine practice and therefore it 
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provided additional exposure to attention from professionals. Usually, only if psychological 
problems are obvious, the medical team refers patients for mental health care. CAU was 
chosen as comparison condition, because it resembles the current care for youth with IBD 
in our institute best. However, mere participation in the trial may have had a positive effect 
on all patients due to increased awareness and (unintended) psychoeducation. It has been 
described before that merely answering questions or participate in a trial can influence 
behavior or emotions. For example, McCambridge48 recently described that the ‘question-
behavior effect’ can occur in randomized trials. Moreover, Arrindell49 has described the 
re-test effect: in patients with psychiatric problems mean scores of psychopathology often 
decrease at follow-up (without any formal intervention). A first assessment can heighten 
awareness of anxious or depressive symptoms, which can cause a respondent to try to deal 
with these symptoms (by talking more about it or try to think different) or lead to more 
introspection or self-monitoring.49 The awareness caused by receiving information about 
the study and receiving the psychological assessment may have contributed to the fact 
that all patients improved. It can be perceived as some form of support, like in the control 
conditions of earlier trials in youth with IBD.9, 14
 Second, the overall patient group had a low disease burden, both psychologically as 
well as somatically. Included patients experienced only subclinical anxiety and/or depressive 
symptoms, as randomization was not ethical for patients with clinical mental health 
disorders. We mainly included patients in clinical remission, because for patients with severe 
disease activity adherence to the CBT protocol might have been complex. For the subclinical 
anxiety and/or depressive symptoms mere participation may have been enough to improve. 
This raises the question: which IBD-patients should receive psychological treatment? When 
we analyzed those patients with the highest levels of subclinical anxiety and/or depressive 
symptoms still no differences between CBT and CAU were observed. However, a recent 
trial showed a significant effect of CBT compared to a waiting list on QOL, anxiety, and 
depression in adult IBD patients, of whom 70% met criteria for a psychiatric disorder.50 This 
implies that IBD patients with severe psychological problems can actually benefit from CBT. 
Furthermore, for adolescents with IBD, when compared to supportive therapy, CBT has 
been shown to improve somatic depressive symptoms as well as clinical disease activity and 
ESR (Erythrocyte Sedimentation Rate), but only in patients with CD and moderate clinical 
disease activity.51 This suggests that patients with active disease can benefit from CBT. For 
these patients, however, sessions should be delivered with great flexibility, as they may not 
be able to adhere to weekly ‘live’ sessions.
 Third, the PASCET-PI may not be suited enough to improve subclinical anxiety and/
or depressive symptoms. However, an earlier study using the original PASCET-PI protocol in 
a group of patients selected on elevated depression, did find an effect on these subclinical 
depressive symptoms, and also on comorbid anxiety disorders.12 In our trial patients 
experienced more anxiety symptoms than depressive symptoms, which can have influenced 
the results. Nevertheless, CBT is the most evidence-based psychological therapy for both 
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anxiety and depression.11 In general, CBT techniques do have an effect on both anxiety and 
depressive symptoms, with even higher effect sizes found for anxiety than for depression.52 
This implies that PASCET-PI may be effective, as to both anxiety and depressive symptoms. 
In adults with IBD, mixed results are found with respect to the effectiveness of CBT on 
psychological as well as somatic symptoms.47, 53 Several recommendations are made17, 
47 to focus on patients with for example decreased HRQOL or experiencing psychological 
problems and to take into account high attrition rates in power and sample size calculations. 
In our trial these recommendations were covered by selecting patients on anxiety and/
or depression and by having very low attrition. The mixed findings in IBD are consistent 
with mixed findings on the effect of preventive CBT programs for subclinical anxiety and/
or depression in youth.54 As our patients experienced subclinical psychological and somatic 
symptoms, the treatment can be considered as preventive (for the development of clinical 
disorders). Further studies are needed to examine this type of preventive effects, especially 
in patients with IBD, as psychological problems can also affect the disease course.55, 56
 Fourth, although a sample size of 70 participants should be large enough for the 
expected effect sizes for CBT on anxiety and/or depression, perhaps we would have found 
a significant group difference with a larger sample size. Originally, to take into account 
possible attrition, we aimed to enroll 100 patients31, which we could not achieve. Revised 
power calculations still indicated that we had sufficient power to investigate the effect 
of the PASCET-PI, using n = 70. With this sample size one would expect to see at least a 
trend towards a difference between the two groups, but this was not the case. Moreover, 
compared to earlier trials, a strength of the present study was the very low attrition rate and 
that almost all (95%) patients completed disease-specific CBT.
 Fifth, it may be possible that the effect of the PASCET-PI sustains on the longer-
term, whereas the effect of the control group diminishes over time. The course of IBD can 
be fluctuating, and perhaps the knowledge and skills taught in the PASCET-PI can be more 
useful when patients suffer from more disease activity or flares during a longer period of 
follow-up. Patients themselves often expressed that this was a motivation to participate in 
the therapy (“I have no complaints now, but the CBT skills can be useful in the future, when 
I have a flare”). Data on longer follow-up assessments will be available for analyses later.
 In summary, strengths of the current study are that we included patients with a 
broad and clinical relevant age, with both anxiety and/or depressive symptoms, and that 
our study had very low attrition. Moreover, no patients in the control group sought mental 
health care. Furthermore, as our study sites encompass both rural and urban hospitals, 
this strengthens the generalizability and external validity of our findings. Although the age-
specific instruments were most appropriate for the patients in our study, statistically it was 
a limitation that using different instruments made it difficult to combine all patients in one 
analysis and that we could perform the linear mixed models only in subgroups. Originally the 
study was sufficiently powered to analyze mean symptom change of anxiety and depression. 
Due to the fact that finally multiple instruments had to be used to cover the age-range, this 
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was not possible. However, a revised power calculation for the chi-square analyses with 
the reliable change index indicated that we had enough power with the total of 70 patients 
in the RCT. Another limitation was the relatively small sample size. Therefore, our results 
should be interpreted with caution. We recommend screening for anxiety and/or depressive 
symptoms in youth with IBD, as these symptoms can affect disease course55, 56, and health-
related quality of life.57 Subclinical symptoms may develop into more severe psychological 
disorders which even have a greater impact.58, 59 CBT may be more effective in patients with 
more severe psychological symptoms or more IBD disease activity. This, however, should 
be examined in studies with a different design (i.e. not with standard medical care as 
comparison condition). Based on our clinical experience, we consider PASCET-PI as suited 
also for patients with more severe IBD symptoms, but with great flexibility in delivery (over 
the phone or in the hospital when patients are hospitalized). Yet, future research is needed 
to find out how the PASCET-PI or CBT can be best delivered to those patients, which patients 
with IBD benefit most from psychological treatment, but also how the long-term course of 
disease activity is associated to the long-term course of anxiety/depression.
 In conclusion, in our RCT all patients improved in their symptoms of anxiety and 
depression, and their HRQOL over time (3 months). At the immediate post-treatment 
assessment, we found no additional effect for a disease-specific CBT on improving subclinical 
anxiety and depressive symptoms or HRQOL in adolescents and young adults with IBD, when 
compared to CAU. We hypothesize that the awareness the study elicited and the possible 
(unintended educational) support provided may have had a strong positive effect on all 
patients. CBT could be beneficial for patients with more severe psychological symptoms or 
IBD patients with clinical disease activity.
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APPENDIX 1. Outline of the PASCET-PI12,31
Session number Content of session
Session 1
Live (60 min)
Introduction of ACT & THINK model and PASCET-PI, building work alliance, psycho-
education about IBD and depression or anxiety, illness narrative
Session 2
Live (60 min)
Mood monitoring, explaining link between feelings, thoughts and behaviors, 
discussing feeling good and feeling bad, problem-solving
Session 3
By telephone (30 min)
Link between behavior and feelings: Activities to feel better
Session 4
Live (60 min)
Be Calm and Confident: relaxation exercises
Session 5
Live (60 min)
Be Calm and Confident: positive self versus negative self, training social skills
Session 6
By telephone (30 min)
Talents: developing talents and skills makes you feel better
Session 7
Live (60 min)
Social problem solving, discussing the ACT skills and introduction of the THINK 
skills with discussing negative thoughts (Think positive)
Session 8
By telephone (30 min)
Help from a friend, Identify the ‘Silver Lining’, and No replaying bad thoughts
Session 9
By telephone (30 min)
Keep trying – Don’t give up, making several plans to use the ACT & THINK skills
Session 10
Live (60 min)
Quiz on ACT & THINK model, discussing use of ACT & THINK skills in the future, 
updating illness narrative
Booster 1
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, 
personalizing ACT & THINK skills
Booster 2
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, 
personalizing ACT & THINK skills
Booster 3
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, 
personalizing ACT & THINK skills
Family 1
Live (60 min)
Parental view on IBD, family situation, psycho-education about IBD and depression 
or anxiety, introduction of ACT & THINK model and PASCET-PI
Family 2
Live (60 min)
Parental view on progress, the ACT & THINK skills that are most effective for the 
patient, expressing emotions within family, family communication, family stress game
Family 3
Live (60 min)
Parental view on progress, family communication, parental depression or anxiety
Abbreviations: IBD = Inflammatory Bowel Disease; PASCET-PI = Primary and Secondary Control Enhancement 
Training for Physical Illness.
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APPENDIX 2. Calculati on of Reliable Change Index (RCI) variables
Step 1. Calculati ng the standard error of diff erence for each parti cipant, separately for 
anxiety and depression:
In which x1 and x2 are the individual’s scores on baseline and at follow up, respecti vely. S1 is 
the pre-test variance for that instrument. rxx is the test-retest reliability of the instrument as 
reported in the manual.
•  SCARED (10-20 years): rxx = .81
36   | S1 = 13.389  | Sdiff = 8.253
•  HADS-A (21-25 years): rxx = .89
60   | S1 = 2.373  | Sdiff = 1.113
•  CDI (10-17 years): rxx = .86
21  | S1 = 4.648  | Sdiff = 2.459
•  BDI-II (18-25 years): rxx = .93
22   | S1 = 4.38  | Sdiff = 1.639
Step 2. Calculati ng the diff erence between the follow up and the baseline for each 
parti cipant, separately for anxiety and depression.
Step 3. Calculati ng the RC value for each parti cipant, separately for anxiety and depression.
Step 4. Determining the RCI value for each parti cipant, separately for anxiety and depression. 
Both for anxiety and depression this leads to a variable with three possible values: no reliable 
change, reliable deteriorati on, and reliable improvement. An RC value of between -1.96 and 
1.96 indicates no reliable change (p < .05). When RC is higher than 1.96, this indicates a 
reliable increase in the score (p < .05), i.e. reliable deteriorati on (as for all the instruments 
applies that a higher score represents more symptoms). When RC is lower than -1.96, this 
indicates a reliable decrease in the score (p < .05), i.e. reliable improvement.
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ABSTRACT
Youth with inflammatory bowel disease (IBD) often experience psychological difficulties, 
such as anxiety and depression. This random controlled study tested whether a 3 month 
disease-specific cognitive behavioral therapy (CBT) in addition to standard medical care 
versus standard medical care only was effective in improving these youth’s psychological 
outcomes. As this was a preventive study, we included 70 patients (10-25 years) with 
subclinical anxiety and/or depression, and measured psychological outcomes at 6 and 12 
months’ follow-up. In general, patients in both groups showed improvements in anxiety, 
depression, health-related quality of life, social functioning, coping, and illness perceptions, 
sustained until 12 months follow-up. Overall, we found no differences between those 
receiving additional CBT and those receiving standard medical care only. We assume that 
this can be explained by the perceived low burden (both somatically and psychologically) or 
heightened awareness regarding psychological difficulties and IBD. 
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INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal 
tract characterized by periods of active inflammation (with increased clinical symptoms) 
followed by periods of clinical remission. The two main types of IBD are Crohn’s disease 
(CD) and ulcerative colitis (UC). Symptoms are abdominal pain, bloody diarrhea, fatigue, 
fever, and weight loss.1, 2 Pediatric patients may also suffer from anorexia/loss of appetite, 
malnutrition, and experience delayed growth and puberty onset – especially those with 
CD.3, 4 
 Adolescents and young adults (hereafter referred to as youth) with IBD may 
experience various psychological problems related to the disease and its treatment. Firstly, 
they are at risk for anxiety and depression.5, 6 More specifically, a large cohort study found 
that these patients have a higher risk for anxiety or depressive disorders.7 Secondly, they are 
at risk for a lower health-related quality of life (HRQOL) compared to healthy peers8, likely on 
account of more maladaptive avoidant coping.9, 10 In addition, negative illness perceptions 
(i.e., negative cognitions on for example the consequences of the disease or personal 
control) are associated with more negative outcomes in these patients.11, 12 Thirdly, youth 
with IBD also experience sleep problems13, related to anxiety and depression.14 Lastly, their 
social functioning is worse than that of healthy controls.6 In conclusion, youth with IBD are 
likely to experience psychological problems as described above and the interrelationships 
between these problems makes treating this patients somatically and psychologically even 
more complex. 
 Importantly, psychological problems of youth with IBD can influence medical 
outcomes, creating a vicious circle of problems (e.g 15-17). There seems to be a reciprocal 
relationship between these psychological difficulties and clinical symptoms due to gut 
inflammation.18 It has been hypothesized that psychological interventions may positively 
influence the inflammatory disease course.19 Psychological treatment should be focused 
on decreasing anxiety and depression and addressing other psychological problems, such 
as coping or negative illness perceptions, and on improving HRQOL and daily functioning. 
A recent randomized controlled trial (RCT) of Levy et al.20 in pediatric patients with IBD 
tested the effect of a 3-session social learning and cognitive behavioral therapy (SLCBT) 
versus educational support (ES; focusing on the gastrointestinal system, food labels, and 
nutrition) on a large set of psychological outcomes. SLCBT outperformed educational 
support in improving IBD-related quality of life 1 week after treatment and coping and school 
attendance over the course of 12 months, but had no effect on anxiety, depression, and 
functional disability. However, patients were not selected on either somatic of psychological 
symptoms, and therefore, many of them did not have psychological problems. Mikocka-
Walus et al.21 have suggested that targeted psychological treatment may be more useful to 
tackle psychological problems such as elevated anxiety and/or depression. Furthermore, 
Levy et al.20 used an intervention of only 3 sessions, whereas in IBD it has been shown 
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that a full 12-session protocol of disease-specific CBT improved depressive symptoms and 
HRQOL.22, 23
 HAPPY-IBD aimed to test the extent to which disease-specific CBT in youth 
with subclinical anxiety and depression is effective to decrease the negative impact of 
the disease and these subclinical psychological symptoms. By providing CBT for these 
specifically subclinical symptoms, we aimed to improve the disease course and to prevent 
the development of clinical anxiety and depressive disorders. So the study had a perspective 
of secondary prevention. To cover the important life phase of transition from adolescence to 
adulthood, we included youth aged 10-25 years. In this adolescent life phase, IBD can affect 
the psychological development, such as becoming independent from parents, developing 
long-term friendships, and forming an own (sexual) identity. For teenagers, important 
changes are starting secondary education, making new friends at a new school, becoming 
more independent from parents, and spending more time with peers. For late adolescents 
these processes continue and graduating, experimenting with alcohol or drugs, finding a 
(side) job and earning money, and forming an identity will take place as well. Lastly, young 
adults face developmental challenges such as finding a job, leaving home, having long 
lasting romantic relationships, and becoming financially independent.24 A diagnosis of IBD 
can involve a sense of loss in for example body image, future plans, self-confidence, sense 
of control, and roles inside and outside the family context.25 These changes and challenges 
should be considered in the treatment of youth with IBD.
 Earlier we have reported the immediate post-treatment assessment of this RCT, 
three months after baseline: patients in both the CBT and the standard medical care group 
improved on anxiety, depression, and HRQOL, but the level of improvement did not differ 
between groups.26 Considering that IBD has a fluctuating disease course, we re-assessed 
psychological outcomes at 6 and 12 months. We expected that patients who had received 
CBT would be better able to deal with possible flares and be better equipped with skills to 
prevent worsening of their subclinical psychological problems. Since CBT in general aims 
to improve anxiety and depression, these were chosen as primary outcomes. In addition, 
in this study we extended and innovated the range of our outcomes and also measured 
HRQOL, social functioning, coping27, illness perceptions28, and sleep problems.
 In summary, the present study aims to test the effectiveness of a full disease-
specific CBT protocol in addition to standard medical care, 6 and 12 months after the 
baseline assessment, to improve anxiety and depressive symptoms, and other psychological 
outcomes, in youth with IBD (10-25 years old) and subclinical symptoms of anxiety and 
depression, compared to standard medical care only. We hypothesized that patients who 
had received CBT would have more sustained improvement on all psychological outcomes 
than those in the standard medical care group.
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METHODS
For details of this RCT and the 3-month outcomes, see Van den Brink & Stapersma et al.29 
and Stapersma et al.26 This study is a two-armed multi-center parallel group RCT, comparing 
a disease-specific CBT (Primary and Secondary Control Enhancement Training for Physical 
Illness; PASCET-PI30) in addition to standard medical care to standard medical care only 
(care-as-usual, CAU). The latter represents the current usual care for youth with IBD in the 
Netherlands, and was therefore chosen as control condition. Patients were consecutively 
recruited between October 2014 and October 2016 in two academic and four community 
hospitals in urban and rural regions. The trial design adheres to the CONSORT guidelines 
for non-pharmacological treatments.31 The research protocol was approved by the Medical 
Ethics Committee of the Erasmus MC (approval number NL49147.078.14) and confirmed by 
the ethics boards of all participating hospitals. The study was registered with ClinicalTrials.
gov as study number NCT02265588.
Participants and Assessment procedure
Step 1: Inclusion baseline screening 
After patients and/or their parents had provided written informed consent, they were 
included in two steps. Patients from the age of 12 years provided informed consent 
themselves as well, patients of 10 or 11 years provided assent. All patients received a small 
financial reward (25 EUR voucher) for participating.
 Step 1 involved baseline screening of anxiety and depression symptoms, for which 
all consecutive youth (aged 10-25 years) with a confirmed diagnosis of IBD (CD, UC or 
inflammatory bowel disease unclassified) recruited in the abovementioned period were 
eligible.
 Step 2, the actual RCT, included only youth with subclinical anxiety or depression 
established in step 1, as we aimed to examine whether the disease specific CBT could 
prevent clinical anxiety and/or depression. In addition, it is unethical to withhold treatment 
to patients with clinical anxiety and/or depression.
 Subclinical anxiety or depressive symptoms were defined as a score equal or above 
the cutoff of age-appropriate questionnaires, but not meeting criteria for clinical anxiety 
and depression (see below). Subclinical anxiety symptoms were measured with the Screen 
for Child Anxiety Related Emotional Disorders (SCARED; 10-20 years; cutoff ≥26 for boys 
and ≥30 for girls32) and the Hospital Anxiety and Depression Scale – Anxiety Scale (HADS-A; 
21-25 years; cutoff ≥833). Subclinical depressive symptoms were measured with the Child 
Depression Inventory (CDI; 10-17 years; cutoff ≥1334) and the Beck Depression Inventory – 
second edition (BDI-II; 18-25 years; cutoff ≥1435).
 Patients were assumed to suffer from clinical anxiety or depression if they met 
DSM-5 criteria for an anxiety or depressive disorder, as assessed a psychiatric interview 
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(Anxiety Disorders Interview Schedule for Children; ADIS-C36), and scored equal to or above 
the clinical cutoff on age-specific severity rating scales: the Pediatric Anxiety Rating Scale 
(PARS; 10-20 years; cutoff ≥1837) or the Hamilton Anxiety Rating Scale (HAM-A; 21-25 years; 
cutoff ≥1538, 39) for anxiety; the Child Depression Rating Scale Revised (CDRS-R; 10-12 years; 
cutoff ≥4040), the Adolescent Depression Rating Scale (ADRS; 13-20 years; cutoff ≥2041), or 
the Hamilton Depression Rating Scale (HAM-D; 21-25 years; cutoff ≥1742, 43) for depression. 
All above-mentioned cutoffs only served for inclusion of patients and not for analysis 
purposes.
 Patients with clinical anxiety or depression were referred to mental health care. 
Patients with subclinical anxiety or depressive symptoms (but not clinical anxiety or 
depression) were randomized at a ratio 1:1 to receive either PASCET-PI in addition to CAU or 
CAU only.
Randomization
An independent biostatistician provided a computer-generated blocked randomization list 
with randomly chosen block sizes (with a maximum of 6) and stratification by center using the 
blockrand package in the R software package, thereby providing numbered envelopes per 
center. Patients were enrolled by a single investigator (GB). The interviewer (LS) and treating 
physicians had no access to the files in which the randomization result was described. We 
requested patients and parents not to reveal the trial arm assignment to the interviewer and 
treating physicians. Patients and parents received a link to web-based questionnaires, to be 
completed at home. They completed the same set of questionnaires at baseline (no longer 
than 2 weeks before the start of the PASCET-PI), and at the post-assessments (3, 6 and 12 
months after baseline). For both groups, assessments were performed at comparable time 
points (i.e. between 11-13 weeks, 25-27 weeks and 51-53 weeks after randomization).
Intervention
The PASCET-PI is a disease-specific CBT protocol for youth with IBD30, consisting of ten 
weekly individual sessions, delivered in three months. It was provided in a ‘blended 
format’: six sessions were face-to-face with a psychologist (in the patient’s own hospital), 
four sessions by telephone. In addition, parents of patients ≤ 20 years were invited for 
three face-to-face family sessions. Booster sessions were delivered by telephone 4,5 and 
6 months after baseline. The authorized Dutch translation of the PASCET-PI was used, 
developed by the research team. Originally, the PASCET-PI is targeted at depression. For this 
study, the treatment content was adjusted to also target aspects of anxiety such as anxiety 
hierarchy, exposure, cognitive restructuring, and to also target young adults (with more age-
appropriate exercises and lay-out). A more detailed description is provided in Appendix 1 
or Van den Brink & Stapersma et al.29 In short, sessions are focused on discussing, in an 
age-attuned manner, the patient’s illness narrative and the link between behavior and 
feelings, on relaxation, on discussing negative thoughts and cognitive restructuring, and on 
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personalizing the taught skills. The therapists provided age-appropriate information and 
exercises. In this way, the protocol took into account the patient’s psychological, cognitive 
and social development.
 The therapy was provided by licensed (healthcare/CBT) psychologists with 
ample experience working with youth, who had all been trained by the developer (EMS) 
and received monthly supervision by EMWJU (clinical psychologist/professor). Treatment 
integrity was ensured by supervision of the therapists and by rating of audiotaped sessions. 
For details, see Stapersma et al.26 CAU consisted of regular medical consultations of 15-
30 minutes with the (pediatric) gastroenterologist and/or IBD nurse every three months, 
in which overall wellbeing, disease activity, and future diagnostic/treatment plans were 
discussed.
Outcome measures (online questionnaires)
Demographic data were obtained from a semi-structured questionnaire.44 Socioeconomic 
status was based on parents’ occupational level or, for patients living on their own, the own 
occupational level. We classified socioeconomic status into low, middle, and high.45 Ethnicity 
was based on the mother’s country of birth or if the mother was born in the Netherlands, 
the father’s country of birth.46 Disease characteristics were extracted from the electronic 
medical charts.
 Symptoms of anxiety were assessed with the SCARED (for 10-20 years), and the 
anxiety scale of the HADS (for 21-25 years). Both are self-report questionnaires. The SCARED 
has 69-items with 3 response categories (0-2; total score 0-13847). The anxiety scale of the 
HADS has 7-items with 4 response categories (0-3, total score 0-2133). Internal consistency 
at baseline and the three follow-up assessments was .86, .92, .94, respectively, and .94 for 
the SCARED, and .54, .77, .81, .80, respectively, for the HADS-A. Clinical anxiety was defined 
using a psychiatric interview and severity rating scales (as described above in the assessment 
procedure).
 Symptoms of depression were assessed using the CDI (for 10-17 years) and the 
BDI-II (for 18-25 years) self-report symptoms scales. The CDI has 27-items with 3 response 
categories (0-2, total score 0-5434). The BDI-II has 21-items with 4 response categories (0-3, 
total score 0-6335). Internal consistency at baseline and the three follow-up assessments was 
.70, .77, .79, and .81, respectively, for the CDI, and .54, .83, .81, and .84, respectively, for the 
BDI-II. Clinical depression was defined using a psychiatric interview and severity rating scales 
(as described above in the assessment procedure).
 Health-related quality of life (including social functioning) was assessed with the 
self-report questionnaires IMPACT-III (10-20 years) and the Inflammatory Bowel Disease 
Questionnaire (IBDQ; 21-25 years). The IMPACT-III has 35 items, scored 1-5 (total score 35-
17548). The IBDQ contains 32 items, scored 1-5 (total score 32-16049). For both instruments 
a higher score indicates better HRQOL. We included in the analyses the total scores and the 
individual subscale scores for social functioning of both instruments. For the total score, 
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internal consistency at baseline and the three follow-up assessments was .71, .92, .90, and 
.90, respectively, for the IMPACT-III, and .71, .92, .85, and .88, respectively, for the IBDQ. For 
the social functioning subscale score, internal consistency at baseline and the three follow-
up assessments was .67, .54, .59, and .49, respectively, for the IMPACT-III subscale, and .69, 
.85, .48, and .51, respectively, for the IBDQ subscale.
 Coping was assessed using the Cognitive Emotion Regulation Questionnaire 
(CERQ). The CERQ contains 36 items, scored 1-5, subdivided into 9 subscales. These scales 
are divided in two domains: adaptive coping (e.g. positive reappraisal) and maladaptive 
coping (e.g. self-blame and catastrophizing). A higher score indicates more use of a particular 
coping style.50 Internal consistency at baseline and the three follow-up assessments was .89, 
.91, .94, and .94, respectively, for the adaptive coping domain, and .87, .88, .87, and .86, 
respectively, for the maladaptive coping domain.
 Illness perceptions were assessed with the Brief Illness Perceptions Questionnaire 
(B-IPQ51, 52). It contains 9 self-report items on cognitive and emotional representations of 
illness. Eight dimensions (e.g. consequences of illness, personal control, concerns, and 
understanding) are scored from 0-10. A higher score represents more negative illness 
perceptions. Internal consistency at baseline and the three follow-up assessments was .74, 
.79, .78, and .75.
 Sleep problems were assessed using the sleep problem items of the Youth Self-
Report (YSR; for ages 10-1753) and the Adult Self-Report (ASR; for ages 18-2554). These 
questionnaires contain three comparable items on sleep problems (scored 0, 1 or 2), of 
which the scores were added up: ‘I sleep more than most other people during day and/or 
night.’ and ‘I have trouble sleeping.’
 Clinical disease activity was assessed with four validated clinical disease activity 
measures around the moments that patients filled out the online questionnaires on 
psychological symptoms. For patients of 10-20 years with CD, the short Pediatric Crohn’s 
Disease Activity Index (sPCDAI55) was used; for patients with UC and IBD-U the Pediatric 
Ulcerative Colitis Activity Index (PUCAI56). For patients of 21-25 years with CD, the Crohn’s 
Disease Activity Index (CDAI57) was used; for patients with UC and IBD-U the partial Mayo 
score.58 All are physician rated forms (not online), that provide four categories of clinical 
disease activity: remission, mild, moderate, and severe.
Statistical analysis
We tested differences in demographic and disease characteristics between the two groups 
at baseline using t-tests, Mann-Whitney tests and chi-square tests. 
 To be able to combine all participants in one analysis (thereby maximizing power), 
despite the use of age-appropriate instruments, we calculated a Reliable Change Index 
(RCI59) value separately for anxiety and depression (primary outcomes) for each participant, 
at each assessment. The RCI of an instrument is calculated from the standard error of 
measurement (SEM) of the pretest reliability and the test-retest reliability. The RCI can have 
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three possible values; reliably improved; no reliable change; and reliably deteriorated (see 
Appendix 2 for RCI details). Chi-square tests were used to test for differences in RCI values 
between the two groups. These analyses included only patients for whom pre- and posttest 
data were available (see Table 1 for the details on sample sizes for each chi-square test). The 
proportions of patients who developed clinical anxiety and/or depression were compared 
between groups using a separate chi-square test.
 For exploratory analyses, we used linear mixed models (taking into account 
missing data) to compare the change on full-range scores from baseline to 6 and 12 months 
follow-up between groups. The outcomes were anxiety (SCARED or HADS-A), depression 
(CDI or BDI-II), HRQOL (IMPACT-III or IBDQ), social functioning (subscale of IMPACT-III or 
IBDQ), coping (CERQ), illness perceptions (B-IPQ), and sleep problems (YSR or ASR). The 
starting model for all outcomes included a random intercept and fixed factors for time, 
group, and the interaction between time and group. Next, we examined with the use of 
likelihood-ratio tests whether adding a random slope of time and a quadratic term of time 
and the interaction between the quadratic term of time with group improved the model. 
The restricted maximum likelihood method was applied, as this is preferred for relatively 
small sample sizes.60, 61 Because we had no expectations about the relationship between the 
random intercept and slope, we used an unstructured covariance structure was selected, 
which is the most flexible structure.
 Follow-up data were analyzed based on the intention-to-treat principle, unless 
otherwise specified. For the chi-square analyses (with the primary dichotomous outcomes) 
this implied inclusion of only those randomized for whom follow-up data were available 
(since follow-up data were required to calculate the RCI). For the exploratory analyses 
(secondary continuous outcomes), the intention-to-treat principle implied inclusion of all 
randomized patients, also those without follow-up data (since the linear mixed models take 
into account missing data and follow-up data were not required). A p value of <.05 was 
considered statistically significant. Data were analyzed using SPSS version 24.
Sample size and power
Sample size and power were based on anxiety and depressive symptoms as primary 
outcomes. Meta-analytic studies in youth without a somatic disease have shown medium-
to-large effect sizes for anxiety symptoms62 and medium effect sizes for depressive 
symptoms.63 These correspond with j >0.40 and j >0.30, for anxiety and depressive 
symptoms respectively. For the main chi-square analyses this means that a sample size of 
70 patients would give us enough power for the anxiety outcomes (>85%, β = 0.14) and 
medium power for the depression outcomes (>60%, β = 0.39).
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RESULTS
Demographic data
In total, 70 patients were randomized; 37 to the PASCET-PI group and 33 to the CAU group 
(see Figure 1). Attrition was very low; only two patients dropped out of the PASCET-PI, and 
only three patients (6 months) and two patients (12 months) did not complete follow-up 
assessments. Demographic variables did not significantly differ between the groups (see 
Appendix 3): percentage males (27.0% vs. 36.4%, p = .401), mean age (18.62 vs. 17.69, p 
= .393), socioeconomic status (p = .348), and ethnicity (p = .749). The number of patients 
included at baseline based on anxiety, depression or both did not differ between groups as 
well (p = .070). The patients’ disease characteristics did not differ between the groups: IBD 
subtype (% CD 48.6% vs. 54.5%), Paris classification at diagnosis (CD location; p = .808, CD 
behavior; p = .243, UC extent; p = .069, UC severity; p = .104), percentage of patients in clinical 
remission (73.0% vs. 78.8%, p = .571), and use of IBD medication (% immunomodulators 
43.2% vs. 48.5% and % biologicals 21.6% vs. 36.4%). However, the median disease duration 
was longer in the PASCET-PI group than in the CAU group (2.59 vs. 1.17 years, p = .039). In 
the PASCET-PI group, 18 patients were aged 10-17 years and 19 patients 18-25 years. In the 
CAU group, 17 patients were aged 10-17 years and 16 patients 18-25 years.
 With respect to treatment integrity, adherence to the protocol was good. The mean 
number of sessions followed in the PASCET-PI group was 9.38 (out of 10). The mean number 
of family sessions followed was 2.57 (out of 3), and the mean number of booster sessions 
followed was 2.59 (out of 3). In all sessions, at least 75% of the topics were discussed.
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Excluded  (n=178)
• Declined to par�cipate – screening (n=169)
• No screening data (n=9)
Lost to follow-up (missing data post assessment)
• 6 months (n=1)
• 12 months (n=1)
Allocated to Care-As-Usual (n=33)
11 care providers in 6 centers performed interven�on
Number of pa�ents treated by each
• care provider (median=3, IQR=2, min=1, max=9)
• center (median=5, IQR=2.5, min=1, max=15)
Allocated to Cogni�ve Behavioral Therapy (n=37)
• Received allocated interven�on (n=37)
• Did not receive allocated interven�on (n=0)
Lost to follow-up (missing data post assessment)
• 6 months (n=2)
• 12 months (n=1)
Discon�nued interven�on (n=2; dropped out intervention, but 
provided post assessment data)
Alloca�on
Follow-Up
Step 2: Inclusion RCT
Randomized (n=70)
Enrollment
Analysed
• Baseline data (n=33)
• Post assessment data at 6 months (n=32)
• Excluded from analysis (n=0)
Analysed
• Baseline data (n=37)
• Post assessment data at 6 months (n=35)
• Excluded from analysis (n=0)
Analysis 6 months
Alloca�on
Excluded  (n=304)
• Not mee�ng inclusion criteria (n=195)
• Too severe anxiety/depression (n=46)
• Declined randomisa�on (n=61)
• Incomplete screening data (n=2)
Step 1: Inclusion baseline screening
Screened for anxiety/depression (n=374)
Assessed for eligibility (n=552)
Analysed 
• Baseline data (n=33)
• Post assessment data at 12 months (n=32)
• Excluded from analysis (n=0)
Analysed
• Baseline data (n=37)
• Post assessment data at 12 months (n=36)
• Excluded from analysis (n=0)
Analysis 12 months
Figure 1. CONSORT study flow chart 
Abbreviations: RCT= randomized controlled trial, IQR= inter quartile range
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Effect of disease-specific CBT on symptoms of depression and anxiety
In the chi-square tests, some cells in the cross-tabulation were smaller than 5. Only few 
patients (0-4) were in the ‘Reliable increase of score / deterioration’ category (i.e. deteriorated 
in anxiety or depression). Therefore, we combined this category with the ‘No reliable change’ 
category, to test if the PASCET-PI and CAU groups differed with respect to the proportions 
of patients who had improved on anxiety or depression. In these main analyses, RCI values 
for anxiety (χ2 (1) = .226, p = .801) and depression (χ2 (1) = 2.680, p = .141) after 6 months 
did not differ between the groups, and neither did the RCI values for anxiety (χ2 (1) = .337, 
p = .626) after 12 months. This indicates that in both groups a similar proportion of patients 
improved. For depression after 12 months, the RCI values differed significantly between the 
groups, indicating that a higher proportion of patients in the CAU group improved than in the 
PASCET-PI group (χ2 (1) = 5.460, p = .026), see Table 1. In the PASCET-PI group, two patients 
developed clinical anxiety and/or depression during follow-up, versus one patient in the CAU 
group, which was not significantly different (χ2 (1) = .240, p = .543). 
Table 1. Crosstabulation of 6 and 12 month RCI of symptoms of anxiety and depression 
versus group
6 months
Reliable increase of score /  
deterioration or no reliable change
Reliable decrease of score / improvement Total
RCI categories anxiety (SCARED or HADS-A)
CAU 11 (34.4%) 21 (65.6%) 32
CBT 14 (40.0%) 21 (60.0%) 35
Note. Pearson Chi-square = .226, p = .801, φ = -.058 (95%BI .000-.293). Numbers in parentheses indicate row percentages
RCI categories depression (CDI or BDI-II)
CAU 11 (34.4%) 21 (65.6%) 32
CBT 19 (54.3%) 16 (45.7%) 35
Note. Pearson Chi-square = 2.680, p = .141, φ = .200 (95%BI .000-.439). Numbers in parentheses indicate row percentages
12 months
Reliable increase of score / deterioration or no 
reliable change
Reliable decrease of score / improvement Total
RCI categories anxiety (SCARED or HADS-A)
CAU 12 (37.5%) 20 (62.5%) 32
CBT 16 (44.4%) 20 (55.6%) 36
Note. Pearson Chi-square = .337, p = .626, φ = .070 (95%BI .000-.306). Numbers in parentheses indicate row percentages
RCI categories depression (CDI or BDI-II)
CAU 8 (25.0%) 24 (75%) 32
CBT 19 (52.8%) 17 (47.2%) 36
Note. Pearson Chi-square = 5.460, p = .026, φ = .283 (95%BI .036- .521). Numbers in parentheses indicate row percentages
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 To provide more insight into age differences, we also performed the chi-square 
analyses separately for the 10-17-year-olds and the 18-25-year-olds. The results were 
almost completely similar to the chi-square analyses in the total group (data not shown). 
However, a higher proportion of 18-25-year-olds in the CAU group improved on depression 
after 12 months than in the PASCET-PI group (χ2 (1) = 6.349, p = .019).
 The exploratory analyses gave similar results as the chi-square analyses. For all 
outcomes, the residuals of the models were approximately normally distributed. For the 
SCARED and the IMPACT-III, the final model included a fixed factor for time and group, a 
random intercept, and a random slope for time, since the likelihood-ratio test indicated 
that adding a random slope for time improved the model significantly. Because this was not 
the case for all the other outcomes, the respective models did not include a random slope 
for time. For the BDI-II, the final model included fixed factors for time group, and for the 
interaction between time and group, and a random intercept. For all the other outcomes, 
however, including a fixed factor for the interaction between time and group did not improve 
the model. Therefore, for all other outcomes the final model included fixed factors for time 
and group, and a random intercept. For the SCARED, HADS-A, and BDI-II, adding a quadratic 
term of time significantly improved the model. Then adding the interaction between the 
quadratic term of time and group did not improved the model for these outcomes.
 No significant time-group (PASCET-PI versus CAU group) interaction effect was 
found for anxiety (SCARED: p = .798; HADS-A: p = .997), depression (CDI: p = .693), HRQOL 
(IMPACT-III Total score: p = .117; IBDQ Total score: p = .247), social functioning (IMPACT-
III Social functioning: p = .407; IBDQ Social functioning; p = .879), coping (CERQ Adaptive 
coping: p = .506; CERQ Maladaptive coping: p = .592), illness perceptions (B-IPQ: p = .474) 
and sleep problems (YSR/ASR: p = .858). The only significant time and group interaction 
was found on the BDI-II (p = .025, favoring the CAU group over the course of 12 months). 
Therefore, for all outcomes except the BDI-II, the effect of time was similar for both groups. 
Table 2 presents the coefficients for time presented for the model without the interaction 
of time and group; only for the BDI-II the estimate is presented for the model with the 
interaction of time and group included. For all outcomes (except sleep problems; p = .070), 
the average effect of time was significant, indicating that over the course of 12 months, 
patients improved on their psychological outcomes (anxiety, depression, HRQOL, social 
functioning, coping, and illness perceptions). For the SCARED, HADS-A, and BDI-II, the 
quadratic effect was significant. This indicates that for these outcomes the model follows a 
quadratic trajectory over the course of 12 months.
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DISCUSSION
In the current RCT we examined the long-term effects of a disease-specific CBT on 
psychological outcomes of youth with IBD. The results showed that, overall, both groups 
improved on anxiety and depressive symptoms, HRQOL, social functioning, coping, and illness 
perceptions and that these improvements sustained until the final follow-up assessment 
at 12 months. In both groups a similar proportion of patients improved in anxiety and/or 
depression (main analyses) and the groups did not differ in the proportion of patients that 
developed clinical anxiety and/or depression. However, in general, no differences between 
the CBT and CAU groups were found. 
 Our results are partly in line with results of earlier similar trials. Levy et al.20 found 
that three sessions of social learning and cognitive behavioral therapy (SLCBT) outperformed 
educational support, but only in improving HRQOL (after 1 week of follow-up), coping 
and school attendance (after 12 months of follow-up), and in parent- and child-reported 
distract/ignore coping of the child. In line with our results, no beneficial effect of SLCBT was 
found on anxiety, depression, or coping or functional disability. Szigethy et al.22 compared 
CBT with supportive nondirective therapy and found that CBT outperformed supportive 
nondirective therapy in improving disease activity after three months, with a difference of 
10 points in raw disease activity scores from pre- to post-intervention. When only data of 
patients with active CD were analyzed, CBT was more effective than supportive nondirective 
therapy in improving disease activity and somatic depressive symptoms after three months 
of treatment.64
 Explanations for the lack of an effect of the disease-specific CBT in our trial may 
be the following. First, most patients in our study experienced no or only mild somatic 
symptoms at baseline, reflected by low IBD disease activity scores. Receiving the full 
protocol of CBT may have been “over-treatment” in patients with a rather low burden of 
disease, somatically as well as psychologically. Many patients remarked that the acquired 
skills would be useful and necessary in times of disease exacerbations. Thus, we hypothesize 
that CBT may be more useful for patients with severe anxiety/depression and/or those with 
active disease.
 Second, patients in the control group may have received more than just standard 
medical care, because they participated in the trial. Via the informed consent form and the 
invitation by the medical staff, they were informed about psychological problems in IBD. 
Then, they were systematically screened with questionnaires and diagnostic interviews. This 
provided them with the opportunity to express their emotions and concerns, which may 
have evoked feelings of reassurance and safety. The created awareness may have benefitted 
all patients, and may have been enough to improve the subclinical anxiety and depression. 
This also may be an explanation for the fact that so few patients in both groups developed 
clinical anxiety and/or depression.
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 It is unexpected and counter-intuitive that at 12 months of follow-up the proportion 
of patients that had improved on depressive symptoms was the highest in the CAU group, 
albeit this was only the case for the 18-25-year old patients. Youth in this age range have a 
more advanced cognitive development than younger peers. Those receiving CBT may find 
themselves confronted with the life-long impact of IBD (on for example long-lasting romantic 
relationships, work, and career prospects. This may maintain the depressive symptoms. 
Still, this unexpected finding, may have been a chance finding, considering the number of 
statistical tests. and also considering that at 3 and 6 months no difference in depression was 
found between the CBT and CAU groups. 
 Furthermore, at baseline the disease duration in the CBT group was significantly 
longer than in the CAU group (2.59 vs. 1.17 years). This may have had an effect on the 
outcomes, since several studies showed that a shorter disease duration is associated with 
lower HRQOL or more emotional/behavioral problems.65, 66 Patients in the CBT group may 
have had fewer psychological problems, and, therefore, less room to improve. This is not 
likely, however, considering the fact that both the RCI analysis and the exploratory linear 
mixed models took into account the baseline psychological outcomes scores.
 In addition, since the PASCET-PI was originally developed and found effective 
for improving mainly depression22, it was unexpected that we found no differences on 
depressive symptoms. Furthermore, we found no additional effect on anxiety symptoms, 
although we adapted the PASCET-PI to also target anxiety. Szigethy et al.64 only found an 
additional effect of CBT on somatic depressive symptoms and disease activity in patients 
with active CD. In our study approximately three-quarters of the patients were in clinical 
remission, which may explain differences in results.
 We also did not find differences between the groups in improvement in coping and 
negative illness perceptions. For coping or illness perceptions to change after psychological 
treatment, these should explicitly have been made the focus of treatment. The PASCET-
PI contains components that may influence coping (e.g. practicing with positive thinking) 
and illness perceptions (e.g. discussing the illness narrative of the patient). Perhaps, there 
was too little focus on challenging coping styles in the current protocol. An alternative 
explanation may be that the patients experienced little negative illness perceptions, due 
to the low levels of disease activity (e.g.67, 68). However, the secondary analyses were 
exploratory (and conducted in subgroups of patients based on age). As a consequence, this 
study may have not been the most suitable to investigate coping and illness perceptions. 
Future studies should therefore investigate how coping and illness perceptions can be the 
focus of psychological treatment to improve anxiety and depression. 
Clinical and future directions
Considering the results of the current study and that of earlier studies into CBT for youth 
with IBD20, 22, 64, it remains unclear which patients with IBD will benefit the most from CBT, 
how the intervention should be delivered, and which outcomes improve the most.  
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 Based on our findings, providing a full protocol of disease-specific CBT seems 
not necessary for preventive purposes. We assume that that patients with more clinical 
anxiety and/or depression likely will benefit more from CBT, as was found in both youth22 
and adults with IBD.69 Moreover, although this is not clear yet, a full protocol of CBT may be 
more helpful for improving their psychological as well as somatic symptoms of IBD patients 
who suffer from active disease. However, since these patients are often hospitalized or 
need intensive pharmacological treatment, it is important to find out how the CBT can be 
delivered best to them (e.g. via telephone or Internet). Group interventions in the hospital 
have been shown to be promising in youth with IBD70 and effective in youth with chronic 
illnesses (including IBD71). Furthermore, apart from anxiety, depression and HRQOL, other 
clinically relevant psychological outcomes such as social functioning, school attendance, or 
treatment adherence may be important to target as well. Psychological interventions aiming 
at these outcomes have been shown to be effective in youth with either IBD or other chronic 
illnesses.72, 73 
Strengths and limitations
One of the strengths of the current study is the randomized and prospective design, in 
which the interviewer and the treating physicians were blinded to the group assignment. In 
addition, we included patients with a broad and clinical relevant age range and our findings 
have external validity since patients came from both rural and urban centers (including 
different therapists). Furthermore, the study had very low attrition and we investigated 
several psychological outcomes. An important limitation is that we did not control for 
attention placebo effects. We chose to use standard medical care as control condition, 
because it was already known that CBT as state-of-the-art psychotherapy performs better 
than placebo for anxiety and depression. Therefore, we deemed this as the most clinical 
relevant comparison, considering that this resembles our current care best. Furthermore, 
the relatively small sample size is a limitation, although the study was sufficiently powered. 
In addition, to cover the whole age-range, we had to use several different age-specific 
instruments, making it difficult to combine all patients in one analysis. Consequently, the 
exploratory linear mixed models could only be performed on subgroups.
Conclusion
The current RCT showed that, in general, patients in both the CBT and the control group 
remained stable or improved on their psychological outcomes 6 and 12 months after 
baseline. CBT did not have an additional effect in improving anxiety, depression, HRQOL, 
social functioning, coping, illness perceptions, and sleep problems, when compared to CAU. 
We think that a full protocol of CBT was not necessary in patients with relatively low somatic 
and psychological burden and that the awareness created by participating in an RCT had a 
positive effect on the psychological outcomes of patients in both groups.
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APPENDIX 1A. Outline of the PASCET-PI 29, 30
Session number Content of session
Session 1
Live (60 min)
Introduction of ACT & THINK model and PASCET-PI, building work alliance, psycho-education 
about IBD and depression or anxiety, illness narrative
Session 2
Live (60 min)
Mood monitoring, explaining link between feelings, thoughts and behaviors, discussing feeling 
good and feeling bad, problem-solving
Session 3
By telephone (30 min)
Link between behavior and feelings: Activities to feel better
Session 4
Live (60 min)
Be Calm and Confident: relaxation exercises
Session 5
Live (60 min)
Be Calm and Confident: positive self versus negative self, training social skills
Session 6
By telephone (30 min)
Talents: developing talents and skills makes you feel better
Session 7
Live (60 min)
Social problem solving, discussing the ACT skills and introduction of the THINK skills with 
discussing negative thoughts (Think positive)
Session 8
By telephone (30 min)
Help from a friend, Identify the ‘Silver Lining’, and No replaying bad thoughts
Session 9
By telephone (30 min)
Keep trying – Don’t give up, making several plans to use the ACT & THINK skills
Session 10
Live (60 min)
Quiz on ACT & THINK model, discussing use of ACT & THINK skills in the future, updating illness 
narrative
Booster 1
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & 
THINK skills
Booster 2
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & 
THINK skills
Booster 3
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & 
THINK skills
Family 1
Live (60 min)
Parental view on IBD, family situation, psycho-education about IBD and depression or anxiety, 
introduction of ACT & THINK model and PASCET-PI
Family 2
Live (60 min)
Parental view on progress, the ACT & THINK skills that are most effective for the patient, 
expressing emotions within family, family communication, family stress game
Family 3
Live (60 min)
Parental view on progress, family communication, parental depression or anxiety
Abbreviations: IBD= Inflammatory Bowel Disease; PASCET-PI= Primary and Secondary Control Enhancement 
Training for Physical Illness.
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APPENDIX 1B. Tree Diagram
Domain
Interven�on
Techniques
Sub-Techniques
Cogni�ve behavioral therapy
Cogni�ve interven�ons Behavioral interven�ons
Social support Cogni�verestructuring
Psycho-
educa�on
Goals & 
Planning Relaxa�on
Behavioral
ac�va�on
Improving
rela�on-
ships
Help from
a friend
No 
nega�ve
thoughts
Think
posi�ve
Improving
knowledge
Problem-
solving
Relaxa�on
exercises Ac�vi�es
Discover & 
develop
talent
Parental
involvement
Family 
communica�on
Parental
psycho-
educa�on
Expressing
emo�ons in 
familiy
Parental
depression & 
anxiety
7177
LONG TERM EFFECT OF CBT ON PSYCHOLOGICAL OUTCOMES
APPENDIX 2. Calculati on of Reliable Change Index (RCI) variables
Step 1. Calculati ng the standard error of diff erence for each parti cipant, separately for 
anxiety and depression:
In which x1 and x2 are the individual’s scores on baseline and at follow up, respecti vely. S1 is 
the pre-test variance for that instrument. rxx is the test-retest reliability of the instrument as 
reported in the manual.
•  SCARED (10-20 years): rxx = .81
47   | S1 = 13.389  | Sdiff = 8.253
• HADS-A (21-25 years): rxx = .89
74   | S1 = 2.373  | Sdiff = 1.113
• CDI (10-17 years): rxx = .86
34  | S1 = 4.648  | Sdiff = 2.459
• BDI-II (18-25 years): rxx = .93
35   | S1 = 4.38  | Sdiff = 1.639
Step 2. Calculati ng the diff erence between the follow up and the baseline for each 
parti cipant, separately for anxiety and depression.
Step 3. Calculati ng the RC value for each parti cipant, separately for anxiety and depression.
Step 4. Determining the RCI value for each parti cipant, separately for anxiety and depression. 
Both for anxiety and depression this leads to a variable with three possible values: no reliable 
change, reliable deteriorati on, and reliable improvement. An RC value of between -1.96 and 
1.96 indicates no reliable change (p < .05). When RC is higher than 1.96, this indicates a 
reliable increase in the score (p < .05), i.e. reliable deteriorati on (as for all the instruments 
applies that a higher score represents more symptoms). When RC is lower than -1.96, this 
indicates a reliable decrease in the score (p < .05), i.e. reliable improvement.
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APPENDIX 3. 
Baseline demographic and disease characteristics
PASCET-PI group (n=37) CAU group (n=33) p value
Demographic status
Male, n (%) 10 (27.0) 12 (36.4) .401a
Age, mean (SD), years 18.62 (4.27) 17.69 (4.82) .393b
SES, n (%) 
Low 8 (21.6) 4 (12.9)
.348aMiddle 15 (40.5) 10 (32.3)
High 14 (37.8) 17 (54.8)
Ethnicity, n (%) (n = 64)
Dutch / Western 30 (81.1) 25 (80.6)
.749a
Other 7 (18.9) 6 (19.4)
Included on, n (%)
Anxiety 30 (81.1) 20 (60.6)
.070a
Depression 0 (0.0) 3 (9.1)
Both 7 (18.9) 10 (30.3)
IBD subtype, n (%) 
Crohn’s disease 18 (48.6) 18 (54.5)
.808aUlcerative colitis 14 (37.8) 12 (36.4)
IBD-U 5 (13.5) 3 (9.1)
Paris classification at diagnosis, n (%)
CD: location† (n = 36)
L1 4 (22.2) 2 (11.1)
.813a
L2 4 (22.2) 4 (22.2)
L3 6 (33.3) 8 (44.4)
+ L4a/L4b 4 (22.2) 4 (22.2)
CD: behavior (n = 36)
Nonstricturing, nonpenetrating 18 (100.0) 16 (88.9)
.243c
Stricturing, penetrating, or both 0 (0.0) 2 (11.1)
UC: extent‡ (n = 34)
Limited: E1 + E2 11 (57.9) 4 (26.7)
.069a
Extensive: E3 + E4 8 (42.1) 11 (73.3)
UC: severity
Never severe 18 (94.7) 11 (73.3)
.104c
Ever severe 1 (5.3) 4 (26.7)
Clinical disease activity, n (%)
Remission 27 (73.0) 26 (78.8)
.571a
Mild 10 (27.0) 7 (21.2)
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Disease duration, median, years 2.59 1.17 .039d
IBD Medications, n (%)
Aminosalicylates 18 (48.6) 12 (36.4) .300a
Immunomodulators 16 (43.2) 16 (48.5) .660a
Biologicals 8 (21.6) 12 (36.4) .173a
Corticosteroids§ 2 (5.4) 5 (15.2) .170c
Enemas 3 (8.1) 1 (3.0) .352c
No medication 2 (5.4) 1 (3.0) .543c
Abbreviations: PASCET-PI= Primary and Secondary Control Enhancement Training for Physical Illness; CAU= 
Care-As-Usual; SD= Standard Deviation; IBD= Inflammatory Bowel Disease; IBDU= Inflammatory Bowel Disease 
Unclassified; SES; Socioeconomic Status.
Notes: a chi-square, b ANOVA, c Fisher’s Exact test, d Mann-Whitney test | * UC includes IBD-U patients, † L1: 
ileocecal, L2: colonic, L3: ileocolonic, L4a: upper gastrointestinal tract proximal, and L4b distal from Treitz 
ligament ‡ E1: proctitis, E2: left sided colitis distal of splenic flexure, E3: extensive colitis distal of hepatic flexure, 
E4: pancolitis § prednisone (oral and intravenous) and budesonide (oral)
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CHAPTER 8
ABSTRACT
Background
Anxiety and depressive symptoms are prevalent in patients with inflammatory bowel 
disease (IBD) and may negatively influence disease course. Alternatively, disease activity 
could be affected positively by treatment of psychological symptoms. We investigated the 
effect of cognitive behavioral therapy (CBT) on clinical disease course in 10-25-year-old IBD 
patients experiencing subclinical anxiety and/or depression. 
Methods 
In this multicenter parallel group randomized controlled trial, IBD patients were randomized 
to disease-specific CBT in addition to standard medical care (CBT + Care us usual [CAU]) or 
CAU only. The primary outcome was time to first relapse in the first 12 months. Secondary 
outcomes were clinical disease activity, fecal calprotectin and C-reactive protein (CRP). 
Survival analyses and linear mixed models were performed to compare groups.
Results
Seventy patients were randomized (CBT+CAU=37, CAU=33), with a mean age of 18.3 years 
(±50% < 18 y) (31.4% male, 51.4% Crohn’s disease, 93% in remission). Time to first relapse 
did not differ between patients in the CBT+CAU vs CAU group (n=65, p=0.915). Furthermore, 
clinical disease activity, fecal calprotectin and CRP did not significantly change over time 
between/within both groups. Exploratory analyses in 10-18-year-old patients showed a 9% 
increase/month of fecal calprotectin as well as a 7% increase/month of serum CRP in the 
CAU group, which was not seen in the CAU+CBT group.
Conclusions
CBT did not influence time to relapse in young IBD patients with subclinical anxiety and/
or depression. However, exploratory analyses may suggest a beneficial effect of CBT on 
inflammatory markers in children. 
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INTRODUCTION
 Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]) is 
a chronic inflammatory disorder of the intestine, and is often accompanied by embarrassing, 
invalidating and unpredictable intestinal and systemic symptoms.1 
 Having IBD in adolescence impacts the lives of young IBD patients and is a threat 
to a healthy psychosocial development. Patients may suffer from an altered self-image2, the 
unpredictability of the disease, social isolation3, family and school dysfunction, and school 
problems.4, 5 Consequently, having IBD challenges a smooth transition to adulthood.6 Studies 
show that adolescent and adult IBD patients are at risk for anxiety and depression7, 8 Recent 
meta-analyses in children and adults have shown pooled prevalence rates ranging from 
16.4-35.1% for anxiety symptoms, and 15.0-21.6% for depressive symptoms.9, 10 
 The bidirectional relationship between IBD and psychological problems can be 
explained in terms of the ‘brain-gut’-axis11, meaning that the presence of anxiety and/or 
depressive symptoms or disorders can increase intestinal inflammation and may contribute 
to disease relapse, and conversely, intestinal inflammation can negatively influence mood.11, 
12 Several cross-sectional studies support this hypothesis by showing an association between 
clinical disease activity and symptoms of anxiety9, 12-14 or depression.9, 12, 13 In addition, this 
association has also been studied longitudinally. In a recent systematic review 5 out of 11 
studies reported an association between depressive symptoms and worsening of disease 
course.15 Similarly, for anxiety symptoms some studies did report this association 12, 16, while 
others did not.17, 18 Besides the influence of anxiety and/or depressive symptoms on disease 
activity and disease course, IBD patients with psychological symptoms are at risk for school 
or work absenteeism19, 20, lower therapy adherence8, higher health care utilization8, 14, all 
leading to high societal costs.21 Therefore, studies on the effect of psychological treatment 
on disease course and these other aspects are warranted.
 At present, cognitive behavioral therapy (CBT) is the most effective evidence based 
psychological treatment for anxiety and depressive symptoms and disorders in patients of 
all ages22,23 and has been found to be effective in reducing anxiety and depressive symptoms 
in both pediatric24,25 and adult26 IBD patients. 
 Studies investigating the effect of CBT on disease activity or disease course in patients 
with both anxiety and/or depressive symptoms or disorders are scarce. A randomized trial 
by Szigethy et al. (2014) studied two psychotherapies (CBT and supportive nondirective 
therapy) in adolescents with IBD with both minor and major depression. The authors report 
an improvement in clinical disease activity scores (raw increase of ±10 points on both the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn’s Disease Activity 
Index (PCDAI)) in the first 3 months in both groups, favoring CBT.25 In addition, a pilot study 
including 9 patients investigated the effect of CBT on clinical disease activity (PCDAI, PUCAI) 
in adolescent IBD patients suffering from an anxiety disorder, and showed that clinical 
disease activity improved from mild to inactive in half of the patients after 3 months.24 
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 Therefore, we performed a randomized controlled trial (RCT) in IBD patients aged 
between 10 and 25 with subclinical anxiety and/or depression and evaluated the effect of 
CBT on the course of anxiety, depression, disease course and inflammatory markers. The 
current study focused on the effect of 3 months of CBT on disease course in the following 
year. The primary outcome was time to first relapse, secondary outcome measures were 
clinical disease activity, C-Reactive Protein (CRP) and fecal calprotectin. We hypothesized 
that CBT would promote sustained remission, prolong the time until the first relapse and 
reduce clinical disease activity and inflammatory markers. 
MATERIALS AND METHOD
Design 
This multicenter parallel group RCT was designed according to the CONSORT guidelines 
for trials of non-pharmacologic treatments27 and was registered at ClinicalTrials.gov with 
study number NCT02265588. Participants were recruited from two university and four 
community hospitals in the South-West of The Netherlands from September 2014 until 
October 2016. Initially, only adolescents aged 10-20 years were included in the study, a few 
months after start of recruitment patients aged 21-25 years were also recruited. We chose 
to include adolescent and young adult patients because the impacts and challenges of a 
chronic disease in this unique life phase are different compared with what pediatric or adult 
patients are facing. 
 Eligible patients were screened for anxiety and/or depressive symptoms. 
Patients with symptoms of anxiety or depression or both were included, because anxiety 
and depressive symptoms often occur together and can both impact disease activity in 
IBD.16,28 Patients with subclinical/elevated symptoms, who did not meet the criteria of a 
psychiatric disorder, were randomized to either a 3-month course of disease-specific CBT 
(CBT+CAU) in addition to Care as Usual or to the control condition, Care as Usual (CAU). 
After randomization, medical and psychological data were collected at baseline, and at 3, 
6, and 12 months. Nine-month medical data was only collected if in routine medical care 
patients had scheduled appointments every 3 month. For more information regarding the 
study design, see van den Brink et al. (2016).29
Measurements
Demographic characteristics Age and gender were collected at baseline. Socioeconomic 
status was classified using the occupational level from parents or, if patients lived on their 
own, patients.30 Ethnicity was derived from the Rotterdam’s Quality of Life Interview.31 
 Clinical characteristics At baseline, disease type, age at diagnosis, disease duration, 
disease phenotype at diagnosis (Paris or Montreal classification)32, previous and current 
therapy, previous bowel surgery and previous relapses were collected. 
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 Anxiety and depressive symptoms For anxiety the Screen for Child Anxiety Related 
Emotional Disorders33 (SCARED; 10-20 years; cutoff ≥26 for boys and ≥30 for girls) and the 
Hospital Anxiety and Depression Scale – Anxiety Scale34 (HADS-A; 21-25 years; cutoff ≥8) were 
used. For depression the Child Depression Inventory35 (CDI; 10-17 years; cutoff ≥13) and the 
Beck Depression Inventory – second edition36 (BDI-II; 18-25 years; cutoff ≥14) were used. 
 Clinical disease activity Clinical disease activity was assessed by four validated, 
physician-reported, age appropriate instruments, with higher scores indicating more active 
disease. In UC patients the Pediatric Ulcerative Colitis Activity Index37 (PUCAI; 10-20 years; 
score 0-85) and the partial Mayo38 (pMayo; 21-25 years; score 0-9) were used. In CD patients, 
the Pediatric Crohn’s Disease Activity Index39 (PCDAI; 10-20 years; total score 0-100) and the 
Crohn’s Disease Activity Index40 (CDAI; 21-25 years; score 0-600) were used. 
 Relapse The presence of a relapse at any time point during follow-up was determined 
by the treating physician. For UC, relapse was defined as follows: (a) clinical disease activity 
score above cut-off (PUCAI >34 or an increase of ≥20 points or pMayo ≥341, 42) or (b) fecal 
calprotectin above 250 µg/g43 or (c) inflammation at endoscopy and (d) intensification of 
treatment. For CD, relapse was defined as: (a) clinical disease activity score above cut-off 
(PCDAI >30 or an increase of ≥15 points or CDAI score >15040, 44) or (b) fecal calprotectin 
above 250 µg/g43 or (c) inflammation at endoscopy and (d) intensification of treatment. 
In addition, perianal disease requiring intervention in CD patients was also considered a 
relapse. If patients experienced a relapse at baseline, this relapse was not taken into account 
and monitoring for relapse started after remission was achieved.
 Inflammatory markers C-reactive protein (CRP) and fecal calprotectin were 
obtained during visits to the outpatient clinic as part of routine clinical care. 
Recruitment and procedure
Step 1: Screening 
Eligible patients (and parents, for patients age 10-20 years) were informed about the study 
by their treating (pediatric) gastroenterologist. Preferably, patients were recruited when they 
were in clinical remission, considering the impact of the intervention. The following in- and 
exclusion criteria were used: (1) a diagnosis of IBD conform current diagnostic criteria45-47 (2) 
age 10-25 years and (3) informed consent provided by patients and (if necessary) parents. 
Exclusion criteria were: (1) (parental report of) intellectual disability, (2) current treatment 
for mental health problems (pharmacological and/or psychological), (3) insufficient mastery 
of the Dutch language, (4) CBT in the past year (for at least 8 sessions), (5) a diagnosis 
of selective mutism, bipolar disorder, schizophrenia, autism spectrum disorder, obsessive-
compulsive disorder, posttraumatic or acute stress-disorder, (6) participation in another 
interventional study and (7) anxiety/depressive disorder. After written informed consent, an 
email with a link to the online questionnaires was sent to the patients (and parents). Anxiety 
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and depressive symptoms were assessed using age-appropriate self-report instruments (see 
measurements). For more information regarding step 1, see van den Brink et al. 2018.13 
Step 2: Inclusion RCT
If patients scored above the cut-off of the anxiety and/or depression questionnaire, a trained 
psychologist performed a diagnostic psychiatric interview (Anxiety Disorders Interview 
Schedule - Child and Parent Versions (ADIS-C/P)48) by telephone to determine the severity 
of the symptoms using age appropriate severity rating scales. The Pediatric Anxiety Rating 
Scale49 (PARS; 10-20 years; cut-off ≥18) and the Hamilton Anxiety rating scale50, 51 (HAM-A; 
21-25 years; cut-off ≥15) were used for anxiety symptoms. Depression was rated using the 
Child Depression Rating Scale Revised52 (CDRS-R; 10-12 years; cut-off ≥40), the Adolescent 
Depression Rating Scale Revised53 (ADRS-R; 13-20 years; cut-off ≥20) and the Hamilton 
Depression Rating Scale54, 55 (HAM-D; 21-25 years; cut-off ≥17). A psychiatric disorder was 
defined as meeting criteria for an anxiety or depressive disorder on the ADIS-C/P and a score 
equal to or above the clinical cut-off on the rating scale. Patients with subclinical anxiety/
depression (elevated symptoms of anxiety and/or depression not meeting the criteria for a 
psychiatric disorder) were eligible for randomization. Patients with an anxiety/depressive 
disorder were directly referred for psychological treatment and were excluded from the RCT 
since it would be unethical to randomize patients to the CAU condition.
Randomization
Patients with subclinical anxiety and/or depression were randomized to CBT+CAU or 
CAU with a 1:1 ratio. An independent biostatistician provided a computer-generated 
blocked randomization list with randomly chosen block sizes (with a maximum of 6) and 
stratification by center using the blockrand package in the R software package thereby 
providing numbered envelopes per center. After randomization, treatment in the CBT+CAU 
group started within a maximum of 4 weeks. The physicians assessing the disease activity 
and the psychologist conducting the diagnostic interviews were blinded for outcome of 
randomization. As patients could not be blinded, they were explicitly asked not to discuss 
the outcome of randomization with their treating physician. 
Intervention
The Primary and Secondary Control Enhancement Therapy (PASCET) is a manual-based 
CBT protocol, originally designed to treat depression.56 In this study the PASCET-Physical 
Illness (PASCET-PI) was used, an IBD-specific modification which encompasses the illness 
narrative (i.e. perceptions and experiences of having IBD), disease-specific psychoeducation, 
techniques for coping with pain, social skills training and emphasis on IBD-related cognitions 
and behaviors.57 The protocol was modified to treat anxiety as well, and adjustments were 
made to make it age appropriate for patients aged 21-25 years. Participants received ten 
weekly sessions in a timespan of twelve weeks (6 face-to-face, 4 by telephone), three 
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additional family sessions (for patients <18 years and voluntary for patients >18 years living 
with their parents) and after the first 12 weeks three-monthly booster sessions. Patients 
were considered treatment completers if they had followed at least 8 sessions. The therapy 
was provided by all licensed (healthcare/CBT) psychologists, who received onsite training 
from the developer (E.M. Szigethy) of the PASCET-PI and executed the therapy in their own 
hospital or center.
 CAU consisted of regular medical appointments with the (pediatric) 
gastroenterologist every 3 months, involving a 15-30 minute consultation discussing 
overall wellbeing, disease activity, results of diagnostics tests, medication use, and future 
diagnostic/treatment plans, but no psychological intervention.
Sample Size and Power 
In our previously published study protocol, the primary outcome was defined as relapse 
rate per group in the first year after randomization.29 As the study continued and inclusion 
appeared challenging, we decided to also include 21-25 year old patients and re-estimate 
the sample size.58 Adapting the primary outcome to time to first relapse reduced the 
required sample size. 
 Literature shows that in general, approximately 40% of IBD patients have at least 
one relapse per year.59, 60 Based on expert opinion and previous studies61, 62 a 30% difference 
was expected between the 2 groups (survival rate 0.6 CBT; 0.9 CAU). To detect a difference 
of 0.3 in survival rate after 52 weeks of follow up, with a 2-sided significance level of 5% and 
80% power, 37 patients were need in each group. With 65 patients in remission at baseline, 
the study had a power of 77%. 
Statistical Analysis
Descriptive statistics were computed for demographic and clinical characteristics for the 
entire cohort and each treatment group. T, Chi2/Fisher exact and Mann-Whitney-U tests 
were used where appropriate, to assess baseline differences between treatment groups.
 For the primary outcome time to first relapse, survival analyses were performed. 
Kaplan-Meier curves were tested with a two-sided log rank test. For this analysis, patients 
with a relapse at baseline were excluded. For the longitudinally measured secondary 
outcomes clinical disease activity, CRP and Calprotectin, differences between the groups 
were assessed using linear mixed effects models to account for the correlations in the 
repeated measurements. All 4 clinical disease activity scores were converted to a 0-1 
score (Supplementary Table 1, Step 1). This pooled disease activity score enabled us to 
include all patients in one analysis. As all three secondary outcomes had a non-normal 
distribution, transformations were done to assure normality. CRP and calprotectin were 
transformed using the natural logarithm. For pooled clinical disease activity, a two-step 
logistic transformation was performed (Supplementary Table 1, Step 2 and 3). In all three 
linear mixed models, treatment condition (result of randomization), time in months and the 
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interaction between time*treatment were added in the specification of the fixed effects. A 
likelihood ratio test (LRT) was used to specify the random effects. With the LRT the model 
with a random intercept only (covariance structure: identity) was compared with the model 
with both a random intercept and random slope (covariance structure: unstructured). 
Restricted maximum likelihood (REML) was applied as the estimation method. Assumptions 
of the models were checked using residual plots. Considering the previous findings in 
pediatric patients25, exploratory analyses were performed in patients 10-18 years of age. 
 All analyses were performed based on the intention-to-treat (ITT) principle. For 
patients with missing and/or incomplete assessments, only available data were used. A 
p-value of <0.05 was considered statistically significant. Data analyses were performed using 
SPSS version 24.0 (IBM SPSS Statistics for Windows, Armonk, NY, USA). 
ETHICAL CONSIDERATIONS
This study conformed to the principles of the Declaration of Helsinki and was approved 
by the Institutional Review Board of the Erasmus Medical Center and of each participating 
center. 
RESULTS
Patient characteristics
A total of 552 patients were eligible to participate, of which 374 patients completed 
the anxiety and depression questionnaires at baseline. Of the 371 patients who 
completed both questionnaires, 47.4% experienced elevated symptoms of anxiety 
and/or depression. Of the 134 patients who participated in the diagnostic psychiatric 
interview, 46 patients (34%) met the criteria for a psychiatric disorder and 88 patients 
(66%) experienced subclinical symptoms of anxiety and/or depression13. Of these 88, 70 
patients (80%) gave consent for randomization (CBT+CAU (n=37) CAU (n=33)) (Figure 1). 
 Of all randomized patients, 68.6% were female, ± 50% was <18 years of age 
(median age [interquartile range]: 18.27 [14,5 – 22,37] years. 51.4% had a diagnosis of CD, 
80.9% had a Western ethnicity and socioeconomic status was respectively low, middle and 
high in 17.1%, 36.8% and 45.6% (data not shown). Patients were included based on anxiety 
symptoms (71.4%), depressive symptoms (4.3%) or both (24.3%). Five patients experienced 
a relapse of IBD at baseline. 
 There were no baseline differences between the CBT+CAU versus the CAU group 
for demographic and disease characteristics, except for disease duration (p = 0.03) and 
corticosteroid dependency the past 3 months (p = 0.03) (Table 1). 
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Protocol adherence
Thirty-four out of 37 (92%) patients allocated to CBT+CAU completed ≥8 CBT-sessions 
(treatment completers). The other 3 patients followed 5, 3 and 1 sessions respectively. The 
mean number of treatment sessions followed was 9.38. 
 During follow-up, 2 patients in the CAU group (at 6 and 9 months) and 1 patient 
in the CBT+CAU group (at 3 months) developed severe symptoms meeting the criteria for 
a psychiatric disorder (2 patients with anxiety disorders, and 1 with anxiety and depressive 
disorder) and were directly referred for psychiatric/psychological help, whereas follow-up 
data was collected for the ITT analysis. Of these patients all follow up assessments were 
completed. Furthermore, on persistent parental request one patient switched from the CAU 
to the CBT+CAU group after 3 months, follow up data was collected, and analyses were 
performed according to the intention to treat principle (CAU group). Three patients missed 
one or more follow-up assessments (1 CAU group, 2 CBT+CAU group): 2 patients missed the 
6-month visit and 1 patient missed all visits after baseline. Nine-month medical data were 
collected for 26 patients. 
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Table 1. Patient characteristics
CBT (n=37)
Median (IQR) or n (%)
CAU (n=33)
Median (IQR) or n (%)
P-value
Gender, Male 10 (27%) 12 (36.4%) 0.40
Age (years) (% <18 years)
Age at diagnosis (years) 
Duration of disease (years)
18.5 (16.1-23.0)(48%) 18.0 (13.7-21.8) (51%) 0.37
15.7 (12.8-17.8) 14.9 (11.2-19.6) 0.90
2.6 (1.8-5.3) 1.3 (0.7-3.3) 0.03
Disease Type CD
UC
IBD-U
18 (48.6%) 18 (54.5%) 0.84
14 (37.8%) 12 (36.4%)
5 (13.5%) 3 (9.1%)
Paris classification at diagnosis*: CD location† (N=36) 0.83
L1 4 (22.2%) 5 (27.8%)
L2 6 (33.3%) 4 (22.2%)
L3 8 (44.4%) 9 (50.0%)
+ L4a/L4b 4 (22.2%) 4 (22.2%) 1.00
CD: behavior 1.00
Nonstricturing, non 
penetrating
18 (100%) 18 (100%)
Stricturing, penetrating, 
or both
0 (0%) 2 (11.1%)
Perianal disease 4 (22.2%) 4 (22.2%) 1.00
UC: extent (N=34)‡ 0.07
Limited: (E1+E2) 11 (57.9%) 4 (26.7%)
Extensive: E3+E4 8 (42.1%) 11 (73.3%)
UC: severity, ever severe 1 (5.3%) 4 (26.7%) 0.15
Clinical Disease activity¥ Remission
Mild 
Moderate 
Severe
29 (78.4%) 26 (78.8%) 0.55
6 (16.2%) 7 (21.2%)
2 (5.4%) 0 (0%)
0 (0%) 0 (0%)
CRP (mg/L) 2.0 (1.0-5.0) 1 (0.3-4.4) 0.19
Fecal calprotectin (µg/g) 67.5 (24.8-318.5) 169 (19.5-563.0) 0.73
Current medication use Aminosalicylates
Immunomodulators
Biologicals
Corticosteroids¶
Enemas§
No medication 
18 (48.6%) 12 (36.4%) 0.30
0.17
0.66
0.83
0.12
1.00
17 (45.9%) 16 (48.5%)
8 (21.6%) 12 (36.4%)
2 (5.4%) 3 (9.1%)
4 (10.8%) 0 (0%)
2 (5.4%) 1 (3%)
Steroid dependence past 3 months 3 (8.1%) 9 (27.3%) 0.03
Baseline relapse 4 (10.0%) 1 (3.0%) 0.36
Relapse preceding year 15 (40.5%) 10 (30.3%) 0.39
Bowel resection in history 3 (8.1%) 2 (6.1%) 1.00
8191
EFFECT OF CBT ON CLINICAL DISEASE COURSE
EIM II 7 (18.9%) 4 (12.1%) 0.44
Hospital type University Hospital 16 (43.2%) 15 (45.5%) 0.85
Anxiety and/or depressive 
symptoms
Anxiety symptoms
Depressive symptoms
Both
30 (81.1%)
0 (0.0%)
7 (18.9%)
20 (60.6%)
3 (9.1%)
10 (30.3%)
0.08
Abbreviations: IQR: interquartile range, CD: Crohn’s Disease, UC: ulcerative colitis, IBD-U: IBD-unclassified, CRP: 
C-reactive protein; CBT: cognitive behavioral therapy+ Care as Usual, CAU: Care as Usual
Notes: *UC includes IBD-U patients †L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: upper gastrointestinal tract 
proximal and L4b distal from Treitz ligament ‡E1: proctitis, E2: left sided colitis distal of splenic flexure, E3: 
extensive colitis distal of hepatic flexure, E4: pancolitis ¥ Based on clinical disease activity scores (pMayo, PCDAI, 
PUCAI, CDAI) ¶prednisone (oral and intravenous) and budesonide (oral) § aminosalicylate or corticosteroid enemas 
||EIM: involving skin (31.5%), eyes (1.75%), liver and biliary tracts (10.5%), joints (33.3%) and bones (28.1%). 
 
  
 
 
 
 
 
 
Assessed for eligibility (n=552) 
Excluded  (n=178) 
♦   Declined to par�cipate (n=170) 
♦   No screening data (n=8)  
Enrollment 
Excluded (n=304) 
♦   no symptoms anxiety/depression (n=195) 
♦   Too severe anxiety/depression (n=46) 
♦   Refused interview (n=42) 
♦   Declined randomisa�on (n=18) 
♦   Incomplete screening data (n=3)  
Analysed (n=33) 
♦ Excluded from analysis  (n=0) 
Discon�nued interven�on, missed one assessment 
& switch to CBT a�er 3 months (n=1) 
 
Allocated to Care As Usual (n=33) 
Discon�nued interven�on & missed one or more 
follow-up assessments (n=2) 
Discon�nued interven�on but provided data of all 
follow-up assessments (n=1) 
Allocated to interven�on (n=37) 
♦ Received allocated interven�on (n=37) 
♦ Did not receive allocated (n=0) 
Analysed (n=37) 
♦ Excluded from analysis (n=0)  
Alloca�on 
Analysis 
Follow-Up 
Randomised (n=70) 
Screened for anxiety and/or 
depressive symptoms (N=374) 
Figure 1. Consort study flowchart
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Primary outcome: time to first relapse 
During 52 weeks of follow up, 16 patients (43.2%) in the CBT+CAU group and 16 patients 
(48.5%) in the CAU group experienced one or more relapse. For the 65 patients in remission 
at baseline, no difference in time-to-relapse between groups was found (p 0.915) (Figure 2). 
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Figure 2. Survival curve time to first flare 
Abbreviations: CBT: cognitive behavioral therapy + Care as Usual, CAU: Care as Usual
Secondary outcomes
Clinical disease activity
Linear mixed model analysis showed no difference in the course of (pooled) clinical disease 
activity over time between both groups (interaction time*treatment not significant) (Table 
2). In addition, no significant changes were found within either the CBT+CAU or the CAU 
group (Table 2). Raw means of the 4 clinical disease activity scores over time are displayed 
in Figure 3. 
 Similarly, exploratory analysis in patients <18 years (n=35) showed no significant 
difference between both groups (p = 0.20), or within the CBT+CAU (p = 0.92) or the CAU (p = 
0.085) group (data not shown). In addition, there was no difference in CD versus UC patients 
(data not shown).
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Table 2. Results Linear mixed models (n=70)
Time Interaction time*treatment
β 95% CI p value β 95% CI p value
 Clinical disease activity 
 Within group CBT -0.006 -0.052 - 0.040 0.80
CAU 0.012 -0.036 - 0.061 0.61
 Between groups -0.019 -0.085 - 0.048 0.59
C-reactive protein (mg/dL) 
 Within group CBT -0.015 -0.050 - 0.020 0.41
CAU 0.021 -0.015 - 0.057 0.24
 Between groups -0.036 -0.086 – 0.014 0.158
Fecal calprotectin (µg/g) 
Within group CBT -0.019 -0.075 - 0.037 0.50
CAU 0.005 -0.052 - 0.063 0.851
Between groups -0.025 -0.11 - 0.056 0.543
Abbreviations: CI: confidence interval, CBT: cognitive behavioral therapy+ Care as Usual, CAU: Care as Usual; β: 
Beta-coefficient
Notes: ”Within group” displays whether there is a significant (p-value <0.05) change over time within either the 
CBT or the CAU group. “Between group” reflects whether the course over time is significantly different between 
the CAU and CBT group (p-value interaction time*treatment < 0.05)
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Figure 3. Raw means of clinical disease activity scores over time
Abbreviations: PUCAI: Pediatric Ulcerative Colitis Activity Index; pMayo: partial Mayo; PCDAI: Pediatric Crohn’s; 
Disease Activity Index; CDAI: Crohn’s Disease Activity Index; CBT: cognitive behavioral therapy+ Care as Usual, 
CAU: Care as Usual
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Inflammatory markers: Fecal calprotectin and C-reactive protein 
For CRP and fecal calprotectin, no significant differences were found between the CAU and 
CBT+CAU group (interaction term not significant). In addition, no significant change was found 
over time within each group (Table 2, raw means displayed in Supplementary Figure 1). 
 Exploratory analysis in 10-18-year-old patients (n=35) showed that for calprotectin, 
the interaction between time*treatment was significant (Beta-coefficient (β) -0.11, 95% CI 
[-0.195 - -0.031], p = 0.008). A statistically significant increase was seen in the CAU group 
over time (β 0.085, 95% CI [0.028-0.143], p = 0.004), whereas no change was found in the 
CBT+CAU group (β -0.028, 95% CI [-0.087 - 0.031], p = 0.35). Reverse transformation to the 
original scale revealed a 9% increase per month in the CAU group (data not shown). For CRP, 
no change was observed within the CBT+CAU group over time (β -0.012, 95% CI [-0.070 – 
0.046], p = 0.68), whereas a significant increase in the CAU group was observed (β 0.069, 
95% CI [0.011 – 0.13], p = 0.022). Reverse transformation to the original scale revealed a 7% 
increase per month in the CAU group. The interaction between time*treatment approached 
significance (β -0.081, 95% CI [-0.164 – 0.001], p = 0.054) (data not shown). For both CRP 
and calprotectin, there was no difference between CD and UC patients (data not shown).
DISCUSSION
This study was the first to investigate the effect of CBT versus CAU only on subsequent disease 
course in young IBD patients with subclinical anxiety and/or depression. We showed that 
time to first relapse in the first year after randomization did not significantly differ between 
patients in the CBT+CAU versus the CAU group. Furthermore, (pooled) clinical disease 
activity, CRP and fecal calprotectin also did not significantly change over time between the 
CBT+CAU and the CAU group, or within both groups. Exploratory analyses in 10-18-year-old 
patients suggested a significantly different course of fecal calprotectin between groups, with 
an increase in the CAU group. In addition, the difference in the course of CRP between the 
CAU and CBT+CAU group approached significance, with an increase in the CAU group. These 
results could suggest a possible positive effect of CBT on fecal calprotectin and CRP levels in 
10-18-year old patients, with perhaps a positive influence on intestinal inflammation in the 
longer term. However, this should be replicated in larger patient cohorts.
 Within the ‘brain-gut-axis’ it is hypothesized that a decrease in anxiety/depressive 
symptoms is accompanied by a decrease in (intestinal) inflammation and vice versa and 
that it may promote sustained remission. In the current trial both groups equally improved 
in anxiety/depressive symptoms and HRQOL after 363 and 6-12 months (Stapersma et 
al., submitted). Therefore, it is not surprising that we did not find a difference in clinical 
outcomes. As an improvement in anxiety and depressive symptoms within the CBT+CAU 
and CAU group over time was observed63, improvement in clinical outcomes within both 
groups could have been expected. Low baseline clinical disease activity and low baseline 
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inflammatory activity could also explain why we did not find an improvement in clinical 
disease activity scores, CRP or calprotectin in the whole sample. 
 Several studies reported on the effect of CBT on clinical disease course, specifically 
relapse rate, clinical disease activity and CRP. Time-to-relapse has not been studied before. 
Three studies included adolescent24, 25, 64, and three included adult65-68 IBD patients. Only 2 
pediatric studies selected patients based on anxiety24 or depression.25 In all these studies 
mostly patients in clinical remission or with mildly active disease were included. At first, Levy 
et al. tested the effectiveness of a brief (3 session) CBT (versus education support condition) 
in 185 adolescent IBD patients unselected for anxiety and depression and mainly in disease 
remission (63%). In line with our results, they reported no difference in relapse rate between 
the 2 conditions. An exploratory analysis in patients who experienced ≥2 or more flares in 
the year prior to the study, showed a decrease in relapse rate following CBT (CBT 16.7%, CAU 
52.9% p=0.04).64 However, this subanalysis was limited by the liberal definition of relapse, 
without considering objective items such as treatment intensification. Secondly, Szigethy 
et al. (2014) studied the effect of 2 psychotherapies (CBT versus supportive nondirective 
therapy) in 217 adolescents with IBD and minor/major depression. Although it is not 
reported in the article, looking at the mean PCDAI and PUCAI scores, it can be assumed that 
most patients were in remission or had mildly active disease. An improvement in depressive 
symptoms, HRQOL and pooled clinical disease activity after 3 months was found in both 
groups. However, it should be noted that this improvement corresponded with a rather 
small, not clinically relevant, decrease in raw disease activity scores of ±10 points on the 
PCDAI /PUCAI that was reported to be larger in the CBT group.25 A third study of interest was 
performed by Mickocka-Walus et al.: it investigated whether adding 10 sessions (face-2-face 
or online) CBT to standard medical care influenced clinical disease activity in 176 unselected 
adult IBD patients. Approximately 75% of patients had quiescent disease at baseline. No 
difference in remission rates after 12 months (73.2% CBT vs 71.7% CAU) or in clinical disease 
activity scores or CRP levels after 12 and 24 months were reported.66, 67
 In conclusion, studies reporting on the effect of CBT or other psychotherapies on 
disease course in IBD patients with (sub)clinical anxiety and/or depression are scarce.69 Only 
1 trial in pediatric IBD patients in remission or with mildly active disease reported a small 
improvement in clinical disease activity after CBT (and supportive non directive therapy).25 
As far as we know, no studies are available investigating the effect of psychotherapy on 
disease course in IBD patients with at least moderately active disease and suffering from 
(sub)clinical anxiety/depression.
 Our finding that CBT did not influence time to relapse, relapse rates or clinical 
disease activity is in accordance with the 2 previous studies in patients unselected for 
anxiety/depression.64, 66 In contrast, Szigethy et al. did find a small improvement in disease 
activity over time in both psychotherapy groups, favouring CBT.25 In addition, due to the 
short follow up, it is unclear how this improvement would evolve in the longer term. It 
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should be noted Szigethy et al. (2014) is the only RCT to date performed in patients selected 
for emotional symptoms (minor/major depression).
 It is possible that CBT is more effective in improving disease course (reducing 
inflammation) in patients with more severe anxiety/depression, as more improvement in 
psychological symptoms can be gained. This could be supported by Szigethy et al. (2014) 
who also included patients with major depression (±60%). In studies that did not select 
patients on anxiety/depression64, 66, 67, no improvement in clinical disease activity was found 
and only one study68 found a decrease in anxiety/depressive symptoms.
 Considering we did not find an effect of CBT on clinical disease course, it is possible 
that CBT has an effect on other measures of disease course, such as disability, healthcare 
use (e.g. visits to the Emergency Room) and school absenteeism. This is supported by a 
study by Keerthy et al. (2016), reporting a significant reduction in IBD-related healthcare use 
following CBT.70 We attempted to analyse school absenteeism in our sample, but could only 
collect data from patients 10-18 years because in The Netherlands only elementary and high 
schools register (reasons for) absenteeism. For 18 out of 35 children data was available (CBT: 
n=6, CAU: n=12), unfortunately, due to high heterogeneity of the registration methods used 
and missing data, analysis was not possible.
 It is not likely that baseline differences influenced our results. First, the longer 
disease duration in the CBT+CAU group could be accompanied by better coping strategies, 
providing an advantage in learning certain CBT-specific skills. As the improvement of 
psychological symptoms was similar in both groups63 (Stapersma et al. 2018, submitted) 
and disease course did not change over time, any influence of disease duration is unlikely. 
Second, baseline corticosteroid dependency in the past three months was higher in the CAU 
than in the CBT+CAU group (27.3% vs. 8.1%). This could indicate higher disease activity in 
the CAU group. However, considering there were no differences in other markers of disease 
activity (baseline clinical disease activity scores, relapse rates, CRP, fecal calprotectin and 
current steroid use) between both groups (see Table 1), it is plausible that this baseline 
difference was attributable to a type I error. 
Strengths and limitations  
Major strengths of this study are its multicenter RCT-design and the unique study population: 
pediatric and young adult IBD patients from regional as well as tertiary medical centers, 
which increases generalisability. In addition, and contrary to other studies,24, 25 we included 
patients based on subclinical anxiety and/or depression as these symptoms often occur 
together. Moreover, because CBT has previously been found to have a significant effect over 
and above placebo in previous studies71, CAU was chosen as a control condition because 
it resembles current clinical care best. These 2 aspects combined provided us with the 
opportunity to determine whether CBT prevents the development of subclinical into clinical 
disorders. Additionally, we included all IBD-types and pooling of clinical disease activity 
scores enabled us to study disease activity for all patients simultaneously. To investigate the 
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course of disease, we followed patients for 1 year after randomization, which is longer than 
in previous studies.25, 65, 68 Furthermore, the use of an IBD-specific CBT protocol and the low 
attrition, especially when compared to other studies25, 64, 66, 67, strengthen our study. Lastly, 
we were the first to incorporate fecal calprotectin levels and assess the effect of CBT on CRP 
levels in children. 
 Inevitably, our trial has some limitations. First of all, the study was relatively 
underpowered, as not all eligible patients were willing to participate in our trial with 
a time-consuming psychological intervention. This is a well-known problem in RCTs with 
a psychological intervention.25, 66 Another limitation is the relatively unequal result of 
randomization (37 vs 33), most likely due to randomization with random block sizes. 
Furthermore, the large number of patients with a Western ethnicity (80.9%), reduce the 
generalisability of our findings. Additionally, considering the majority of included patients 
were in clinical remission at baseline, we could not investigate whether the effect of CBT on 
disease activity would be greater in a population with active disease. Moreover, it would 
have been interesting to have included factors such as treatment adherence or IBS symptoms 
because they can both impact disease outcomes but are also affected by psychological 
symptoms. As previously mentioned, the effectiveness of CBT on psychological outcomes 
is published in separate publications (Stapersma et al. 2018 submitted).63 It is known that 
parental behavior and psychopathology are important determinants for children’s behavior. 
Therefore, a questionnaire measuring parental anxiety and depression was incorporated in 
the study design, which will be part of future analyses. Lastly, impact of disease was evaluated 
using the disease specific health related quality of life questionnaires, questionnaires that 
partly assess impact of disease. Unfortunately, validated patient reported outcomes of for 
example disease burden (symptom burden or disability) are not available for pediatric IBD. 
If available, they would have provided additional insight regarding experienced disease 
burden. Similarly, we did not include a validated measure of fatigue in our design, although 
this is a common invalidating complaint in IBD patients, possibly responsive to psychological 
interventions.
Directions for future research
The variation in study design, and mixed results from the available studies investigating the 
effect of CBT on disease course, force us to be careful drawing conclusions. Large, sufficiently 
powered studies, that factor in high attrition rates in sample size calculation, are necessary. 
In addition, several subgroups of patients (e.g. severe anxiety/depression, patients with at 
least moderately active IBD) need to be studied to determine whether there are certain 
patient groups in which CBT does influence disease course. Furthermore, other formats of 
psychotherapeutic interventions ánd other treatment modalities (e.g. group or e-therapy) 
with varying intensity should also be investigated in patients with (sub) clinical anxiety/
depression, as most studies have been performed in patients unselected for psychological 
problems. 
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CONCLUSION
In conclusion, CBT added to CAU does not influence subsequent clinical disease course 
in young IBD patients with subclinical anxiety and/or depression. However, the findings 
suggest that CBT may have a positive effect on inflammatory markers in pediatric patients. 
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Supplementary Table 1. Stepwise transformation clinical disease activity scores
Step 1: S’
S’: transformation to a [0,1] scale by dividing each individual score by the maximum score for that instrument 
(PCDAI 100, CDAI 600, PUCAI 85, pMayo 9).
Step 2: S’’
S” = [S’ * (n-1) + 0.5]/n   
(n=number of patients included in RCT: 70)
Step 3: S’’’
S’’’ = Ln (S’’/1-S’’)  
2
4
6
8
10
50
baseline 3 months 6 months 12 months
CR
P 
(m
g/
L)
250
500
1000
baseline 3 months 6 months 12 months
Fa
ec
al
 c
al
pr
ot
ec
tin
 (μ
g/
g)
CBT
CAU
Supplementary Figure 1: Raw means of CRP and Calprotectin levels over time
Supplementary Figure 1. Raw means of CRP and Calprotectin levels over time

PART II
Transiti on

Self-eﬃ  cacy did not predict the 
outcome of the transition to 
adult care in adolescents with 
infl ammatory bowel disease
Gertrude van den Brink, Martha A.C. van Gaalen, Marieke Zijlstra,
Lissy de Ridder, C. Janneke van der Woude, Johanna C. Escher
Acta Paediatr. 2019;108(2):333-338
CHAPTER 10
ABSTRACT
Aim
It can be difficult for adolescents with inflammatory bowel disease (IBD) to make the 
transition from paediatric to adult care. We studied the outcomes of this process and 
defined what constituted a successful transition. 
Methods
In 2008, 50 adolescents who attended our IBD transition clinic completed IBD-yourself, a 
self-efficacy questionnaire that we had previously developed and validated. We approached 
the subjects in 2014, two to six years after they transferred to adult care, and 35 agreed 
to take part in the current study. The outcome of transition was assessed by our newly 
developed Transition Yourself Score. In addition, the relationship between self-efficacy and 
the outcome of the transition was measured. 
Results
The mean age of the patients was 21.8 years and 69% suffered from Crohn’s disease. The 
transition process was successful in 63% of cases, moderately successful in 31% and failed 
in 6%. A successful transition was associated with effective use of medication and clinical 
remission at the time of transfer, but could not be predicted by self-efficacy. The Transition 
Yourself Score will be validated in future studies.
Conclusion
Nearly two-thirds (63%) of the adolescents who attended the IBD transition clinic had a 
successful transition to adult care. 
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SELF-EFFICACY AND OUTCOME OF TRANSITION
INTRODUCTION 
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of the 
intestine and manifests in adolescence in about 25% of cases.1, 2 As IBD is a lifelong disease, 
all paediatric patients will need to undergo the transfer to adult care. It is advisable to have 
a transition period to prepare patients and parents for the transfer, which refers to the 
actual handover of the patient to adult healthcare.3 A failed transition can adversely affect 
IBD related outcomes. It can increase non-adherence, non-attendance, hospitalisation rates 
and the need for surgery.4, 5 During the transition process, patients, their parents and the 
paediatric and adult gastroenterologist have specific tasks. Patients should acquire disease 
knowledge, autonomy and self-management6, 7, while parents need to stimulate their child’s 
independence and physicians should be knowledgeable about adolescents’ developmental 
and health issues and prepare them for transfer.3 Transition programmes are designed to 
facilitate the transition process and increase knowledge and self-management.3, 8 Self-efficacy, 
a person’s belief in their capability to organise and execute the actions required to deal with 
prospective situations, is thought to be a prerequisite for self-management.9, 10 It reflects 
self-care responsibility and has been shown to be a predictor of readiness to transfer.11 We 
previously developed and validated IBD-yourself, a specific IBD knowledge and self-efficacy 
questionnaire.12 
 The optimal model for IBD transitional care is currently unknown, as is the definition 
of a successful transition, due to the scarcity of outcome research. We aimed to develop 
a tool, the Transition Yourself Score, to measure the success of transition. The Transition 
Yourself Score was applied to our IBD transition cohort to assess transition outcomes one 
year after transfer. In addition, we assessed the predictive value of self-efficacy for successful 
transition.
METHODS
Participants
In 2008, 50 patients from our IBD transition clinic participated in the validation study of the 
self-efficacy questionnaire, IBD-yourself.12 Of these, 35 gave informed consent to participate 
in the current study in 2014. Data on patient characteristics, disease type, treatment and 
outpatient clinic visits after transfer were retrieved from their medical records. The study 
was approved by the Medical Ethics Committee of the Erasmus Medical Centre, Rotterdam, 
The Netherlands. 
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IBD transition clinic
Adolescents aged 16 to 18 years old with IBD are seen at the outpatient clinic, which is 
located in the adult gastroenterology department. A multidisciplinary team, consisting of a 
paediatric gastroenterologist, a paediatric IBD nurse specialist, an adult gastroenterologist 
and a family therapist, discuss all patients before the start of the clinic. Patients visit the clinic 
at least four times a year, where they are seen by either the paediatric gastroenterologist or 
the paediatric IBD nurse specialist. Once a year the adolescent patients also meet the adult 
gastroenterologist, to get acquainted with the adult healthcare system. During clinic visits, 
both the nurse and doctors check for disease knowledge, self-efficacy and self-management 
skills. Around the age of 18, patients are transferred, either within our centre or to a hospital 
closer to home. The choice of the adult care team depends primarily on the complexity 
of the disease and secondarily on the patient’s preference and where they live. As part of 
the routine care for all patients, irrespective of their disease severity, an appointment at 
the gastroenterology department is made within three to six months after transfer. At this 
time an extensive transfer letter, including the patient’s medical history, is sent to the adult 
medical healthcare provider, with a copy to the patient.
Measurements
Transition Yourself Score 
A score reflecting the outcome of the transition process was developed based on previous 
literature13 and the outcome of a focus group meeting with IBD experts. The Transition 
Yourself Score was applied to participants one year after their transfer to adult care. The 
following items were rated: adherence to visits at the gastroenterology outpatient clinic, 
adherence to medication and qualitative evaluation of transition by the patient. A pre-test 
of the score with a representative group of 10 patients resulted in minor adjustments in the 
language.
 We scored the adherence to the visits to the adult gastroenterologist by determining 
when the patients first appeared in the gastroenterology outpatient clinic. The percentage 
of missed scheduled outpatient visits within the first year was calculated by dividing the 
number of missed visits by the number of planned visits times 100. Rescheduled visits were 
not counted as non-attendance. Adherence to medication was determined by an adherence 
interview (Table S1).14 The interview contained 10 questions regarding medication use, 
missed medication and the experienced burden of the medication regimen. Patients could 
receive one point per question, with a maximum score of 10. Prescriptions for supplements, 
such as calcium or iron, were not included in the assessment of medication adherence. Low 
adherence was indicated by a score below six, medium by a score of six to eight and high 
by a score of eight or more. At enrolment, patients retrospectively graded the transition 
process on a 10-point scale, where one was very poor and 10 was excellent and these scores 
are recorded in Table 1. A total score below five indicated a failed transition, five or six was 
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moderately successful and above six was successful. For the analysis we combined failed 
and moderately successful transition into the unsuccessful transition category, to reflect 
that improvements were needed in this group. We then compared those findings with the 
group of subjects who had a successful transition.
Table 1. Transition Yourself Score
Items Score Frequency (n=35), n (%)
Time to first outpatient visit to adult gastroenterologist
Unknown or after 12 months 0 1 (2.9)
After 6-12 months 1 3 (8.6)
Within 3-6 months 2 31 (88.6)
Non-attendance rates at outpatient clinic < 12 months after transfer
>25% 0 2 (5.7)
10-25% 1 3 (8.6)
None / <10% 2 30 (85.7)
Medication adherence
Low adherence 0 4 (11.4)
Medium adherence 1 17 (48.6)
High adherence 2 5 (14.3)
No medication prescribedA 9 (25.7)
Quality of transition (grade 0-10) B
< 5.5 0 0
5.5-7 1 11 (31.4)
>7 2 24 (68.6)
Total score:
Failed transition <4
 
2 (5.7)
Moderate successful transition 5 or 6 11 (31.4)
Successful transition >6 22 (62.9)
Notes:  A These patients were given two points in total transition score. B as experienced by the transferred 
patient
IBD-yourself
IBD-yourself is questionnaire that was previously developed and validated by our research 
group to explore knowledge about IBD and self-efficacy.12 It covers a number of domains, 
such as knowledge of IBD, diagnostic tests and medication use. Higher scores indicated 
higher overall levels of self-efficacy. As the number of questions could differ between 
patients, we just provided scores for each domain and no total score (Table S2).12 
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Data regarding relapses, disease related complications, admissions, surgery and pregnancies 
were retrieved from medical charts. Clinical relapse was defined as a relapse with a change 
in treatment strategy and, or, hospital admission.
Statistical analysis
Statistical analyses were completed using SPSS 18.0 for Windows (SPSS Inc, Chicago, USA). 
Significance was set at p<0.05. Descriptive statistics were calculated as percentages for 
discrete data and medians with interquartile ranges (IQR) for continuous data. The chi-square 
test or Fisher’s exact test was used to analyse categorical data. Correlation between the IBD-
yourself and transition success was examined using Spearman’s correlation coefficient and 
the Mann-Whitney U test.
RESULTS
Patients’ characteristics
There were 35 adult patients who gave their informed consent, with a median age of 21.9 
years and interquartile range (IQR) of 21.1-22.6. Of the 50 patients who took part in the 
2008 study, two declined participation, one patient had died from a metastasised rectal 
adenocarcinoma due to Hermansky Pudlak syndrome and 12 patients had been lost to 
follow up. The clinical and demographic characteristics are shown in Table 2, in the column 
total. The baseline characteristics of the 35 participants and 15 non-participants did not 
differ (data not shown), except for educational status. Of the non-participants, 80% had low 
educational status compared to 46% of the participants. 
Outcome of transition at one year after transfer
Almost 90% of the patients visited the adult outpatient clinic in the first three to six months 
after transfer. In addition, 85% of the patients missed less than 10% of their outpatient visits 
in the first year after transfer. Most patients had medium medication adherence. Almost 70% 
of patients valued the quality of their transition as good, scoring it above a seven. When we 
used the total Transition Yourself Score, the transition was successful in 22/35 (63%) patients, 
moderately successful in 11 (31%) and failed in two patients (6%) (Table 1). A female patient with 
Crohn’s disease failed the transition as she did not adhere to her medication, did not appear 
for her first appointment and presented more than one year after transfer in the emergency 
department with a clinical relapse. The other patient was a male patient with Crohn’s disease 
who was transferred to a community hospital, but was lost to follow up after transfer. 
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Table 2. Patient characteristics
Total 
(n=35)
Unsuccessful 
transition¥ (n=13)
Successful transition 
(n=22)
p value§ 
Age at diagnosis (years), (median, IQR) 13 (12-15) 14 (11.5-15.0) 13 (12.0-15.0) 0.875
Months in transition clinic before transfer 
(median, IQR)
13 (5-18) 10 (5.0-18.0) 13 (4.8-17.8) 0.811
Disease duration at transfer (median, IQR) 7 (7-10) 4.1 (3.0-6.9) 4.5 (2.9-6.1) 0.864
Years after transfer at inclusion in study
<2 
2-4 
4-6 
2 (5.7%)
20 (57.1%)
13 (37.1%)
1 (7.7%)
7 (53.8%)
5 (38.5%)
1 (4.5%)
13 (59.1%)
8 (36.4%)
1.0
Gender (male), no (%) 15 (42.9%) 3 (23.1%) 12 (54.5%) 0.070
Disease type, CD, no (%) 24 (68.6%) 9 (69.2%) 15 (68.2%) 1.0
Medication at transfer‡
Aminosalicylates
Immunomodulators
Anti-TNF 
Prednisone 
No medication
9 (25.7%)
25 (71.4%)
12 (34.2%)
2 (5.7%)
1 (2.9%)
3 (23.1%)
9 (69.2%)
5 (38.5%)
1 (7.7%)
0
6 (27.2%)
16 (72.7%)
7 (31.8%)
1 (4.5%)
1 (4.5%)
0.840
Active disease during transfer 5 (14.3%) 4 (30.8%) 1 (4.5%) 0.052
Relapse within first year after transfer 10 (28.6%) 5 (38.5%) 5 (22.7%) 0.444
Educational level
Low
Medium
High
16 (45.7%)
13 (37.2%)
6 (17.1%)
7 (53.8 %)
3 (23.1%)
3 (23.1%)
9 (40.1%)
10 (45.5%)
3 (13.6%)
0.467
Notes: ‡ Some patients were prescribed more than one kind of medication ¥ moderately successful and failed 
transition § successful versus unsuccessful transition. Percentages are displayed as column percentages  
Factors influencing outcome of transition
The clinical and demographic characteristics did not differ significantly between the group 
with successful and unsuccessful transition (Table 2). In the group with unsuccessful 
transition. 80% had active disease before their transfer to adult care and this approached 
significance (p=0.052). Female patients were more likely than males to have an unsuccessful 
transfer (p=0.069) (data not shown).
Relation between adolescent self-efficacy and successful transition 
Spearman’s correlation showed a significant correlation for the outcome of transition and 
the IBD-yourself domain that covered actual behaviour in medication use (r=0.397, p=0.025, 
n= 35). In parallel, adolescents with a successful transition had significantly higher scores in 
the domain of actual behaviour in medication use (Mann Whitney U test: U=60.0, z=-2.208, 
p=0.027). As shown in Table 3, the scores of each IBD-yourself domain were divided in three 
groups, namely low, medium and high. A non-significant trend was seen in seven of the 
domains, with more patients having a high score in the successful transition group.
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Of the 35 patients, 10 patients (29%) had a relapse with clinical consequences in the first 
year after transfer. In 50% of these patients, the outcome of their transition was scored as 
either moderately successful or unsuccessful. In contrast, the transition was unsuccessful in 
30% of patients without relapsing disease. No significant differences were found between 
the patients with or without relapse with respect to the outcome of their transition, therapy 
adherence and missed outpatient clinic visits (data not shown). Of the 35 patients, two 
underwent surgery, namely resection of the remaining colon after hemi-colectomy and
Table 3. IBD- yourself and outcome of transition
Domains IBD Yourself Unsuccessful transition 
(failed&moderate) (n=13), 
n (%)
Successful transition 
(n=22), n (%)
Self-efficacy in knowledge of IBD (n=35)
12-14 points
15-17 points
18-20 points
2 (15.4%)
6 (46.2%)
5 (38.5%)
1 (4.5%)
12 (54.5%)
9 (40.9%)
Self-efficacy in knowledge of diagnostic tests (n=35)
14-17 points
18-21 points
22-24 points
2 (15.4%)
7 (53.5%)
4 (30.8%)
4 (18.2%)
8 (36.4%)
10 (45.5%) 
Self-efficacy in knowledge of medication (n=27)
17-22 points
23-27 points
28-32 points
4 (40.0%)
4 (40.0%)
2 (20.0%)
4 (23.5%)
6 (35.3%)
7 (41.2%)
Actual behaviour medication use (n=32)*
7-10 points
11-14 points
15-17 points
1 (10.0%)
7 (70.0%)
2 (20.0%)
2 (9.1%)
3 (13.6%)
17 (77.3%)
Self-efficacy in skills for independent outpatient clinic visits (n=35)
12-20 points
21-28 points
29-36 points
2 (15.4%)
5 (38.5%)
6 (46.2%)
3 (13.6%)
9 (40.9%)
10 (45.5%) 
Actual behaviour outpatient clinic (n=26)
4-6 points
7-8 points
10 (90.9%)
1 (9.1%)
9 (60.0%)
6 (40.0%)
Self-efficacy in coping with IBD (n=34)
5-8 points
9-12 points
13-16 points
1(8.3%)
4 (33.3%)
7 (58.3%)
1 (4.5%)
6 (27.3%)
15 (68.2%)
Self-efficacy in knowledge of transition process (n=31)
32-42 points
43-52 points
53-62 points
3 (25.0%)
4 (33.3%)
5 (41.7%)
2 (10.5%)
8 (42.1%)
9 (47.4%)
Self-efficacy in transfer readiness (n=34)
4-6 points
7-8 points
10 (76.9%)
3 (23.1%)
14 (66.7%)
(33.3%)
*p<0.05 
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resection of perianal skintags, one Crohn’s disease patient developed a perianal fistula 
and received antibiotics and two patients developed a new extra intestinal manifestation 
(arthralgia). One patient became pregnant during anti-tumour necrosis factor treatment 
and delivered a healthy baby. None of the patients developed a malignancy during the study 
period. 
DISCUSSION
Our study showed that in our IBD transition clinic, transition was successful in 63% of 
patients and moderately successful in 31% of patients. This modest success ratio indicates 
that there is room for improvement in our IBD transition strategy, both in general and in 
individual patients. 
 To our knowledge, only one previous study has described the outcome of transition 
in IBD care.15 Non-adherence rates were in accordance with our cohort, but higher rates of 
hospitalisation and disease complications were found after transfer. However, it is not clear 
at what point in the transition process this was assessed.
 The outcome of transition has also been described in paediatric patients with other 
chronic diseases with success varying from 42-53% of patients.16-19 All these studies used a 
restricted definition of success, namely attending the first one or two visits in adult care. 
In our clinic the transition process starts early, at the age of 16, with early involvement 
of the adult gastroenterologist. This could explain the relatively higher rates of successful 
transition in our cohort compared to the cohorts of patients with other chronic diseases.
 A scoring system for the outcome of transition in IBD is currently not available and 
we decided to develop such an instrument, the Transition Yourself Score. In 2015, a ranking 
list with key elements and indicators of successful transition in general was published.13 
This list, together with previous literature, supports the elements of the Transition Yourself 
Score.13, 19-21 A qualitative evaluation by the patient was included because patient experiences 
are of essential importance, reflect continuity of care and should be taken into account.13
 We hypothesised that patient or disease related factors can influence the outcome 
of transition as well as the actual transition clinic. Our study indicated that female patients 
and patients with an active disease before transfer might be at risk for unsuccessful 
transition. 
 Unsuccessful transition may have serious consequences, such as non-adherence, 
hospitalisation or surgery. To our knowledge, there have not been any studies that have 
measured successful transition and correlated these to the clinical outcomes after transfer. 
Unfortunately, because of the limited size of our study, we were not able to do that either.
 As discussed earlier, it has been suggested that self-efficacy is a prerequisite for 
self-management and transfer readiness.10, 11 Whitfield et al.22 investigated self-efficacy 
in adolescent IBD patients and found that mean self-efficacy scores were higher in older 
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patients, but not in patients with longer disease duration. Remarkably, communication 
with the doctor did not improve with age and about 80% of patients above 18 years of 
age reported that they were not independent when it came to disease management tasks. 
Unfortunately, this study did not assess if patients actually used the skills they claimed 
to possess. It could be that self-efficacy does not always correlate with actual behaviour. 
Our study showed that actual behaviour could be associated with transition success. Since 
the publication of the IBD-yourself, another self-efficacy scale for adolescents and young 
adults has been developed and validated, but studies using this scale have not yet been 
published.23 
 This study had several limitations: the recruitment from a single centre, the 
retrospective nature and the small sample size limited the statistical analysis and 
generalisability. In addition, recall bias could have influenced the patients’ recollections 
of the item quality of the transition process, since some patients participated several 
years after their transfer. Moreover, socioeconomic status was higher in participants than 
non-participants, which could have influenced the results of our study. Furthermore, the 
Transition Yourself Score needs to be validated and IBD-yourself needs to be compared to 
other measures of self-efficacy for further validation. Lastly, the generalisability may be 
limited because of country specific transition approaches, but the general elements chosen 
to classify the success of transition can be tailored to each local situation. 
CONCLUSION
Despite these limitations, this study was the first to evaluate the outcome of transition in 
IBD by using a new score, the Transition Yourself Score. We showed that, after attending 
our IBD transition clinic, 63% of patients had a successful transition. The IBD-yourself, 
which measured self-efficacy, did not predict a successful transition, which can question the 
importance of self-efficacy. We stress the importance of not only assessing self-efficacy or 
self-management, but also the outcome of transition and clinical disease course after transfer. 
If predictors for a successful transition can be identified, then transition programmes can be 
optimised. The Transition Yourself Score is a simple tool to assess the efficacy of transition 
programmes, but it needs to be validated. 
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SUPPLEMENTARY TABLES
Table S1. Questions adherence interview
1 Did you forget to take your IBD medication (pills, tablets, enemas or suppositories) in the past two weeks or did you 
forget your last planned infusion/injection? (Yes=0, No=1)
2 Did you skip your medication in the past two weeks because you think they do not help or even make you feel worse? 
(Yes=0, No=1)
3 When you are not at home, do you bring along your IBD medication? (Yes=1, No=0)
4 Sometimes medication is not taken on purpose (for other reasons than forgetting), did that happen to you past two 
weeks? (Yes=0, No=1)
5 Did you take your medication(s) for IBD yesterday? And (if you get infusions or take injections): did you receive your most 
recent planned infusion/injection? (Yes=1, No=0)
6 Do you sometimes skip your medication(s) when you feel good and have no symptoms of your disease? (Yes=0, No=1)
7 Are you bothered by the fact that you have to take medication? (yes=0, no=1)
8 Do you find it hard to remember to take or inject your medication or go to the hospital for your infusion? (Yes=0, No=1)
9 Do you receive help from somebody else in remembering to take your medication or plan your infusions? (yes=0, no=1)
10 When you run out of medication, do you actively arrange a new prescription (yes=1, no=0)
Table S2. Domains and scoring IBD-yourself (20)
Domain Number of 
questions
Score range
1 VAS on general independency 1 0-100
2 VAS on perceived disease burden 1 0-100
3 Self-efficacy in knowledge of IBD 5 0-20
4 Self-efficacy in knowledge of diagnostic tests 6 0-24
5 Self-efficacy in medication use 8 0-32
6 Actual behaviour regarding medication use 4 0-20
7 Self-efficacy in skills for independent outpatient clinic visits 9 0-36
8 Actual behaviour at the outpatient clinic 4 0-8
9 Self-efficacy in coping with IBD 4 0-16
10 Self-efficacy in knowledge of transition process 14 0-70
11 Self-efficacy in transfer readiness 2 0-8
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CHAPTER 11
ABSTRACT
Background
Transition programs are designed to prepare adolescent Inflammatory Bowel Disease 
(IBD) patients for transfer to adult care. It is still unclear which outcome parameters define 
‘successful transition’. Therefore, this study aimed to identify outcomes important for 
success of transition in IBD.
Methods
A multinational Delphi study in patients, IBD-nurses and paediatric and adult 
gastroenterologists was conducted. In Stage 1, panellists commented on an outcome list. 
In Stage 2, the refined list was graded from 1-9 (least-very important), by an expert and a 
patient panel. In stage 3, the expert panel ranked important outcomes from 1 to 10 (least-
most important). Descriptive statistics and Mann-Whitney-U tests were performed.
Results 
The final item list developed in Stage 1 was tested by the expert (n=74 participants,52.7% 
paediatrics) and patient panel (n=61, aged 16-25 y, 49.2% male). Respectively, 10 and 11 
items were found to be important by the expert and patient panel. Both panels agreed on 
8 of these items, of which 6 reflected self-management skills. In Stage 3, the expert panel 
formed a top-10 list. The three most important items were: decision making regarding IBD 
(mean score 6.7), independent communication (mean score 6.3) and patient satisfaction 
(mean score 5.8).
Conclusion
This is the first study identifying outcomes that IBD-health care providers and patients deem 
important factors for successful transition. Self-management skills were considered more 
important than IBD-specific items. This is a first step to further define success of transition 
in IBD and subsequently evaluate the efficacy of different transition models. 
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INTRODUCTION
In up to 25% percent of patients inflammatory bowel disease (IBD; Crohn’s disease [CD] and 
ulcerative colitis [UC]) manifests during late childhood or adolescence.1,2 As IBD is a lifelong 
disease all of these patients will need to undergo transfer of paediatric to adult care. To 
optimise this transfer and minimise adverse outcomes, it is advised to have a transition 
period where patients (and parents) are prepared for the actual transfer.3,4 Transition is 
defined as the purposeful planned movement and preparation of adolescents and young 
adults with chronic medical conditions from child-centred to adult-oriented healthcare 
systems.5 In the transition process the patient, parent, paediatric gastroenterologist, adult 
gastroenterologist and IBD-nurse have specific tasks.3,6 Patients should acquire (disease) 
knowledge, autonomy and self-management.7-11 Parents need to allow their adolescent 
child more independence. Physicians and nurses should support the transition process, be 
knowledgeable of adolescents’ developmental and health issues and prepare adolescents 
for the changes that will be encountered in the adult health care system.6,12,13 Transitional 
programs are designed to facilitate all these processes 12,14,15 and prepare the individual 
patient for his/her transfer by helping to increase knowledge as well as to reach a higher 
level of self-management.
 As summarised in the UK guideline on transition in patients with chronic digestive 
diseases, inadequate transition arrangements have been associated with adverse outcomes 
across several medical conditions, such as diabetes16, heart disease17 and sickle cell disease.18 
In IBD, studies investigating the impact of structured transition are scarce. Studies showed 
that the lack of a structured transition service negatively impacted adherence19,20 and 
attendance19,20, and was associated with a higher hospitalisation and surgery rate.19 On the 
other hand, structured transition programmes have been shown to result in better disease 
related outcomes21,22, improved self- and disease knowledge and improved quality of life.22,23 
 Although many different models for transitional care have been proposed in 
IBD (e.g. 4,12,14,24), there is no evidence that one particular model is more effective than 
others.3 In addition, a clear definition on success of transition in IBD is lacking.12,19,25 Two 
recent studies identified general, non-disease specific indicators for success of transition in 
adolescent medicine. Outcomes such as quality of life, continuity of care, self-management, 
therapy knowledge and adherence were recognised as important outcomes for success of 
transition.26,27 Continuity of care is considered a core issue27, this was also emphasised in a 
systematic review that showed engagement in adult care (attending first (two) visits) and 
retention in adult care (continuing to attend scheduled clinic appointments) were often 
used in studies investigating transition in chronically ill adolescents.28 
 In another recent study, in IBD patients, their parents and paediatric health care 
providers, were asked to select 5 of items from the Transition Readiness Assessment 
Questionnaire (TRAQ), thought to be important for successful transition. All three 
stakeholders had a different selection of items29, but all selected items related to adherence, 
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communication with the doctor, calling in case of problems or adverse reactions to 
medication.29
 As emphasised in the European Crohn’s and Colitis Organisation (ECCO) topical 
review on transitional care in IBD, it is important to identify objective outcome measures 
that can be used to define successful transition in IBD.3 Therefore, the primary aim of this 
study was to identify outcomes that health care providers working with IBD patients think 
are important for success of transition in IBD, using a Delphi procedure in 3 types of health 
care providers working with IBD patients. Our secondary aim was to compare the outcomes 
identified by health care providers to outcomes selected by a patient panel, which was 
recruited in second instance.
MATERIALS AND METHODS
To identify health care transition outcomes for IBD, we conducted a three-stage Delphi30-33 
process, a commonly used method for reaching consensus. The survey consisted of 
three rounds, which were designed and distributed using an online survey programme 
(SurveyMonkey). At each stage, all experts were contacted via e-mail explaining the task 
to be done, and a web link was included to complete the questionnaire. At each round, 
participants were given 2 weeks to send in their reply. Every two weeks a reminder was 
sent to all participant who had not yet replied. After 3 reminders, the web link was closed. 
We decided to give only factual feedback after each round, to avoid influencing panellists’ 
opinion.34 The study started July 2016 and ended March 2018. 
Delphi Panel
The Delphi panel was composed based on a practical approach. To achieve international 
consensus, experts in the field of IBD from around the world were invited to participate. 
Our main aim was to create a balanced panel of all health care providers working with 
IBD patients in the transition process. Therefore, paediatric gastroenterologists, (adult) 
gastroenterologists, paediatric and adult IBD nurses were invited. The first step in composing 
the Delphi Panel was inviting all members of the ‘Paediatric IBD Porto and Interest Groups 
of European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)’ 
and the authors of the European Crohn’s and Colitis Organisation Topical Review on 
transitional care in IBD.3 The ‘Paediatric IBD Porto Group’ is a group of 36 paediatric IBD 
experts from the (ESPGHAN) whose goals are to generate collaborative international 
research and to provide a leadership role concerning current diagnosis and management of 
IBD in children. The IBD Interest Group is an open growing group of 48 ESPGHAN members 
at the time of the study who participate in all activities generated by the Porto group such 
as collaborative studies and guidelines preparation. Both groups mostly consist of paediatric 
gastroenterologist from Europa as well as Israel and some from North America. A total of 91 
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panellists were invited and were asked to participate as well as invite a paediatric IBD-nurse, 
adult gastroenterologist and adult IBD nurse, from their own hospital. From the 91 invited 
panellists 31 (34%) agreed to participate. The 31 panellists invited another 43 physicians or 
nurses and vouched for their credentials. In addition, the website of the hospital where they 
worked was also checked to double check their credentials. This resulted in 74 panellists 
(here-after ‘Expert panel or panellists’; Figure 1). 
 After completing the Delphi stages in the expert panel, we concluded that also 
including the perspective of the adolescent and young adult patients would be of great added 
value. Therefore, we proceeded to include adolescent and young adult patients, hereafter 
defined as ‘patient panel or patients’. The patients were recruited from two sources: (a) an 
ongoing study into transition at the IBD outpatient transition clinic in the Erasmus Medical 
Centre in Rotterdam (the study was approved by the Medical Ethics Committee and patients 
provided informed consent), and (b) young adult IBD patients from the Dutch Crohn and 
Colitis patient organisation. All patients were given three weeks to complete the survey and 
provided information with regard to their sex, age, disease duration and disease type. The 
patient panel participated in stage 2 only, but were asked after completing stage 2 if they 
thought an item was missing.
Invita�on Delphi Expert Panel 
Porto-group, IBD-interest-group, ECCO topical review group
N=91 
Round 1
N=74 panellists
31/91 invited panellists participated
43 participants through extension of 
invitation to local gastroenterologists
and IBD-nurses
Round 2
N= 64 panellists
Round 3
N=64 panellists
10 panellist did not respond after
several reminders
2 panellist did not respond after
several reminders
Pa�ent panel
IBD Transition Clinic Erasmus and Patients from Dutch Crohn
and Colitis foundation
N=61
Round 2
N= 61 pa�ents
Figure 1. Flowchart composition Delphi panel
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CHAPTER 11
Stage 1
In this first stage, a literature review4,19,20,26-28,35,36 was performed and a list with items related 
to outcome of transition was created. This list was sent to the research team, and was 
discussed in a joined meeting. The 23-item list was sent to all 74 participants of the expert 
panel (Figure 2A). In stage 1, participants were asked to comment on the list, for example 
to state if they thought an item should be removed from the list (for reasons of not being 
associated to outcome of transition), merged with another item, or rephrased. Additionally, 
participants were invited to add new items to the list. Lastly, all panellists were asked to 
complete a short form to collect demographic characteristics, such as their name, academic 
degree(s), department, position and details about the hospital where they work (name, city, 
country and hospital type (community vs tertiary hospital)). 
The research team analysed all responses from stage 1, at first each member evaluated 
the responses individually, and in a meeting consensus was reached. Criteria to accept 
items were (a) suggestions to refine or specify items if it improved clarity or (b) every new 
suggested item related to outcome of transition. Items were rejected or deleted if (a) they 
were not related to outcome of transition (but to for example organisation or availability 
or the IBD transition clinic) or (b) showed large similarity with an item already on the list. 
Similar outcomes were categorised into themes. Country-specific items were deleted, as our 
aim was to achieve international consensus. 
Stage 2
In the second stage, participants were given a brief summary of the results of stage 1, 
indicating that some items were deleted, rephrased or reformulated, and explaining that 
the new item list with outcomes of transition consisted of 26 items (Figure 2B). In stage 
2, the panellists were asked to rate each item on a scale from 1 (least important outcome 
of transition) to 9 (very important outcome of transition). At all times, participants could 
contact the research team to comment or clarify. Before start of the study, the research 
team agreed to use the ‘Rand UCLA criteria for agreement’, often used in Delphi studies 
26,37, to categorize the outcomes as important, equivocal or not important. A threshold for 
retaining transition outcomes was established, based on the overall level of agreement 
among participants. Outcomes were labelled important when they had a mean of 7-9 
without disagreement, outcomes rated 4 to 6 were considered equivocal, and outcomes 
rated 1 to 3 were rated as not important. Disagreement was defined as 30% of ratings are in 
lower third (rating 1-3) and 30% upper third (7-9).38 Two members of the research team (GB 
and JCE) analysed the responses and calculated means for each outcome and determined 
whether disagreement was present. This stage was also completed by the adolescent and 
young adult patient panel, recruited in second instance.
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CHAPTER 11
Stage 3
In the third stage, the expert panel was given a brief summary of the results of stage 2, 
indicating that using the Rand UCLA criteria, the item list with 26 items was reduced to 
ten. In stage 3, this list with 10 important outcomes was sent to the panel with the request 
to rank the items from 1 to 10, with ‘1’ meaning least important outcome of transition, 
and ‘10’ reflecting essential outcome of transition. It was emphasised that each item could 
receive only 1 position between 1-10. Thus, the expert panel was now instructed to rank the 
important items from stage 2 in a top 10 list, forcing them to re-prioritise the items and state 
which ones they consider most important.
Statistical analysis
Descriptive statistics were used to summarise the panellists’ opinions for closed questions 
at each round. Data were analysed with SPSS 23 (IBM) and were conducted blind to the 
names of the participants. Open comments were analysed qualitatively and clustered 
into main themes. For stage 2, according to the ‘Rand UCLA criteria for agreement’ mean 
scores were calculated per item, and proportions were given to determine disagreement. 
Because of a non-normal distribution of the data, subgroups (e.g. patients panel vs expert 
panel or paediatric vs adult providers) were compared using a Mann Whitney U test. Holms 
correction for multiple testing was used39, a corrected p-value below p<0.05 was considered 
significant.
RESULTS
Delphi Panel
A total of 74 participants, from 17 countries, agreed to participate in the Delphi expert panel. 
Seventy seven percent of the experts came from Europe (n=57; Austria n=2, Croatia n=1, 
Czech Republic n=2, Denmark n=3, England n=18, Finland n=1, Germany n=2, Greece n=2, 
Hungary n=2, Italy n=1, Lithuania n=1, Scotland n=7, Spain n=1, the Netherlands n=14), the 
other participants came from Israel (n=8), Canada (n=3) and the United States (n=6) (Table 
1). Participants belonged to one of the four core groups: paediatric gastroenterologist, 
paediatric IBD nurse, gastroenterologist or adult IBD nurse. The clinical research fellow was 
a medical doctor (MD) working in paediatrics (‘paediatric gastroenterologist group’), the 
transition manager had a Bachelor of Science in adolescent care (‘paediatric nurse group’) 
and the fellow paediatric gastroenterology was an MD working in paediatrics (‘paediatric 
gastroenterologist group’). Of the 74 panellists, 40.5% were male, 91.9% worked in a tertiary 
hospital, 52.7% worked in the paediatric department and 30% of panellists were IBD nurses 
(Table 1). 
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Table 1. Demographic characteristics expert panel (n=74)
N. %
Gender Male, % 40.5
Hospital Type Community Hospital
Tertiary Hospital
6 (8.1)
68 (91.9)
Department Paediatrics 
Gastroenterology
Internal Medicine
39 (52.7)
29 (39.2)
6 (8.1)
Position Paediatric Gastroenterologist
Paediatric IBD nurse 
28 (37.8)
10 (13.6)
Gastroenterologist
Adult IBD nurse 
22 (29.7)
11 (14.9)
Clinical research fellow 
Transition manager
Fellow paediatric Gastroenterology
1 (1.4)
1 (1.4)
1 (1.4)
Continent of origin Europe  57 (77.0)
North America 9 (12.2)
Asia 8 (10.8)
Patient Panel (only participating in stage 2)
A total of 61 adolescent and young adult patients were recruited. 67.2% originated from the 
IBD-transition clinic in the Erasmus Medical Centre, 49.2% was male and mean age was 18.7 
years (Table 2).
Table 2. Demographics patient panel (n=61)
N. % or Median 
(IQR)
Recruited from Dutch Crohn and Ulcerative Colitis Patient organisation
IBD Transition Clinic Erasmus Medical Centre
20 (32.8)
41 (67.2)
Age (years) Range
Median (IQR)
16.5-24.7
18.7 (18.1-20.1)
Gender Male 30 (49.2)
Disease duration (years) Range
Median (IQR)
1-18 
5.0 (3.0-7.0)
Disease type Crohn’s disease
Ulcerative Colitis
IBD unclassified
34 (55.7) 
23 (37.7)
4 (6.6)
Abbreviations: IQR: interquartile range
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Stage 1 
All 74 panellists included in the expert panel responded to stage 1. Many panellists responded 
with suggestions for rephrasing of items already on the list, such as timely medication 
refill, refilling own prescriptions. Using the suggestions from the panellists, several items 
were rephrased, split into more parts or specified (see Figure 2A and B). Five items were 
removed from the list (italic items Figure 2A) for the following reasons: Items 7, 9 and 10 
were removed because of their country- and patient-specific nature. In addition, items 6 
and 9 were removed because they were not considered to reflect outcome of transition, and 
other items reflecting autonomy and knowledge were already on the list. Three new items 
were suggested by the panel and added to the list: growth target achieved, stable weight 
and missed school/work days (items 24-26 Figure 2B). The new list consisted of 26 items 
(Figure 2B). Some panellists also suggested items only reflecting disease related knowledge 
and organisation of the transition process (e.g. good collaboration of paediatric and adult 
gastroenterologist), and these were not used to refine the list with outcomes.
Stage 2
Of the 74 panellists in the expert panel, 64 (86.5%) responded to stage 2, rating each item 
with a number from 1-9 (9=most important outcome for transition). Of the 64 remaining 
participants, 14 were IBD-nurses (21.8%), 28 (43.8%) paediatric gastroenterologists and 22 
(34.4%) gastroenterologists. Nine out of 10 non-responders worked in a tertiary hospital 
(one paediatric gastroenterologist, seven IBD nurses, one research fellow, one transition 
manager). 
 Table 3 shows the mean ratings for each of the 26 items for both the expert 
and the patient panel. For the expert panel, 10 items had a mean score above 7 without 
disagreement, indicating important outcomes. Top-5 outcomes at this stage were (starting 
with the most important item): Attends first adult GE appointment as planned (mean 7.92, 
Standard Deviation [SD] 1.4), patient satisfied about transition process (mean 7.89, SD 1.5), 
contacting IBD service independently (mean 7.81, SD 1.1), independent communication 
(mean 7.79, SD 1.2) and shows ability to make decisions regarding IBD (mean 7.59, SD 1.2). 
The least important outcomes were ’necessity surgery’, ‘independent attendance outpatient 
clinic’, ‘participation sports/hobbies’, ‘necessity steroids’, and ‘stable weight’. Continent of 
origin did not influence grading. Female members of the expert panel gave a significantly 
higher grade to the items ‘patient satisfaction’ (mean males 7.2(SD 1.6); mean females 8.4 
(SD 1.0); p 0.008), ‘Parental satisfaction’ (mean males 6.1(SD 1.9); mean females 7.6(SD 1.3); 
p 0.008), and ‘Growth outcomes achieved’ (mean males 5.1(SD 2.3); mean females 7.0(SD 
2.6); p 0.024).
 For the patient panel, 11 of the 26 items had a mean score above 7 without 
disagreement. The top five outcomes were (starting with the most important item): 
independent communication (mean 8.39, SD 0.8), shows ability to make decisions regarding 
IBD (mean 8.16, SD 1.3), adherence to medication, (mean 8.08, SD 1.6), ability to recall 
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dose/frequency medication (mean 7.92, SD 1.5) and timely refilling own prescriptions 
(mean 7.82, SD 1.7). Least important outcomes were: ‘necessity of surgery’, ‘necessity of 
steroids’, number of ‘hospitalisations’, ‘ER visits’ or ‘flares’ (Table 3). No additional items 
related to success of transition were suggested by the patient panel. Sex did not influence 
grading within the patient panel (data not shown).
 Comparing the grades from expert (n=64) and the patient (n=57) panel (Table 3), 
showed that both the patient and the expert panel identified the same 8 items as important 
(mean grades for these items were quite similar (<1 point difference between both groups). 
Additionally, the patient panel found ‘attends all GE appointments in first year following 
transfer’, ‘parents satisfied with transition’ and ‘refilling prescriptions on own’ important, 
and the expert panel considered ‘attend first GE appointment as planned’ and ‘within the 
first 3-6 months after transfer’ important. For some of the ‘non-important’ items (mean < 7) 
differences between both panels were large: disease related outcomes (Items 13,14,16,19-
21) and ‘school/work absence’ (item 26) received a significantly lower mean score by the 
patient panel (range 2.6-3.3) compared to the expert panel (range 5.5-6.6).
 Comparing the different providers within the expert panel (adult (n=32) vs paediatric 
(n=32) health care providers; paediatric (n=28) vs adult (n=22) gastroenterologists; nurses 
(n=13) to physicians (n=50)) did not show significant differences after correction for multiple 
testing. 
Stage 3
Of the 64 experts, 62 responded to stage 3. Table 4 and Figure 2D display the top-10 ranking 
of the important outcomes from stage 2. For the panel as a whole ‘ability to make decisions 
regarding IBD’ (mean 6.7, SD 2.7), ‘independent communication’ (Mean 6.3, SD 2.8) and 
‘patient satisfaction’ (mean 5.8, SD 2.4) were the top-3 outcomes, whereas ‘attends first 
GE appointment within the first 3-6 months after transfer’ (mean 4.4, SD 3.2), ‘contact IBD 
service independently’ (mean 5.2, SD 2.4) or ‘attends first GE appointment as planned’ (5.4, 
SD 3.6), received lower scores (Table 4). Differences for the 3 provider types are shown in 
Table 4. Comparing the different providers within the expert panel (adult (n=32) vs paediatric 
(n=28) health care providers (see supplementary Figure 1); paediatric (n=28) vs adult (n=22) 
gastroenterologists; nurses (n=12) to physicians (n=50)) did not show significant differences 
after correction for multiple testing. 
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DISCUSSION
The primary objective of this study was to identify outcomes that three types of health 
care providers responsible for the care of IBD patients (gastroenterologists, paediatric 
gastroenterologists, and IBD-nurses) thought were important for success of transition in 
IBD patients. Our secondary aim was to compare these outcomes to the outcomes selected 
by a patient panel recruited in second instance, i.e. who only participated in stage 2 of 
this Delphi study. In stage 2, ten and 11 out of 26 items were identified as important by 
the expert (n=64) and the patient panel (n=61), respectively (Stage 2, Table 3). Surprisingly, 
results show that both the expert and patient panel thought the same items were important 
for success of transition: 8 items were identified as important in both the patient and the 
expert panel. Of these, 6 items concerned self-management skills and autonomy (e.g. 
independent communication, medication adherence), while the other 2 items were more 
general: Health related Quality of Life and patient satisfaction about transition process. In 
addition, both panels thought that attendance to adult GE appointments was important, but 
gave slightly different grades (difference < 1 point) to the relevant items (items 1-3, Table 
3). Similarly, ‘satisfaction of parents about transition process’ was considered important in 
both panels, and almost reached the threshold for importance in the expert panel. Likewise, 
‘independent attendance at outpatient clinic’ received a low grade (<6) by both the expert 
and the patient panel, possibly reflecting that both value or at least do not disapprove the 
presence of parents. 
 Only the expert panel provided a top-10 ranking (=stage 3) of the important 
items, and this showed that from the 10 important items, decision-making, independent 
communication and patient satisfaction were considered most important for success 
of transition in IBD patients. Comparing the top-10 of different providers did not show 
significant differences.
 Remarkably, not one of the IBD/disease-specific items (e.g.surgery, inflammatory 
markers) were found to be important. The patient panel gave even lower grades than the 
expert panel. This is in accordance with previous studies discussing successful transition in 
other chronic diseases such as congenital heart defects40, rheumatological diseases41,42, and 
congenital adrenal hyperplasia.43 In all these studies successful transition was not defined by 
disease-specific items, but by attendance to the first (one or two) visits of the adult health 
care provider. This seems a restricted definition of success. However, continuity of care 
is seen as a core outcome of transition27, and is often studied as outcome of transition28. 
Incorporating disease outcomes in the definition of successful transition can be complicated 
considering the heterogeneous course of chronic diseases such as IBD as well as the case 
mix that occurs when patients with a severe course are seen in (academic) centers.6 Philpott 
et al. (2018) therefore plea for including patient-driven outcomes in the definition of 
successful transition, such as trust in the adult health care system and autonomy.6 
11
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In IBD, several studies investigated outcomes of transition. A study by Bollegala et al. 
retrospectively compared outcomes 1 year before vs 1 year after transfer (n=95, no 
structured transition program) and report fewer outpatient clinic visits and more non-
compliance, but no differences in other aspects of health care utilisation.20 Furthermore, 
a survey by Bennett et al. showed no differences in compliance, complications, surgery, 
hospitalization rate or number of flares between 46 IBD patients who had transferred to 
adult care (without a structured transition program) and 36 age-matched patients who 
received care in adult setting from the beginning.44 At last, Cole et al. showed that patients 
who did not attend a transition service, more often needed surgery, hospitalization, and 
had higher non-attendance and lower treatment adherence than patients that did attend 
a transition service.19 These studies suggest that clinical outcomes might be different for 
patients that followed a structured transition program and those who did not, with possibly 
better outcomes after structured transition. However, at this point, it is unknown whether 
absence from the transition program itself is a risk factor for adverse outcomes or if absence 
is just a surrogate marker of patients that are not able to attend the transition program due 
to a complicated course of IBD.
 So far, a definition of successful transition in IBD has not been formulated. 
Previously, our research group designed a score measuring success of transition in IBD (the 
Transition Yourself score).45 The score comprised four elements: time to first outpatient 
visit to adult gastroenterologist, adherence to visits at the gastroenterology outpatient 
clinic, adherence to medication and qualitative evaluation of transition by the patient. The 
Transition Yourself Score was developed based on literature review and a focus group review 
with IBD experts, but has not yet been validated. In addition to validating the score, our 
research group considered it important to ask the opinion of a larger IBD expert panel in 
identifying items reflecting success of transition and also ask patients’ opinion. 
 Two recent studies used a Delphi study to identify general, non-disease specific 
indicators for success of transition in adolescent medicine.26,27 First, Fair et al. included 117 
experts, mainly from the US (88%), and 70% paediatric professionals. In the final stage, 
10 important outcomes were found: Achieving optimal QoL, self-managing own condition, 
understanding characteristics and complications of condition, knowing names and purposes 
of medication, adherence to medication, attending most medical appointments, having a 
medical home, avoidance unnecessary hospitalizations, understanding health insurance, 
and having a social network. Second, Suris and Akre included 37 adolescent health workers 
(mainly physicians) from 15 countries. Items found to be important for success of transition 
were: patient not lost to follow up, no missed consultations, trusting relationship with 
provider, attention for self-management, first visit adult care within the first 3-6 months 
after transfer, number of ER visits, patient/family satisfied transfer, maintaining stable 
disease or improvement.26 
 The selected items in both studies partly resemble the important items identified 
in this study. However, some of the items are described in general words, e.g. ‘managing 
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your own condition’, which covers several items from our item list. Due to this lack of 
specificity, it remains unclear which specific items are valued most by the panellists in the 
previous studies. Furthermore, only Suris and Akre’s list included a disease related item: 
stable disease or disease improvement. In our expert and patient panel disease specific 
parameters received low grades. Moreover, disease knowledge was included in the final 
outcome list by Fair et al. We chose not to include knowledge of disease in our refined list 
for stage 1, because items implying disease knowledge were already on the list. 
Strengths and limitations
This study was strengthened by the appropriate use of the Delphi procedure, and the use 
of a large multinational expert panel, including health care providers from 17 countries. 
Secondly, formation of the Delphi panel was initiated by inviting two pre-existing expert 
groups with a leadership role and expertise in the care of adolescent IBD patients to form 
the Delphi Panel. Extension of this invitation eventually led to the inclusion of 74 paediatric 
gastroenterologists, gastroenterologists and IBD nurses from both the paediatric and adult 
department. Thirdly, in second instance also a patient panel was composed to provide the 
patient perspective in grading the 26 items in stage 2. Lastly, the expert panel was balanced 
with 50% of panellists from both the paediatric and adult department.
 The study was limited by a low response rate in the first invitation round (34%), 
although 31 opinion leaders in IBD with great experience in transition did participate, and 
the final panel consisted of 74 members. In addition, the majority of experts worked in 
Europe, which may reflect a Western perspective. Second, 90% of panellists worked in 
tertiary hospitals, although this is a limitation, it makes sense considering the fact that most 
paediatric IBD patients are treated in tertiary hospitals.46 Third, although using the widely 
accepted RAND UCLA criteria for agreement, items with a mean below 7 were now labelled 
‘not important’, which could be judged as too stringent. Fourth, it would have been better 
if the patient panel was included from the beginning of the study, so that all three Delphi 
stages would have been completed by all participants at the same time. Fifth, the subgroup 
analyses performed within the expert panel had relatively low number of participants. 
Finally, to assure clarity of all items in the list, we chose to specify the items as much as 
possible. As a consequence, sometimes several items concerned the same topic, but had a 
different emphasis (e.g. 3 items about medication adherence (item 4-6 Figure 2B). 
Conclusion
This is the first study investigating outcomes reflecting successful transition in IBD patients 
using a multinational expert panel and comparing the results to a patient panel. Experts and 
patients agreed to a great extent: 8 out of 26 items were found to be important for success 
of transition, of which 6 items concerned self-management skills/autonomy. Remarkably, no 
IBD-specific item was found important. The three most important outcomes in the top-10 
list from the expert panel were independent decision-making, independent communication 
11
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and patient satisfaction and did not differ between paediatric gastroenterologists, 
gastroenterologist and IBD-nurses. Identifying these outcomes can facilitate the definition 
of successful transition and subsequently the construction of an objective score measuring 
success of transition. After validation, this score could be used to test the efficacy of the 
different transition programs, in order to improve transitional care worldwide. 
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Supplementary Figure 1. Top-10 outcomes stage 3: Paediatric versus adult providers
Note: Ranking 1 (least important) to 10 (most important); Providers includes physicians as well as nurses 
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The studies in this thesis are focused on two themes relevant to adolescent and young 
adult IBD patients (also called young IBD patients): I) psychosocial problems, especially 
anxiety and depression and effectiveness of cognitive behavioural therapy (CBT) on medical 
and psychosocial outcomes, and II) transition to adult care. In Chapter 2 we performed a 
systematic review with meta-analysis regarding the prevalence of anxiety and depression in 
paediatric IBD. Chapter 3 gave an introduction of HAPPY-IBD, our multicentre randomised 
trial investigating the effectiveness of cognitive behavioural therapy (CBT) on psychological 
outcomes and clinical disease course in young IBD patients with subclinical symptoms 
of anxiety and/or depression. Chapter 4 and 5 described the results of stage I of HAPPY-
IBD: the screening of 374 Dutch adolescents and young adults with IBD on anxiety and/or 
depression and discussion of prevalence rates and risk factors. Chapter 6 and 7 reported 
on the short and long-term psychological results: the effectiveness of a disease specific CBT 
on anxiety, depression and Health Related Quality of Life in young IBD patients. Chapter 
8 focussed on the effect of CBT on clinical disease course and inflammatory markers and 
Chapter 9 explored the brain-gut axis in IBD and investigated plasma protein profiles in IBD 
patients with anxiety/depression. 
 Chapter 10 and 11 studied the outcome of transition in IBD patients. In Chapter 10 
we proposed a composite score measuring success of transition and in Chapter 11 a more 
thorough approach was used to identify outcomes reflecting successful transition by asking 
the opinion of a large expert and patient panel in a multinational Delphi study, as a first step 
towards defining successful transition and developing a validated transition success score. 
In this discussion the findings of our studies are discussed in three parts 1) anxiety and 
depression in paediatric IBD, 2) our multicentre randomised trial HAPPY and 3) transition. 
For each part, main findings are discussed in the light of current clinical practices and 
evidence, and recommendations for future research are given. 
ANXIETY AND DEPRESSION IN YOUNG PATIENTS WITH IBD
Prevalence of anxiety and depression in paediatric IBD
Studies investigating anxiety and depression in paediatric IBD have reported greatly varying 
prevalence rates (anxiety symptoms 21-50%2; depressive symptoms 03-33%4). Only a few 
studies investigated the prevalence of anxiety and depressive disorders. To gain more insight 
into the prevalence of anxiety and depression in paediatric IBD we performed a systematic 
review with a meta-analysis (Chapter 2) including all available studies published between 
1994-2017. Of the 28 studies included, most investigated anxiety (n=10) or depressive 
(n=22) symptoms, only a few reported on anxiety (n=3) or depressive (n=4) disorders. Pooled 
prevalence estimates for anxiety and depressive symptoms were respectively 16.4% (95% 
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confidence interval [CI] 6.8-27.3%) and 15.0% (95% CI 0-9.3%). For anxiety and depressive 
disorders this was much lower, respectively 4.2% and 3.4%. 
 Pooled prevalence rates of anxiety and depressive symptoms were higher 
compared to a community sample of Dutch adolescents5, but lower compared to meta-
analyses in paediatric diabetes and asthma (range 27-33%).6,7 In addition, prevalence rates 
were also lower than reported in a recent systematic review in adult IBD (anxiety symptoms 
35.1%; depressive symptoms 21.6%).8 The differences in prevalence rates between children 
and adults could be explained by the higher prevalence of anxiety/depression in adults in 
the general population9, 10 and the possibly increased disease burden in adults due to a 
longer and more complicated disease course of IBD. However, it is necessary to be careful 
comparing pooled prevalence rates to each other, considering the great variation in the 
used instruments and cut-offs.
 Studies investigating which factors influence prevalence rates of anxiety and 
depressive symptoms, focused on disease type and clinical disease activity.8 In our study, we 
investigated whether disease type, clinical disease activity or gender influenced prevalence 
rates and only found that studies with a higher percentage of active disease had a higher 
rate of depressive symptoms. To what extent factors such as disease duration, medication 
use, disease phenotype impact the prevalence of anxiety and depression in paediatric IBD, 
should be investigated in future studies. 
 As in other systematic reviews investigating prevalence of anxiety and depression, 
heterogeneity in study designs complicated meta-analysis in our study and forced us to be 
cautious in drawing firm conclusions. By performing this meta-analysis we gained the insight 
that for cross-cultural comparison of studies, future studies should use uniform screening 
measures, with the same comparable cut-offs.11 In addition, future systematic reviews 
would benefit if studies presented data separately for possible influencing factors such as 
disease type, clinical disease activity and different types of medication.
Stage I HAPPY-IBD: screening anxiety and depression
After finishing our systematic review, prevalence rates from our own multicentre trial in 
the South West region of the Netherlands became available. HAPPY-IBD is one of the first 
studies investigating both the prevalence of anxiety and depression in young IBD patients. 
We decided to study anxiety and depression simultaneously, because it is known that anxiety 
can precede depression and that they often present concomitantly.12 In addition, combining 
adolescents and young adult patients in research is important13, considering they are at a 
unique (transitional) stage in their emotional, cognitive and social development. Our study 
showed surprisingly high prevalence rates (Chapter 3): of the 372 patients, 177 (47.6%) 
patients experienced elevated symptoms of anxiety and/or depression. Anxiety symptoms 
(28.3%) were more prevalent than depressive symptoms (2.9%), but also many patients 
suffered from both (15.8%). An innovative aspect, and also a major strength of our study, 
was that we measured severity of the elevated psychological symptoms using a psychiatric 
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interview in 134/177 patients. Clinical, severe symptoms were found in 46 (34.3%) patients 
(50% anxiety disorder, 10.8% depressive disorder, 32% both). Mild, subclinical symptoms 
were present in 88 (65.6%) patients. 
 Compared to previous studies, our cohort had a higher prevalence of anxiety 
symptoms2, 4, 14, whereas the prevalence of depressive symptoms seemed to be lower.4, 15, 16 
Few studies report on the prevalence of combined anxiety and depressive symptoms. The 
lower prevalence of depressive symptoms, could be explained by the relatively low cut-offs 
of the CDI questionnaire used in previous studies (915 or 1017, versus 13 in our study), which 
actually correspond to scores within the average range.18 Secondly, the higher percentage 
of patients with active disease in the other studies could also explain the higher rates of 
depressive symptoms. Nevertheless, in our cohort with 75% of patients in clinical remission, 
high prevalence rates of anxiety symptoms and combined anxiety and depressive symptoms 
were found. 
 Insight in risk factors for anxiety and depression is necessary to help health care 
professionals identify those at risk. Active disease has repeatedly been shown to associate 
with anxiety and depressive symptoms.2, 8, 11, 15, 19, 20 This was also confirmed in our cohort, and 
emphasises that disease control is important for physical and mental health. In addition, we 
also showed female gender to be a predictor for anxiety/depressive symptoms.20, 21 Contrary 
to other studies, we have not found an association with socio-economic status22, steroid 
use23 or perianal disease.24 
 Considering the high prevalence of anxiety/depressive symptoms in IBD patients 
and the fact that they are often not recognised in a consultation in the outpatient clinic, it is 
likely that these problems are often missed and remain untreated.25, 26 However, considering 
the impact of psychological symptoms on patients’ lives, on the experienced disease 
burden and health care utilisation19, 23, 27-30 , it is important to identify those suffering from 
psychological symptoms. The only way to identify patients in need is to screen IBD patients 
regularly on anxiety and depression.
Implement screening in clinical practice
In the current international guidelines for paediatric31, 32 and adult33-37 patients with IBD, 
screening for psychological problems is not (yet) part of standard care for IBD patients. 
Current international guidelines for adolescents with other chronic diseases, such as diabetes 
and cystic fibrosis (CF), recommend to screen yearly for at least anxiety and depression.38-40 
Screening at the outpatient clinic can be done using (digital) questionnaires (at home or 
in the waiting room) or by the doctor/nurse during clinic visits. Many questionnaires are 
available measuring depression or anxiety in paediatric patients41, of which a selection 
is available and validated in Dutch and/or in IBD. However, the disadvantage of many of 
these questionnaires is that they are often long and time consuming. Shorter validated 
questionnaires measuring anxiety/depression, such as the Patient Health Questionnaire 
(PHQ-9; 9 questions) for depression42, and the Generalized Anxiety Disorder-7 (GAD-7; 7 
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questions)43 are available (also in Dutch), but were originally designed for adult patients. 
However, in recent years, they are increasingly used in adolescents in secondary/tertiary 
care44-46, and have also been used in paediatric IBD.47 
 Instruments measuring anxiety/depression with only two or three questions, and 
therefore suitable for screening by a physician/nurse during the outpatient clinic visit are 
scarce. Short versions of the PHQ-9, (the PHQ-2) or the GAD-7 (GAD-2), or the SCARED 
(SCARED-5) are available, but are not sufficiently validated in adolescents (in secondary/
tertiary care).48-50
 To our knowledge, only one study previously investigated implementation of 
psychological screening in paediatric IBD patients. Iturralde et al. (2017) studied the 
implementation of screening for depression in three paediatric subspecialty clinics in the 
USA (IBD; n=32), cystic fibrosis (CF; n=27) and diabetes (DM; n=50). Patients were screened 
using the PHQ-9, positives screens (total score ≥ 11 or suicidal thoughts) received a same 
day behavioural health assessment. In total 16 patients screened positively on the PHQ-9 
(IBD n=5; CF n=3; DM n=8) and received a referral for mental health services. The study 
demonstrated that screening was feasible (did not interrupt patient flow) and acceptable to 
both patients and health care providers.47
 In summary, the importance of screening for psychological problems in young IBD 
patients is not (yet) recognised in international guidelines. However, the recently updated 
Dutch guideline for children and adolescents with IBD (www.richtlijnendatabase.nl: IBD) 
does recommend to screen paediatric patients yearly for anxiety and depression. The best 
way to conduct this screening at, or during, the outpatient clinic is not yet clear. Sufficiently 
validated short screening tools for children and adolescents with IBD are not available yet. 
Promising tools could be the PHQ-9/PHQ-2, GAD-7/GAD-2, which are also incorporated 
in the screening guidelines for adolescents and (young) adults with cystic fibrosis39 and 
suggested for use in IBD patients.51 
Future directions
To gain better insight into the prevalence and risk factors for anxiety and depression in 
(paediatric) IBD, future studies should use uniform screening measures, with the same 
comparable cut-offs. In addition, to clarify the association with other risk factors and anxiety/
depression, such as disease type, clinical disease activity and medication (e.g. anti –TNF), 
future studies need to present prevalence rates separately for these factors. Furthermore, 
many studies, especially in paediatric IBD, used cross-sectional designs to identify disease-
related risk factors for anxiety/depression. Longitudinal observational designs are necessary 
to study the associations of disease related factors and anxiety/depression over time. Lastly, 
studies investigating screening for psychological symptoms in (paediatric) IBD are warranted 
to determine the best screening method (instrument, frequency, necessary follow-up) and 
cost-effectiveness. 
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HAPPY-IBD: RANDOMISED CONTROLLED TRIAL INVESTIGATING THE 
EFFICACY OF COGNITIVE BEHAVIOURAL THERAPY ON PSYCHOLOGICAL 
SYMPTOMS AND CLINICAL DISEASE COURSE
Effect of cognitive behavioural therapy (CBT) on (subclinical) anxiety and depression 
Within HAPPY-IBD we investigated the effect of CBT in IBD patients with mild/subclinical 
anxiety/depression, because studies have shown that these symptoms are prevalent52-54 and 
that subclinical symptoms can evolve into clinical disorders.52, 55-57 We showed that after 3 
(Chapter 6) and after 6 and 12 months (Chapter 7) there was no difference in the course of 
anxiety and depressive symptoms for patients in both the CBT+CAU group (“CBT”) and the 
CAU group: an improvement in anxiety and depressive symptoms was seen in all patients. 
Our results indicate that CBT added to care as usual (CAU) did not perform better than 
standard medical care in improving subclinical anxiety/depressive symptoms.
 There are several explanations for our findings. At first, all patients, including 
patients in the CAU group, received multiple questionnaires and interviews assessing 
psychological health. This increased attention for psychological health could have elicited 
increased awareness, (unintended) psychoeducation and positively affected mental health 
in all patients.58, 59 Second, our cohort consisted of patients with subclinical anxiety and/or 
depressive symptoms, and IBD mostly in clinical remission (±75% remission, ± 20% mildly 
active disease). For these patients, mere participation in the trial may have been enough 
to improve psychological symptoms and to prevent the development of clinical/severe 
anxiety/depression.
 Compared to other studies, HAPPY-IBD is the first to investigate the effect of CBT 
in young IBD patients with subclinical anxiety and/or depression and to study both medical 
and psychological outcomes. Previous studies in adolescents have focused only on (sub)
clinical depression60, 61, for clinical anxiety only a small pilot study is available.62 Studies by 
Szigethy et al. have shown a reduction in depressive symptoms61 and depressive severity60 
following the same disease-specific CBT. 
 It could be that CBT has a greater effect on psychological outcomes in IBD patients 
with severe (clinical) anxiety and/or depression and at least moderately active bowel 
disease, although no studies are available yet that support this hypothesis. Even in adult 
IBD patients, no studies are available investigating the effectiveness of CBT in (sub)clinical 
depression or anxiety.63 However, in one study investigating the effect of CBT in patients 
with “low mental quality of life”, approximately 70% of patients had Hospital Anxiety And 
Depression scale (HADS)-scores indicative of an anxiety or depressive disorder. The study 
demonstrated that CBT was effective in reducing anxiety and depressive symptoms.64 
Unfortunately, studies investigating the effect of CBT on psychological health in IBD patients 
with at least moderately active disease and suffering from (sub)clinical anxiety/depression 
are not available.63 
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 In general cohorts of IBD patients, unselected for anxiety or depression, several 
studies were done on the effect of CBT in IBD patients. A study in 185 adolescents with IBD 
tested the effectiveness of a 3-session CBT protocol (versus education support condition), 
and found that CBT decreased school absences and improved HRQOL, but did not find an 
effect on anxiety/depression. Two recent systematic reviews also reported no effect of CBT 
on anxiety and depression in adult IBD.63, 65 Results of other psychotherapies on anxiety/
depression in unselected patients showed mixed results, with little or no (long term) effect 
on anxiety and depression.37, 63, 65, 66 It is therefore argued that psychotherapy should only be 
offered to selected patients, with identified needs.67, 68 
Effect of Cognitive Behavioural Therapy (CBT) on clinical disease course
Within the brain-gut axis a bidirectional relationship is hypothesised between psychological 
symptoms and (intestinal) inflammation. Psychological treatment may improve clinical 
symptoms, but also intestinal and systemic inflammation in IBD. 
 Within HAPPY-IBD we investigated whether CBT (in addition to care as usual, 
CAU) influenced clinical disease course (Chapter 8). We showed that time to first relapse, 
(pooled) clinical disease activity, CRP and faecal calprotectin did not differ significantly 
between patients in the CBT and the CAU group during the first year after treatment 
randomisation. Exploratory analyses in 10-18-year-old patients suggested a different course 
of faecal calprotectin and CRP between groups, with a slight increase in the CAU group, 
which could suggest a positive influence on intestinal inflammation on the longer term. 
 We believe our findings can be explained by the fact that in the current trial, both 
groups equally improved in anxiety/depressive symptoms and HRQOL after 369 and 6-12 
months (Stapersma et al., submitted). Concurrently, it is not surprising that we did not 
find a difference in clinical, inflammatory bowel disease-related outcomes between both 
groups. We would however expect clinical outcome (including longer time to relapse / lower 
frequency of relapse) to improve within both groups (as both groups improved in anxiety 
and depressive symptoms over time).69 Low baseline clinical disease activity could also 
explain why we did not find an improvement in clinical or inflammatory activity. 
 The only comparable study in paediatric as well as adult IBD, investigated the effect 
of CBT (versus supportive nondirective therapy) in 217 adolescents with IBD and minor/
major depression and found an improvement in depressive severity, HRQOL and pooled 
clinical disease activity after 3 months in both groups. However, this improvement in clinical 
disease activity was rather small (±10 points on the PCDAI /PUCAI).60 Other studies reporting 
on the effect of CBT on clinical disease course in IBD did not select patients on anxiety/
depression, and included paediatric70 or adult IBD68, 71-73 patients in clinical remission or 
with mildly active disease. No difference in remission68, 72 or relapse rates70, clinical disease 
activity60, 68, 72, 73 or CRP-levels40, 41 between CBT and the control condition were reported.  
 As mentioned, it could be that CBT is more effective in improving disease course 
(reducing inflammation) in patients with more severe anxiety/depression, although only 
12
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few studies provide support for this.60, 64 Similarly, CBT could have a greater influence on 
disease course in patients with at least moderately active disease. Unfortunately, studies 
investigating disease course in IBD patients with at least moderately active disease are not 
available. Lastly, it is possible that CBT has an effect on other measures of disease course 
or disease burden, such as disability, healthcare use (e.g. visits to the Emergency Room), 
school absenteeism or fatigue.74
Brain-gut axis in IBD: the relationship between psychological symptoms and (intestinal) 
inflammation at a molecular level
HAPPY-IBD provided us with the unique opportunity to investigate the relationship between 
anxiety and/or depression and (systemic) inflammation (Chapter 9), and we were the first 
to use a large unbiased inflammatory protein panel (including 92 proteins). Distinctive 
inflammatory protein signatures associated with a) symptoms of anxiety b) symptoms of 
depression, c) presence versus absence of anxiety and/or depression and d) response to CBT 
in IBD. Within these, Leukemia inhibitory factor receptor (LIF-R) and chemokine CCL4 were 
upregulated in patients with psychological symptoms and decreased after CBT, and possibly 
candidate proteins reflecting response to psychotherapy.
 Previous studies investigating the relationship between anxiety and/or depression 
and (systemic) inflammation are scarce: one study previously reported on the association 
between IBD, anxiety/depression and plasma proteins, but investigated a limited selection 
of proteins (Interleukin (IL)-1β, IL-6, CRP). 75 In addition, only one study described an effect of 
a psychological intervention (one session hypnotherapy) on Tumor Necrosis Factor (TNF-α), 
IL-6 and IL-13 levels.76
 In contrast, multiple studies investigated cytokine levels in anxiety and depression 
in otherwise healthy adolescents and adults, or the effect of psychotherapy on inflammation 
in adult IBD. All studies used small (biased) protein panels. Associations between anxiety 
and/or depression and IL-1β, IL-2, IL-6, IL-8, CRP, Interferon-gamma (IFN-γ), Tumor Necrosis 
Factor (TNF-α), and chemokines MCP-1 (CCL2), CCL3, CCL11, CXCL4, CXCL7 were reported.77-86 
Systematic reviews investigating the effect of psychotherapy on inflammation did not show 
any robust associations.87, 88
 In conclusion, using an innovative and unbiased approach with a large protein 
panel, we found distinct plasma protein signatures associating with anxiety and/or 
depression or response to CBT in IBD patients mostly in remission. Several proteins not 
previously investigated in anxiety and depression (in IBD) were now analysed, providing a 
novel perspective on possibly involved proteins. Future studies using large unbiased protein 
panels are necessary to confirm our findings and to investigate whether protein signatures 
are different for several subgroups (e.g. Crohn’s disease versus ulcerative colitis; responders 
versus non-responders to psychotherapy).
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Future directions
As shown, a full protocol of 10 sessions of CBT did not show to be beneficial for IBD patients in 
remission or with mildly active disease but suffering from subclinical anxiety and depression: 
CBT did not perform better in improving psychological or clinical outcomes than CAU. 
Considering we were the first to include IBD patients with anxiety and/or depression ánd 
investigate both psychological and clinical outcomes, more studies with comparable study 
designs are needed to confirm our findings. Furthermore, additional studies are needed to 
gain insight in the best approach for IBD patients with (sub)clinical anxiety/depression. 
 •  Observational studies investigating the natural course of subclinical psychological 
symptoms in IBD, taking into account the clinical course of disease, are needed to 
provide insight into the necessity of an intervention; 
 •   RCTs comparing different psychological interventions with varying treatment 
modalities (e.g. computerised CBT) and intensity (e.g. 3 session protocol) are 
required to determine the most effective treatment strategy; 
 •   To investigate if there are subgroups of IBD patients that would benefit from a full 
protocol of CBT, studies including IBD patients with more severe (clinical) anxiety/
depression and with at least moderately active disease are warranted; 
 •   Lastly, future studies should also include (patient reported) outcomes related to 
burden of disease, irritable bowel symptoms and treatment adherence, to investigate 
if CBT affects more ‘subjective’ outcomes, because these outcomes are known to 
impact health care utilisation and clinical outcomes. 
TRANSITION
Success of transition
As IBD is a lifelong disease, all patients will need to undergo transfer of paediatric to adult 
care. Transfer to adolescent care can be challenging due to several reasons, including the 
differences between paediatric and adult care. Therefore, a transition process is advised, 
in which all stakeholders (patients, parents, paediatric and adult gastroenterologists and 
specialised nurses) have specific tasks. For patients, the most important tasks are to learn 
responsibility for their own health, acquire (disease) knowledge, autonomy and self-
management.89-91 A clear definition of success of transition, or a scoring system measuring 
success of transition in IBD is not yet available.89, 92, 93 
 As a first step in exploring success of transition, we developed a tool in 2014, the 
Transition Yourself Score, to measure success of transition (Chapter 10). The score was 
based on previous literature and a focus group meeting with IBD experts and consisted of 
four items: time to the first gastroenterology outpatient clinic visit, outpatient clinic non-
attendance rates, adherence to medication and a qualitative evaluation of transition by the 
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patient. Applying the score on our cohort of 35 IBD patients, we found that transition was 
successful in 63% of cases, moderately successful in 31% and failed in 6%. 
 We have not psychometrically tested the Transition Yourself Score yet, because we 
felt the need to use a more thorough and objective approach to identify objective outcome 
measures that can be used to define successful transition in IBD.94 Therefore, we developed 
a three stage Delphi study asking a large expert and patient panel about outcomes they 
thought were important for success transition (Chapter 11). The expert panel consisted of 
paediatric gastroenterologist, adult gastroenterologist and IBD nurses. The study started 
with 26 items, of these, 10 and 11 out of 26 items were identified as important by the expert 
(n=64) and the patient panel (n=61) respectively. Surprisingly, the opinion of both the expert 
and patient panel was quite similar: 8 items were identified as important by both the patient 
and the expert panel. Of these, 6 items concerned self-management skills and autonomy 
(e.g. independent communication, medication adherence), while the other 2 items were 
more general: Health related Quality of Life and patient satisfaction about transition process. 
Remarkably, disease-specific items (such as surgery, inflammatory markers) were not found 
to be important, which has also been reported in studies discussing successful transition in 
other chronic diseases.95-98  
 Few studies investigated outcome of transition in IBD. No robust conclusions can 
be drawn, considering the fact that all studies used different designs and outcomes.93, 99, 100 
Two recent Delphi studies identified general, non-disease specific outcomes for success of 
transition in adolescent medicine (so including experts from several subspecialties). Our 
findings partly resemble the selected outcomes in these studies.101, 102
Future directions
With our Delphi study we took the first step in identifying outcomes that both experts and 
patients find important for success of transition. These findings should be confirmed in 
other (international) expert and patient panels. In addition, future research should focus 
on providing a clear definition of successful transition and develop and validate an objective 
score measuring success of transition. After validation, this score should be used to test 
the efficacy of the different IBD transition programs, in order to improve transitional care 
worldwide. 
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The general aim of this thesis was to investigate two themes relevant to adolescent and 
young adult IBD patients: 1) psychosocial problems (especially anxiety and depression) and 
effectiveness of cognitive behavioural therapy (CBT) on medical and psychosocial outcomes, 
and 2) transition from paediatric to adult care. 
PART I concerns anxiety and depression in paediatric IBD and the effectiveness of a 
disease specific CBT protocol examined in a randomised controlled trial (RCT). Chapter 2 
presents a systematic review and meta-analysis investigating the prevalence of anxiety 
and depression in paediatric IBD patients. A total of 28 studies were included (n=8107, 
51.3% male, 67.1% Crohn’s disease, mean age 14.3 years). Of importance is the distinction 
between psychological symptoms and disorders: disorders reflect severe symptoms that 
cause significant impairment in daily life and are diagnosed based on an interview using 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. Symptoms are 
usually measured with self-report questionnaires, and patients with elevated symptoms 
(who do not meet all criteria of a disorder) suffer from milder (or so-called subclinical) 
symptoms, but do not experience such a significant impairment in their daily life as patients 
with a diagnosed disorder. Of the 28 included studies, most investigated anxiety (n=10) 
or depressive (n=22) symptoms, while only a few reported on anxiety (n=3) or depressive 
(n=4) disorders. Pooled prevalence estimates for anxiety and depressive symptoms were 
respectively 16.4% and 15.0% . For anxiety and depressive disorders this was much lower, 
respectively 4.2% and 3.4%. Meta-regression showed that studies with a higher percentage 
of patients with active disease had a higher rate of depressive symptoms. Comparing with 
pooled prevalence rates in adult IBD, the found prevalence rates in paediatric IBD patients 
were much lower. We discussed several explanations for this difference, of which one is the 
lower number of studies available in paediatric IBD and the highly varying use of instruments 
and cut-off scores. This forced us to be careful drawing firm conclusions and we strongly 
advise that future studies use the same instruments ánd cut-off scores to gain better insight 
into prevalence rates. 
 In Chapter 3 we present the study protocol of HAPPY-IBD, our multicentre 
randomised controlled trial (RCT) investigating the effectiveness of a disease specific cognitive 
behavioural therapy (CBT) on psychological outcomes ánd clinical disease course in young 
(10-25-year-old) IBD patients with subclinical symptoms of anxiety and/or depression. In the 
RCT patients are randomised to either CBT+ Care as usual, or to CAU only. 
 Chapter 4 and 5 describe the results from the first stage of HAPPY-IBD: the screening 
of 374 Dutch adolescents and young adult with IBD on anxiety and depression using self-
report questionnaires and a psychiatric interview for patients with elevated symptoms. 
In Chapter 4 we showed that 47.4% of patients suffered from anxiety and/or depressive 
symptoms. Mild (subclinical) and severe (clinical) anxiety and/or depressive symptoms were 
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present in respectively 23.6% and 12.4%. Clinical disease activity, faecal calprotectin and 
erythrocyte sedimentation rate were significantly higher in patients with severe psychological 
symptoms. In addition, we found a much higher prevalence of anxiety symptoms (28.3%) 
compared to depressive symptoms (2.9%) or to both anxiety and depressive symptoms 
(15.8%). Active disease significantly predicted depressive symptoms. Female gender and 
a shorter disease duration were significantly associated with the presence of anxiety and/
or depressive symptoms. Considering the high prevalence of anxiety and/or depressive 
symptoms we strongly recommend to screen young IBD patients for anxiety/depression 
when they visit the outpatient clinic.
 In Chapter 5 we aim to explore the associations of psychological factors (illness 
perceptions, coping, anxiety, depression) with health related quality of life (HRQOL), 
controlling for demographic (gender, age, socio-economic status) and clinical factors 
(disease type, clinical disease activity). Using multiple regression analyses, we showed 
that negative illness perceptions and depression were negatively associated to HRQOL. 
 Chapter 6 is the first chapter reporting on stage 2 of HAPPY-IBD; the randomised 
controlled trial, where we included 70 patients who were randomised to either CBT+CAU 
or CAU only. In Chapter 6 we showed that after 3 months (directly after completing 10 
sessions of CBT), overall, patients in both groups either remained stable or improved in 
their symptoms of anxiety and depression according to their reliable change index (RCI). 
Exploratory linear mixed model analyses showed that all patients improved in their 
symptoms of anxiety or depression and improved in HRQOL. 
 In Chapter 7 the long-term effectiveness of CBT on anxiety, depression, HRQOL 
and other psychological outcomes such as social functioning, coping, illness perceptions 
and sleep problems were discussed. On the long term, results showed a similar pattern: in 
both the CBT +CAU and the CAU group a similar proportion of patients improved in anxiety 
and depressive symptoms. In addition, both groups improved on anxiety, depression, 
HRQOL, social functioning, coping and illness perception. Two explanations are given for 
this lack of difference: the extra attention (questionnaires, interviews) that patients in the 
CAU received by merely participating in the RCT could have been enough to improve their 
subclinical symptoms of anxiety and/or depression. In addition, giving a full protocol of CBT 
to IBD patients with subclinical anxiety/depression and mostly in clinical remission seems 
unnecessary.
 In Chapter 8 we focused on the effect of CBT on clinical disease course. We showed 
that there was no difference between the CBT+CAU and the CAU group in the time to first 
relapse or relapse frequency in the first year after randomisation. In addition, CBT did 
not influence (pooled) clinical disease activity scores, and inflammatory markers (faecal 
calprotectin, C-reactive protein). We emphasised that these results are not surprising 
considering both groups equally improved in anxiety/depressive symptoms and hypothesise 
that CBT may be more effective in patients with more severe anxiety/depression and active 
disease. 
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 In Chapter 9 we explored the brain-gut axis in IBD: the bidirectional relationship 
between psychological stress and (intestinal) inflammation and the possibility to improve 
intestinal/systemic inflammation by treating anxiety/depression. Using an innovative and 
unbiased approach with a large protein panel, we found distinct plasma protein signatures 
associating with anxiety and/or depression in IBD patients mostly in remission. These 
immune signatures were altered in patients receiving CBT. Several proteins not previously 
investigated in anxiety and depression (in IBD) were now analyzed, providing a novel 
perspective on possibly involved proteins. Leukemia Inhibitory Factor-Receptor (LIF-R) and 
Chemokine (C-C motif) ligand 4 (CCL4) seemed promising candidate proteins responsive to 
psychotherapy, as they were associated to both the presence of anxiety and/or depressive 
symptoms and decreased after CBT. 
Chapter 10 (in PART II) is the first of two chapters investigating outcome of transition. Here 
we propose a composite score measuring success of transition (Transition Yourself Score) 
consisting of the following items: adherence to visits at the gastroenterology outpatient 
clinic, adherence to medication and qualitative evaluation of the transition process by the 
patient. Failed transition was defined as a total score below 5. In our cohort of 35 patients, 
transition was successful in 63% of cases, moderately successful in 31% and failed in 6%. In 
addition, we demonstrated that self-efficacy, using the IBD-yourself questionnaire, was not 
predictive of success of transition. 
 In Chapter 11 we used a more thorough approach in identifying outcomes reflecting 
successful transition, a step to further define success of transition in IBD. In a three-stage 
multinational Delphi study the opinion of a large expert (n=74) and patient panel (n=61) was 
asked. Analyses showed that, using the RAND UCLA criteria for agreement, 10 and 11 items 
were found to be important for success of transition by respectively the expert and patient 
panel. Remarkably, both panels agreed on 8 of these items, and 6 of the 8 items reflected 
self-management skills. The top-10 list formed by the expert panel in stage 3 showed that 
‘decision making regarding IBD’, ‘independent communication’, and ‘patient satisfaction 
about the transition process’ were the three most important items.
In Chapter 12 (PART III) the main findings of our studies and their scientific and clinical 
implications are discussed and recommendations for future research are given. 
 With respect to anxiety and depression in paediatric IBD: we conclude that future 
studies using uniform screening measures (and cut-offs) are necessary to gain better insight 
into the prevalence of anxiety and depression. Based on the high prevalence we found in our 
patient cohort, we believe that it is justified and necessary to screen young IBD patients for 
anxiety/depression. For IBD patients in remission or with mildly active disease, but suffering 
from subclinical anxiety/depression, a full protocol of CBT did not seem beneficial. The best 
approach for this patient groups remains a question for the future. Furthermore, studies 
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investigating the effect of CBT in IBD patients with more severe (clinical) anxiety/depression 
and with at least moderately active disease are warranted.
 With our transition research, we took the first steps in defining success of transition 
in IBD. Future studies should confirm our findings, formulate a definition of successful 
transition and develop a score measuring success of transition. 
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Het doel van dit promotieonderzoek was om twee onderwerpen te bestuderen die 
belangrijk zijn voor adolescenten en jongvolwassen patiënten met Inflammatory Bowel 
Disease (chronisch Inflammatoire Darmziekten: ziekte van Crohn en Colitis Ulcerosa): 1) 
psychosociale problemen (specifiek angst en depressie) en de effectiviteit van cognitieve 
gedragstherapie (CGT) op medische en psychosociale uitkomsten, en 2) transitie van de 
kindergeneeskundige zorg naar de volwassenen zorg. 
PART I bespreekt angst en depressie bij kinderen en adolescenten met IBD en de effectiviteit 
van een ziekte specifiek CGT protocol dat onderzocht werd in een gerandomiseerd 
gecontroleerd onderzoek (RCT). In Hoofdstuk 2 presenteren we een systematisch 
literatuuronderzoek met meta-analyse naar het voorkomende (de prevalentie) van angst en 
depressie bij kinderen en adolescenten met IBD. In totaal werden 28 studies geïncludeerd 
(totaal aantal patiënten (n)= 8107, 51.3% man, 67.1% Ziekte van Crohn, gemiddelde leeftijd 
14.3 jaar). Van belang is het verschil tussen psychologische symptomen en stoornissen: 
stoornissen beschrijven ernstige symptomen die een belangrijke beperking geven in het 
dagelijks leven en worden gediagnosticeerd met een psychiatrisch interview gebaseerd op 
de Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. Psychologische 
symptomen worden doorgaans gemeten met zelfrapportage vragenlijsten, patiënten met 
verhoogde symptomen (die niet voldoen aan alle criteria voor een stoornis) hebben last 
van mildere (of subklinische) symptomen, maar ervaren een minder grote beperking in het 
dagelijks leven dan patiënten met een gediagnosticeerde stoornis. Van de 28 geïncludeerde 
studies, onderzochten de meeste angst (n=10) of depressieve (n=22) symptomen, enkele 
studies onderzochten angst (n=3) of depressieve (n=4) stoornissen. De geschatte gepoolde 
prevalentie van angst-en depressieve symptomen was respectievelijk 16.4% en 15.0%. Voor 
angst-en depressieve stoornissen was dit een stuk lager, respectievelijk 4.2% en 3.4%. Meta-
regressie analyse toonde dat studies waarin een hoger percentage patiënten actieve ziekte 
had, een hogere prevalentie van depressieve symptomen gevonden werd. Vergeleken met 
gepoolde prevalenties van angst/depressie in volwassen IBD-patiënten, zijn de gevonden 
prevalenties bij kinderen/jongeren met IBD een stuk lager. Verschillende verklaringen voor 
dit verschil werden besproken, waarvan één het kleinere aantal beschikbare studies is in 
kinderen met IBD, met daarbij een groot aantal verschillende instrumenten met verschillende 
cutoff scores. Om deze redenen zijn we voorzichtig met het trekken van conclusies en 
adviseren we dat onderzoeken in toekomst dezelfde instrumenten met dezelfde cutoff 
scores gaan gebruiken, om een beter inzicht te krijgen in de prevalenties.  
 In Hoofdstuk 3 presenteren we het onderzoeksprotocol van HAPPY-IBD, onze 
multicenter gerandomiseerde gecontroleerde studie (RCT) die het effect van een ziekte 
specifieke CGT op zowel psychologische uitkomsten als het ziektebeloop onderzoekt in 
jonge (10-25 jaar) IBD-patiënten met subklinische angst en/of depressie symptomen. In de 
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RCT worden patiënten gerandomiseerd (dat wil zeggen op basis van toeval geloot) aan of 
Cognitieve Gedragstherapie (CGT) + reguliere medische zorg (RMZ), of aan RMZ alleen. 
 Hoofdstuk 4 en 5 beschrijven de resultaten van de eerste fase van HAPPY-IBD: 
het screenen van 374 Nederlandse adolescenten en jongvolwassenen met IBD op angst 
en depressie met zelfrapportage vragenlijsten en een psychiatrisch interview bij patiënten 
met verhoogde symptomen. In Hoofdstuk 4 tonen we dat 47.4% van de patiënten last had 
van angst en/of depressie symptomen. Milde (subklinische) en ernstige (klinische) angst 
en/of depressieve symptomen waren aanwezig bij respectievelijk 23.6% en 12.4% van 
de patiënten. Klinische ziekteactiviteit, fecaal calprotectine en de bezinking (BSE) waren 
significant hoger bij patiënten met ernstige psychologische symptomen. Daarnaast vonden 
we een hogere prevalentie van angstsymptomen (28.3%) vergeleken met depressieve 
symptomen (2.9%) of gecombineerde angst-én depressieve symptomen (15.8%). Actieve 
ziekte was een significante voorspeller voor het hebben van depressieve symptomen. Het 
vrouwelijk geslacht en een kortere ziekteduur waren geassocieerd met de aanwezigheid 
van angst en/of depressieve symptomen. Gezien de hoge prevalentie van angst en/of 
depressieve symptomen adviseren wij met klem om jonge IBD-patiënten te screenen op 
angst en depressie wanneer zij de polikliniek bezoeken.
 In Hoofdstuk 5 exploreren we de relatie tussen psychologische factoren 
(ziektepercepties, coping, angst, depressie) en ziekte-specifieke kwaliteit van leven (KvL), 
gecorrigeerd voor demografische (geslacht, leeftijd, sociaal-economische status) en klinische 
factoren (ziekte type, klinische ziekteactiviteit). Door middel van multipele regressieanalyses 
lieten we zien dat negatieve ziektepercepties en depressie negatief geassocieerd zijn met 
ziektespecifieke KvL.
 Hoofdstuk 6 is het eerste hoofdstuk dat rapporteert over fase 2 van HAPPY-
IBD: het gerandomiseerde gecontroleerde onderzoek (RCT), waarin 70 patiënten werden 
geïncludeerd die gerandomiseerd werden aan of CBT+RMZ of RMZ alleen. In Hoofdstuk 
6 toonden we dat, over het geheel genomen, patiënten in beide groepen na 3 maanden 
(direct na het voltooien van 10 sessies CGT) ofwel stabiel bleven of verbeterden in angst/
depressie symptomen. Exploratieve lineaire mixed model analyses toonden dat alle 
patiënten verbeterden wat betreft hun symptomen van angst of depressie en verbeterden 
in ziektespecifieke KvL. In Hoofdstuk 7 wordt de effectiviteit van CBT op angst, depressie, 
ziektespecifieke KvL en andere psychologische uitkomsten zoals sociaal functioneren, 
ziektepercepties en slaapproblemen op lange termijn besproken. Resultaten op de lange 
termijn toonde eenzelfde patroon: in zowel de CGT+RMZ als de RMZ groep, was het deel 
van de patiënten dat verbeterden in angst/depressieve symptomen gelijk. Daarnaast was 
er in beide groepen evenveel verbetering in angst, depressie, ziektespecifieke KvL, sociaal 
functioneren, coping en ziektepercepties. Twee verklaringen werden gegeven voor het niet 
vinden van een verschil tussen beide groepen: de extra aandacht (vragenlijsten, interviews) 
die patiënten in de RMZ groep kregen door alleen mee te doen aan de RCT, zou al genoeg 
kunnen zijn om te verbeteren in subklinische angst/depressie symptomen. Daarnaast lijkt het 
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onnodig om IBD-patiënten met subklinische angst/depressie symptomen, en grotendeels in 
remissie, een uitgebreid CBT protocol te geven. 
 In Hoofdstuk 8 richtten we ons op het effect van CGT op het beloop van de 
darmontsteking. We lieten zien dat de tijd tot de eerste opvlamming of het aantal 
opvlammingen niet verschillend was tussen de CGT+RMZ en de RMZ groep in het eerste jaar 
na randomisatie. Daarnaast zagen we dat CGT geen invloed had op klinische ziekteactiviteit 
scores en inflammatoire markers (fecaal calprotectine en C-reactief proteine). We 
benadrukten dat deze resultaten niet verassend waren gezien het feit dat beide groepen 
evenveel verbeterden in angst/depressie symptomen en veronderstellen dat CGT wellicht 
effectiever is bij patiënten met ernstigere angst/depressie symptomen en bij patiënten met 
een actieve darmontsteking.
 In Hoofdstuk 9 onderzochten we de hersen-darm-as in IBD: de wederzijdse relatie 
tussen psychologische stress en (intestinale) inflammatie, en de mogelijkheid om intestinale/
systemische inflammatie te verbeteren door angst/depressie te behandelen. Met behulp van 
een vernieuwende en objectieve analysemethode met een groot eiwit panel, vonden we dat 
karakteristieke plasma eiwit profielen geassocieerd waren met angst en/of depressie bij IBD-
patiënten die op dat moment geen klachten hadden van hun darmontsteking (darmziekte 
in klinische remissie). CGT zorgde voor verandering van deze eiwitprofielen. Verschillende 
eiwitten, niet eerder onderzocht in relatie tot angst/depressie (in IBD-patiënten) werden nu 
geanalyseerd, en bieden een nieuw perspectief op mogelijk betrokken eiwitten. Leukemia 
Inhibitory Factor-Receptor (LIF-R) en Chemokine (C-C motif) ligand 4 (CCL4) lijken veelbelovende 
kandidaat eiwitten die veranderen na psychotherapie, gezien het feit dat ze geassocieerd 
waren met de aanwezigheid van angst en/of depressieve symptomen en daalde na CGT. 
Hoofdstuk 10 (PART II) is de eerste van twee hoofdstukken die de uitkomst/succes van 
transitie onderzoekt. In dit hoofdstuk introduceren we een samengestelde score die succes 
van transitie meet (Transition Yourself Score) en bestaat uit de volgende items: verschijnen 
op afspraken op de Maag Darm Lever (MDL) polikliniek, therapietrouw en een kwalitatieve 
evaluatie van het transitieproces door de patiënt. Mislukte transitie werd gedefinieerd als 
een totaalscore onder 5. In ons cohort met 35 patiënten bleek transitie succesvol bij 63% van 
de patiënten, redelijk succesvol bij 31% en mislukt bij 6% van de patiënten. Daarnaast lieten 
we zien dat zelfredzaamheid, gemeten met de IBD-Yourself vragenlijst, geen voorspeller was 
voor succes van transitie. 
 In Hoofdstuk 11 gebruikten we een grondigere methode om uitkomsten die succes 
van transitie weerspiegelen te identificeren, als volgende stap om succes van transitie 
verder te definiëren. Door middel van een Delphi procedure in 3 fasen, vroegen we de 
mening van een groot expert (n=74) en patiënten (n=61) panel. Analyse met behulp van 
de RAND ULCA criteria voor overeenstemming toonde dat respectievelijk 10 en 11 items 
belangrijk werden geacht voor succes van transitie volgens het expert en patiënten panel. 
Opmerkelijk was dat beide panels het eens waren over 8 van deze items, en dat 6 van de 8 
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zelfmanagement vaardigheden betroffen. De top-10 gevormd door het expert panel in fase 
3 toonde dat 'zelfstandig beslissingen maken omtrent IBD', 'zelfstandig communiceren', en 
'patiënt tevreden over transitieproces’ de drie belangrijkste items waren. 
In Hoofdstuk 12 (PART III) worden de belangrijkste bevindingen van onze studies 
bediscussieerd en aanbevelingen voor toekomstig onderzoek gedaan.
 Wat betreft angst en depressie bij kinderen en jongeren met IBD, concluderen we 
dat toekomstige onderzoeken dezelfde instrumenten met dezelfde cutoff scores moeten 
gebruiken, om een beter inzicht te krijgen in de prevalenties. Gezien de hoge prevalentie 
van angst en/of depressieve symptomen gevonden in onze patiëntengroep, adviseren wij 
met klem om jonge IBD-patiënten te screenen op angst en depressie.
 Voor IBD-patiënten die weinig/geen klachten hebben van hun darmontsteking, 
maar wel subklinische angst en/of depressieklachten, lijkt een uitgebreid CGT protocol 
niet nodig. De beste behandelmethode voor deze patiëntengroep blijft een vraag voor de 
toekomst. Daarnaast zijn studies nodig die het effect van CGT onderzoeken bij IBD-patiënten 
met ernstige (klinische) angst/depressie en minstens matig actieve ziekte.
  Met ons onderzoek naar transitie hebben we de eerste stappen genomen om 
succes van transitie in IBD te definiëren. Onze bevindingen moeten bevestigd worden in 
toekomstig onderzoek, daarnaast is een definitie van succesvolle transitie nodig, evenals 
een objectieve score die succes van transitie kan meten. 
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ADIS-C/P Anxiety Disorders Interview Schedule for Children/Parents
ADRS  Adolescent Depression Rating Scale 
BDI-II   Beck Depression Inventory-second edition 
B-IPQ  Brief Illness Perceptions Questionnaire
CAU  Care as Usual 
CBT  Cognitive Behavioural Therapy 
CCL  C-C Motif Chemokine
CXCL  C-X-C Motif Chemokine
CD   Crohn’s Disease 
CDAI  Crohn’s Disease Activity Index
CDI   Child Depression Inventory 
CDRS-R  Child Depression Rating Scale – Revised 
CERQ  Cognitive Emotion Regulation Questionnaire
CRP  C-Reactive Protein 
CSM  Common Sense Model
ECCO  European Crohn’s and Colitis Organisation
EIM  Extra-Intestinal Manifestations
ESPGHAN  European Society for Paediatric Gastroenterology Hepatology and 
Nutrition
FC  Fold Change
GE  Gastroenterology
HADS-A  Hospital Anxiety and Depression Scale – Anxiety scale 
HAM-A  Hamilton Anxiety Rating Scale 
HAM-D  Hamilton Depression Rating Scale 
HPA  Hypothalamic-pituitary-adrenal 
HRQoL  Health-Related Quality of Life 
IBD  Inflammatory Bowel Disease
IBDQ  Inflammatory Bowel Disease Questionnaire
IBD-U  Inflammatory Bowel Disease Unclassified
IFN-y  Interferon gamma
IL  Interleukin
IQR  Interquartile Ranges
LIF-R  Leukemia Inhibitory Factor Receptor
LOD  Lower limit Of Detection
LRT  Likelihood Ratio Test 
LFK  Luis Furuya-Kanamori 
MCP  Monocyte Chemoattractant Protein
PARS  Paediatric Anxiety Ratings Scale 
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PASCET  Primary and Secondary Control Enhancement Therapy 
PCA  Principal Component Analysis
PCDAI   Paediatric Crohn’s Disease Activity 
pMAYO  Partial Mayo 
PUCAI  Paediatric Ulcerative Colitis Activity Index 
RCT  Randomized Controlled Trial
RCI  Reliable Change Index
SCARED   Screen for Child Anxiety Related Emotional Disorders
SEM  Standard Error of Measurement
SES  Socio-Economic Status
SLCBT  Social Learning and Cognitive Behavioral Therapy 
TNF  Tumor Necrosis Factor
TSNE  T-Distributed Stochastic Neighbor Embedding 
TRAQ  Transition Readiness Assessment Questionnaire 
UC   Ulcerative Colitis 
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